SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 1 of 137  
 
 
Clinical Study Protocol  
 
A Phase III Randomised, Double -masked , Parallel Group, 
Multicent re Study to Compare the Efficacy, Safety, 
Pharmacokinetics and Immunogenicity between SB11 (proposed 
ranibizumab biosimilar) and Lucentis¬Æ in Subject s with Neovascu lar 
Age-related Macular Degeneration  
 
 
 
 
 
Product  SB11  (proposed ranibizumab  biosimilar)  
EudraCT Number  2017 -000422 -36 
US pre-IND Number  130331  
Protocol Number  SB11 -G31-AMD  
Study Phase  Phase III  
Version and Effective Date  Amendment 1  Sep 0 1, 2017  
Sponsor  Samsung Bioepis Co., Ltd.  
107, Ch eomdan-daero, Yeonsu- gu, 
Incheon, 21987 
Republic of Korea  
 
 
  
 
  
This document contains confidential information belonging to Samsung Bioepis Co ., Ltd. Your 
acceptance or review of this document constitutes agreemen t that you will not copy or disclose the 
information contained herein to others or use it for unauthorised purposes without written authorisation 
from the Sponsor.  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 2 of 137 SYNOPSIS  
Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
Title of Study:  
A Phase III Randomised, Double -masked , Parallel Group, Multicentre  Study to Compare the Efficacy, 
Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and 
Lucentis¬Æ in Subject s with Neovascular Age-related M acular Degeneration  
Protocol No:  SB11 -G31-AMD  Phase:  III 
Indication:  Neovascular Age-related M acular Degeneration  (AMD)  
Objectives:  
Primary Objective:  
‚Ä¢ To demonstrate the equivalence of efficacy of SB11 to Lucentis¬Æ in subjects with neovascular 
age-related macular degeneration  
 
Secondary Objectives:  
‚Ä¢ To evaluate the safety of SB11 and Lucentis¬Æ 
‚Ä¢ To evaluate the immunogenicity of SB11 and Lucentis¬Æ 
‚Ä¢ To evaluate the systemic exposure of SB11 and Lucentis¬Æ in subjects participating in 
pharmacokinetics ( PK) evaluation   
Study Design:  
This is a randomised, double -masked , parallel group, multicentre  study to evaluate the efficacy , safety , 
pharmacokinetics and immunogenicity of SB 11 compared to Lucentis¬Æ in subjects with neovascular  
AMD . Subjects will be randomised in a 1:1 ratio to receive either SB11 or Lucentis¬Æ (administered via 
intravitreal ( ITV) 0.5 mg every 4 weeks ). Investigational P roducts  (IP) (SB11 or Lucentis¬Æ) will be 
admin istered up to Week 48, and the last assessment will be done at Week 52.  
Number of Subjects:  
Approximately a total of 704 subjects are planned to be randomised into this study.  
Target Population:  Subjects with neovascular AMD  
Eligibility Criteria:  
Only one eye will be designated as the study eye. For subjects who meet eligibility criteria in both eyes, 
the eye with the worse Visual A cuity ( VA) will be selected as the study eye. If both eye s have equal 
VA, the eye with better visual prognosis  (e.g., clear er lens and ocular media and l ess amount  of 
subfoveal scar or geographic atrophy ) will be selected  at the Investigator‚Äôs discretion . If there is no 
objective basis for selecting the study eye, factor such as ocular dominance, other ocular pathology and subject preference should be considered by the Investigator in making the selection.
 
Inclusion criteria  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 3 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
Subjects must meet all of the following criteria to be eligible for the study:  
1. Age ‚â• 50 years at Screening  
2. Newly diagnosed, *active subfoveal Choroidal Neovascularisation (CNV) lesion secondary to 
AMD  in the study eye  
* Active CNV indicates presence of leakage and intra- or sub- retinal fluid which should be 
confirmed by central reading centre  during Screening  
3. The area of CNV must occupy at least 50% of total  lesion in the study eye (confirmed by 
central reading centre  during Screening ) 
4. Total lesion area ‚â§ 9.0 D isc Areas (DA) in size (including blood, scars and neovascularisation ) 
in the study eye (confirmed by central reading centre  during Screening ) 
5. Best Corrected Visual Acuity ( BCVA ) of 20/40 to 20/200 (letter score of 73 to 34) using 
original series Early Treatment D iabetic Retinopathy Study (ETDRS ) chart s or 2702 series 
Number  chart s in the study eye  at Screening and at Week 0 (Day 1)  prior to randomisation 
6. Non-childbearing potential female (e.g., permanently sterili sed, postmenopausal [defined as 12 
months with no menses without an alternative medical cause prior to Screening]) , OR  
Childbearing potential female subjects or male subjects with their ( respectively male or 
female) partners who agree to use at least two forms of appropriate contraception method that 
can achieve a failure rate of less than 1% per year (e.g., established use of oral, injected, 
intravaginal, transdermal or implanted hormonal contraceptive, placement of an intrauterine device or intrauterine hormone- releasing s ystem, bilateral tubal occlusion, vasectomised 
partner, physical barrier, sexual abstinence) from Screening until 3 months after the last  ITV 
injection of IP  
7. Written  informed consent form must be obtained from the subject prior to  any study related 
procedu re (If the subject is legal blindness or illiterate , an impartial witness should be present 
during the entire informed consent discussion ) 
8. Willingness and ability to undertake all scheduled visits and assessments  
Exclusion criteria  
Subjects meeting any of the following criteria are not eligible for the study:  
1. Sub- or intra -retinal h aemorrhage that comprises more than 50% of the entire lesion in the 
study eye, or presence of subfoveal blood equ al to or more than one DA in size (confirmed by 
central reading centre  during Screening ) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 4 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
2. Scar, fibrosis or atrophy involving the centre  of the fovea in the study eye  (confirmed by 
central reading centre  during Screening ) 
3. Presence of CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, 
multifocal choroiditis, angioid streaks , history of choroidal rupture or Pathologic Myopia 
(PM) (confirmed by central reading centre  during Screening ) 
4. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye 
(confirmed by central reading centre during Screening ) 
5. Presence of macular hole at any stage in the study eye (confirmed by central reading centre 
during Screening)  
6. Any concurrent macular abnormality other than AMD  in the study eye which could affect the 
efficacy of IP including but not limited to epiretinal membrane, macular telangiectasia, retinal 
vascular abnormality, etc.  (confirmed by central reading centre during Screening)  
7. History of vitrectomy surgery in the study eye  
8. History of trabecule ctomy or other filtration surgery i n the study eye  
9. History of submacular surgery or other surgical intervention for AMD in the study eye  
10. Any other intraocular surgery (including cataract su rgery) or periocular surgery in the study 
eye within 90 days  prior to randomi sation , except for lid su rgery, which may not have taken 
place within 30 days  prior to randomi sation  
11. Any previous ITV anti-Vascular  Endothelial Growth Factor ( anti-VEGF) treatment  (e.g., 
bevacizumab, aflibercept, ranibizumab) to treat neovascular AMD  in either eye  
12. Any previous sys temic anti- VEGF treatment , within 90 days  prior to randomisation , and such 
treatment will not be allowed during the study  period  
13. Any systemic treatment or therapy ( including prescribed herbal medication) to treat 
neovascular AMD within 30 days prior to ran domi sation, and such treatment  or therapy will 
not be allowed during the study  period. However, dietary supplements , vitamins or mineral 
will be allowed  
14. Any intravitreal injection of corticosteroid (e.g., triamcinolone acetonide) or intravitreal 
corticoste roid implant in the study eye within 180 days  prior to randomi sation , and such 
treatment will not be allowed during the study  period  
15. Topical ocular corticosteroids administered for ‚â• 30 consecutive days in the study eye  within 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 5 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
90 days  prior to randomisatio n  
16. Spherical equivalent of the refractive error in the study eye demonstrating more than 8 diopters 
of myopia . For subjects who have undergone previous refractive or cataract surgery in the 
study eye, the preoperative refractive error in the study eye must  not exceed 8 diopters of 
myopia  
17. Aphakia or absence of the posterior capsule in the study eye (unless it occurred as a result of a 
Yttrium Alumin ium Garnet [YAG] posterior capsulotomy in associatio n with prior posterior 
chamber Intraocular L ens [IOL] impla ntation)  
18. Presence of  scleromalacia in either eye  
19. Current vitreous h aemorrhage in the study eye  
20. Active or recent (within 28 days  prior to  randomi sation ) intraocular, extraocular and periocular 
inflammation or infection in either eye  
21. History of idiopathic or  autoimmune uveitis in either eye  
22. History of retinal detachment in the study eye  
23. History of full-thickness macular hole in the study  eye 
24. History of corneal transplantation surgery  in the study eye  
25. Presence of advanced glaucoma or optic neuropathy that affect or threaten the central visual 
field in the study eye  
26. Uncontrolled ocular hypertension  (defined as intraocular pressure ‚â• 25 mmHg despite 
treatment with anti -glaucoma medication) in the study eye  
27. History of allergy to the fluorescein sodium for injectio n in angiography  
28. Previous participation in clinical stud ies of ocular investigational products to treat neovascular 
AMD in either eye or systemic investigational products to treat neovascular AMD , and such 
participation will not be allowed during the study  period 
29. Previous participation in any studies of  ocular or systemic  investigational products (excluding 
dietary supplements , vitamins and minerals) to treat ocular or systemic disease other than 
neovascular A MD within 90 days  prior to randomisation , and su ch participation will not be 
allowed during the study period even if the investigational product  is dietary supplements , 
vitamins or minerals  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 6 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
30. History or clinical evidence of diabetic retinopathy (except for mild non -proliferative diabetic 
retinopathy)  or diabetic macular o edema in either eye  
31. Any concurrent ocular condition in the study eye which, in the opinion of the Investigator, 
could either increase the risk to the subject safety or which otherwise may interfere with 
evaluation of efficacy or safety including, but not limited to ocular media opacities such as 
corneal opacit y or cataract  that do not allow proper fundus visuali sation and fundus  imaging, 
and ocular surface abnormalities which prevent applanation tonometry during the  study 
period after rando misation  
32. History of other disease, metabolic d ysfunction, physical examination finding, or clinical 
laboratory finding that contraindicates the use of an IP in the opinion of  the Investigator  
33. Pregnant or lactating women. A serum pregnancy test must be required for women of 
childbearing potential at Screening  
34. Employees of Investigational  sites, individuals directly involved with the conduct of the study 
or immediate family members thereof, prisoners, and persons who are legally  
institutionali sed  
35. Stroke, transient ischemic attacks, or myocardial infarction within 90 days prior to 
randomisation  
36. History of recurrent significant infections and/or current treatment for active systemic infection  
37. Known allergic reactions and/or hypersensitivity to ranibizumab or t o any ingredients of the 
investigational product  
38. Prior treatment involving macula with photodynamic therapy with verteporfin, transpupillary  
thermotherapy , radiation therapy, or retinal laser treatment (e,g ., focal laser photocoagulation) 
in the study eye , and such treatment will not be allowed during the study period  
39. Prior treatment with pan -retinal photocoagulation in the study eye, and such treatment will not 
be allowed during the study period  
40. Current use of systemic medications known to be toxic to the lens, retina or optic nerve, 
including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines , 
vigabatrin and ethambutol, and such medications will not be allowed during the study period  
Planned Study Period:  
Screening period will be 21 days.  
IPs (SB11 or Lucentis¬Æ) will be given up to Week 48, and the last assessment will be done at Week 52.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 7 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
Investigational Products:  
‚Ä¢ Test IP : SB11 (proposed ranibizumab biosimilar)  
‚Ä¢ Reference IP : Lucentis¬Æ (ranibizumab)  
‚Ä¢ Route of administration: ITV injecti on 
‚Ä¢ Dose: 0.5 mg every 4 weeks  
Main Criteria for Evaluation  
Primary endpoint  
For US Food and Drug Administration  (FDA) , Korea Ministry of Food and Drug Safety (MFDS)  or 
other regulatory agency submissions for those who are in favour of  the VA, the primary endpoint  is: 
‚Ä¢  Change from baseline in BCVA at Week 8  
For European Medicines Agency  (EMA) or other regulatory agency submission s for those who are in 
favour of  the anatomical parameter , the primary endpoint is:  
‚Ä¢ Change from baseline in Central Subfield Thickness (CST)  at Week 4 (based on assessment by 
central reading centre ) 
Secondary endpoints  
The secondary efficacy endpoints are: 
‚Ä¢ Change from baseline in BCVA over time up to Week 24 and Week 52  
‚Ä¢ Proportion of subjects who lost fewer than 15 letters in BCVA compared to baseline at  Week 24 
and Week 52  
‚Ä¢ Proportion of subjects who gained 15 letters or more in BCVA compared to baseline at  Week 24 
and Week 52  
‚Ä¢ Change from baseline in CST and Central Retinal Lesion Thickness (CRLT)  at Week 24 and Week 
52 (based on asse ssment by central reading centre ) 
‚Ä¢ Change from baseline in total CNV  size at  Week 24 and Week 52 (based on assessment by central 
reading centre) 
‚Ä¢ Proportion  of subjects with active CNV leakage at Week 24 and Week 52 (based on assessment by 
central reading centre) 
The safety endpoints are:  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 8 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
‚Ä¢ Incidence of ocular Adverse E vents (AEs) or serious ocular adverse events  
‚Ä¢ Incidence of systemic AEs and serious systemic adverse events  
The pharmacokinetic endpoints are:  
Blood sampling for PK will be collected in approximately  40 subjects participating in PK evaluation 
(20 subjects per treatment group) . 
‚Ä¢ Systemic exposure measured pre- dose (C trough) and 24 to 72 hours post -dose (close to  Cmax)  
The immunogenicity endpoints are:  
‚Ä¢ Incidence of Anti-Drug Antibodies (ADAs) to rani bizumab 
‚Ä¢ Incidence of  Neutralising Antibodies (NAbs) to ranibizumab  
The exploratory endpoint s are: 
‚Ä¢ Proportion  of subjects with out intra - or sub -retinal fluid  at Week 24 and Week 52 (based on 
assessment by central reading centre) 
The Quality of Life (QOL) is assessed using National Eye Institute 25 -Item Visual Function 
Questionnaire (NEI VFQ- 25). 
‚Ä¢ Change from baseline in subscale scores and composite scores of NEI  VFQ -25 at Week 24 and 
Week 52  
Statistical Methods  
Efficacy analysis  
For US FDA , Korea  MFDS or o ther regulatory agency submissions for those who are in favour of the 
VA, the primary efficacy analysis will be performed for the Full A nalysis  Set (FAS) with the change 
from baseline of BCVA at Week 8  using an analysis of covariance model  with the baselin e BCVA as a 
covariate and region (or pooled centres) and treatment group as factors . The FAS will consist of all 
randomised subjects. The subjects will be analysed based on the treatment they were randomised to by 
intention -to-treat principle. However, sub jects who do not qualify for randomisation and are 
inadvertently randomised into the study will be excluded from the FAS, provided these subjects do not 
receive any IP during the study period. The e quivalence  in BCVA  will be declared if the two -sided 90 % 
Confidence Interval (CI) of the difference of BCVA  Least Squares mean (LS mean) change s from 
baseline at Week 8  between SB11 and Lucentis¬Æ lies within the pre -defined equivalence margin of [‚àí3 
letters, 3 letters ].  
For EMA or other regulatory agency submiss ions for those who are in favour of the anatomical 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 9 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
parameter, the primary efficacy analysis will be performed for the per -protocol set (PPS -CST)  with the 
change from baseline of CST at Week 4 using an analysis of covariance model with baseline CST as a 
covariate  and region (or pooled centres) and treatment group as factors . The PPS -CST consists of all 
FAS subjects who have the first  IP injection at Week 0  (Day 1)  and complete procedures at Week 4  
without any major protocol deviations that have impact on the  CST assessment. The equivalence in 
CST will be declared if the two -sided 95% CI of the difference of CST LS mean change s from baseline 
at Week 4 between SB11 and Lucentis¬Æ lies within the pre -defined equivalence margin  of [‚àí36 Œºm, 36 
Œºm]. 
There is no form al adjustment of type I error rates.  
For the primary analysis with the FAS for BCVA, missing data will be imputed for subjects who drop 
out for the study prior to the primary analysis time -point. A missing -at-random approach will assume 
that subjects who withdraw from a study had missing values similar to similar subjects who completed 
the study in that treatment group. This approach ensures that evidence of lack of equivalence is not diluted when there are missing data. For the components of BCVA, the missing letter will be imputed by multiple imputation method with the assumption of monotone missing pattern and regression method. For the sensitivity analyses, available case analysis and last observation carried forward 
analysis will be performed. All othe r efficacy measurements will be summarised descriptively by 
treatment group and visit.  
Safety analyses  
All reported terms for AEs (ocular or systemic) will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA¬Æ). AEs  including ocular AEs in the study eye and/or fellow eye as 
well as systemic AEs  will be summarised descriptively by treatment group.  
Changes in vital signs and clinical laboratory parameters  will be summarised descriptively by treatment 
group and visit. All other safety varia bles will be summarised descriptively by treatment group and visit 
unless specified otherwise, and all safety variables will be listed.  
Pharmacokinetic analyses  
Blood sampling for PK  will be collected in approximately 40 subjects participating in PK evalua tion 
(20 subjects per treatment group). Formal PK analysis will not be performed. The systemic exposure 
will be summarised descriptively by treatment group  and visit.   
Immunogenicity analyses  
The number and proportion  of subjects with ADA and NAb results ( e.g., ‚Äúpositive‚Äù or ‚Äúnegative‚Äù) will 
be summarised by treatment group and visit.  
NEI VFQ -25 analyses  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 10 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
Subscale scores (general health, general vision, ocular pain, near activities, distance activities, vision -
specific social functioning, vision -specific men tal health, vision -specific role difficulties, vision -
specific dependency, driving, colo ur vision, and peripheral vision) and the composite score, which 
represent overall visual function, will be  calculated, and the change from baseline will be  summarised 
by treatment group and visit.  
Sample size calculation  
For the calculation of the equivalence margin  for BCVA , the mean change s in VA were referred from 
two studies of Lucentis¬Æ in subjects with neovascular AMD. In MARINA study, the mean change of 
VA at Week 24  (Standard D eviation  [SD]) were ‚àí 6.6 (13.31) letters and 6.5 (12.00) letters for placebo 
and 0.5 mg Lucentis¬Æ treatment groups, respectively. In FOCUS study, the mean change (SD) of VA at 
Week 24 were ‚àí5.0 (16.14) letters and 4.0 (14.41) letters for pl acebo and 0.5 mg Lucentis¬Æ treatment 
groups , respectively.  
A fixed -effect meta -analysis of the above two studies estimates a weighted mean change in VA of 12.41 
letters with a 95% CI [10.34  letters , 14.48  letters ]. The derived equivalence limit from meta -analysis is 
4.9 letters at Week 24, but by the agency recommendation the equivalence limit at Week 8 will be 3 
letters for the comparison with the 90% CI of mean difference between treatment groups.  
With the given equivalence margin of [‚àí3 letters, 3 letters], 334 subjects  per treatment group  was 
calculated with the assumptions of the mean difference of 0.5 letters and pooled SD of 12.5 letters at the 
overall 5% significance level. Assuming a 5% loss from randomi sed subjects  after 8 weeks , a sample 
size of 352 subjects  per treatment group  (overall sample size of 704) will give 334 completers per 
treatment group  after 8 weeks , which is estimated to give 80% power to detect the equivalence of 
change from baseline in BCVA  within the margin of  3 letters.  
For the calculation of the equivalence margin for CST, the mean changes in CST were referred from two studies of Lucentis
¬Æ in subjects with neovascular AMD. In MARINA study, the mean change of 
CST at Week 4 (SD) was 8.1 (58.1)  Œºm and ‚àí106 (122.5) Œºm for placebo and 0.5 mg Lucentis¬Æ 
treatment groups, respectively. In PIER study, the mean change (SD) of CST at Week 4 were 15 (94.9) Œºm and ‚àí90 (140.9) Œºm for placebo and 0.5 mg Lucentis
¬Æ treatment groups, respectively.  
A fixed -effect meta -analysis of the above two studies estimates a weighted mean change in CST of 
109.6 Œºm with a 95% CI [ ‚àí146.45 Œºm; ‚àí72.65 Œºm]. The derived equivalence limit from meta- analysis 
is 36 Œºm at Week 4.  
With the given equivalence margin of [ ‚àí36 Œºm, 36 Œºm], 290 subjects per treatment group was 
calculated with the assumptions of the mean difference of 0 between treatment groups, common SD of 
133.3 Œºm at the overall 5% significance level. Assuming a 10% loss from FAS, a sample size of 323 per 
arm (overall sample size of 646) will give 80% power to detect the equivalence within the pre- defined 
margin.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 11 of 137 Name of Sponsor/Company:  Samsung Bioepis Co., Ltd.  
Name of Finished Product:  SB11 (proposed ranibizumab biosimilar)  
Name of Active Ingredient:  Ranibizumab  
Therefore, the sample size of 704 allows enough power to detect the equivalence between treatment 
groups in both situations.  
 
6%SURSRVHG UDQLEL]XPDEELRVLPLODU 
6%*$0'
$PHQGPHQW6HS 
6DPVXQJ%LRHSLV¬± &RQILGHQWLDO 
3DJHRI)/2:&+$576 

)LJXUH*UDSKLFDO6WXG\'HVLJQ 
,&),QIRUPHG &RQVHQW)RUP¬ä5DQGRPLVDWLRQ,79 ,QWUDYLWUHDO 2&72SWLFDO&RKHUHQFH7RPRJUDSK\ %&9$%HVW&RUUHFWHG9LVXDO $FXLW\3.3KDUPDFRNLQHWLF V
:ULWWHQLQIRUPHGFRQVHQW PXVWEHREWDLQHGIURPWKHVXEMHFWSULRUWRDQ\VWXG\UHODWHGSURFHGXUHV 
6FUHHQLQJPXVWEHGRQHZLWKLQGD\V SULRUWRUDQGRPLVDWLRQ 

SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 13 of 137 Table 1. Schedule of Activities  
Procedures  Study  Period 
W: Week  Screening  W0 W1 W4 W8 W12  W16  W20  W24  W28 W32  W36  W40  W44  W48  
EOT24 W52  
EOS / 
ET25 
D: Day 
 (¬± visit window)   D-21 to D -1 D1 D8  
(¬±3) D29 
(¬±7) D57 
(¬±7) D85 
(¬±7) D113  
(¬±7) D141  
(¬±7) D169  
(¬±7) D197  
(¬±7) D225  
(¬±7) D253  
(¬±7) D281  
(¬±7) D309  
(¬±7) D337  
(¬±7) D365  
(¬±7) 
V: Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 
Written i nformed consent1 X                
Inclusion/exclusion criteria  X X               
Demographic data2 X                
Medical/ophthalmic history  X                
Physical examination3 X               X 
Randomisati on4  X               
Vital signs5 X X X X X X X X X X X X X X X X 
BCVA examination6 X X7 X X X8 X X X X X X X X X X X 
OCT9 X X X X10 X X X X X X X X X X X X 
FP/FA11 X        X       X 
Indirect ophthalmoscopy12 
(pre- and post -dose)  X X X X X X X X X X X X X X X X 
Slit lamp examination13 X X X X X X X X X X X X X X X X 
Intraocular pressure14 
(pre- and post -dose)  X X X X X X X X X X X X X X X X 
NEI VFQ -2515  X       X       X 
Clinical l aboratory test16 X     X   X   X    X 
Blood sampling for 
immunoge nicity17  X X X X  X  X   X    X 
Blood sampling for PK18  X X X X  X  X   X    X 
Pregnancy test19 X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 
IP injection20  X21  X X X X X X X X X X X X  
Adverse event monitoring22 Continuously  
Prior  or concomitant  
medication  or therapy23 Continuously  
EOS, End of Study; EOT, End o f Treatment; ET, Early Termination ; ETDRS , Early Treatment Diabetic Retinopathy Study; FA, Fluorescein Angiography; FP, Fundus Photography; IP, 
Investigational Product; NEI VFQ -25, National Eye Institute 25 -item Visual Function Questionnaire; OCT , Optical Coherence Tomography ; PK, Pharmacokinetic s 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 14 of 137 1. Written informed consent must be obtained from the subject  prior to  any study related procedures  
2. Demographic data includes the date of birth  (or year of birth), gender, race and ethnicity.  
3. Physical examination will be performed at Screening and Week 52 ( EOS visit) or ET visit. The physical examination will include  an assessment of the subject‚Äôs general 
appearance, skin, head, neck, throat, lymph nodes, cardiovascular, neurological, thyroid, musculoskeletal/extremities , respiratory systems and the subject‚Äôs abdomen. 
Body weight will be measured and recorded at Screening and Week 52 ( EOS  visit)  or ET visit , but height will be measured and recorded only at Screening . 
4. All subjects ‚Äô eligibility should be  confirmed by the central reading  centre  and Investigator .  
5. Vital signs include blood pressure, pulse rate and body temperature. Vital signs will be assessed at Screening and prior to ITV i njection of IP at each visit until Week 48. 
Vital signs will also be assessed at any time during the visit at Week 52 (EOS visit) or ET visit.  
6. Visual acuity will be assessed in both the study eye and fellow  (non-study)  eye at Screening and prior to ITV injection of IP  at each visit until Week 48. Visual acuity 
will also be assessed at any time during the visit at Week 52 (EOS visit) or ET visit.  Subject must use either original series ETDRS chart s or 2702 series Number chart s 
(at a starting distance of 4 me ters) consistently from Screening to Week 52 (EOS visit) or ET visit. Visual acuity  testing must be performed before dilation of pupils  and 
FP/FA  and OCT assessment . A decrease in visual acuity of ‚â• 15 letters from the last assessment of VA should be reported as AEs/ Serious Adverse Events ( SAEs ) as 
appropriate. If there is a decrease in VA of ‚â• 30 letters from the last assessment of VA or if there is a decrease in VA to the level of Light Perception  or worse , it should 
be reported as SAE.  
7. Investigator must  confirm that the subject can read  between 34 letters to  73 letters  using original series ETDRS chart s or 2702 series Number chart s at Week 0 (Day1)  
prior to randomi sation   
8. Visit at Week 8 is the most critical as the visit is for the primary endpoint assessment for US FDA , Korea MFDS or other regulatory agency submissions for those who 
are in favour of the VA. Thus, every effort should be made to adhere to the visit schedule for the subjects.  
9. OCT  will be performed on the study eye  at Screening and prior to ITV injection of IP at each visit  until Week 48 .  OCT will also be performed at any time during the 
visit at Week 52 (EOS visit) or ET visit. Site staffs who will perform OCT scans in this study must be certified by the central reading centre before study starts.  OCT 
devices registered in an Investigational site should be all from the same manufacture and meet the minimum software requirement, The subject  should use the OCT 
device registered by the central reading centre from Screening to Week 52 (EOS visit)  or ET visit. OCT images will be sent to the central reading centre . 
10. Visit at Week 4 is the most critical as the visit is for the primary endpoint  assessment for EMA  or other regulatory agency subm ission s for those who are in favour of the 
anatomical parameter . Thus, every effort should be made to adhere to the visit schedule for the subjects.  
11. FP/FA  will be performed on the both eyes at Screening  and those images taken from the both eyes will be sen t to the central reading centre. FP/FA will also be 
performed on the study eye  prior to ITV injection of IP at Week 24  and at any time during the visit at  Week 52  (EOS visit) or ET visit. Those images taken from the 
study eye will be sent to the central re ading centre. Site staffs who will perform FA/FP in this study must be certified by the central reading centre before study starts. 
Only FP/FA  device certified by central reading centre is allowed to be used in this study. If one or more FP/FA  devices are certified in a n Investigational  site, a subject 
must use  the same FP/FA  device consistently from Screening to Week 52  (EOS visit)  or ET visit. If any significant change in the posterior pole (i.e. , subretinal 
haemorrhage, macular hole, vitreous ha emorrhage  or opacity, retinal detachment, etc. ) is detected with fundus examination, additional FP and/or FA can be performed at 
the Investigat or‚Äôs discretion , but the images will not be sent to the central reading centre.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 15 of 137 12. Indirect ophthalmoscopy using a standard w ay (i.e., usually using a head -mounted light source and a 20- 30 lens) will be performed on  the study eye at Screening and  
prior to ITV injection o f IP and within 15 minutes after ITV injection of IP  at each visit  until Week 48. Indirect ophthalmoscopy will  also be performed  at any time 
during the visit at  Week 52 (EOS visit) or ET visit . 
13. Slit lamp examination will be performed in both the study eye and fellow eye  (non- study eye)  at Screening and prior to ITV injection of IP  at each visit until Week 48. 
Slit lamp examination will also be performed at any time during the visit at Week 52 (EOS visit) or ET visit.  
14. Intraocular Pressure ( IOP) will be measured using Goldmann applanation tonometry. The same method of IOP measurement must be used in each subject from 
Screening to Week 52 (EOS visit)  or ET visit . IOP will be measured on  the study eye at Screening and  prior to ITV injection of IP and 30- 60 minutes after ITV injection 
of IP at each visit until Week 48. When IOP is measured prior to ITV injection of IP, IOP should be measured after OCT and FP/FA are completed  to avoid corneal 
erosion . IOP will also be measured at any time during the visit at Week 52 (EOS visit) or ET visit.  
15. NEI VFQ- 25 should be performed at Week 0 (Day1) after randomisation. Then,  NEI VF Q-25 should be performed  before  dilation of pupil at Week 0 (Day 1), Week 24  
and Week 52  (EOS visit) or ET visit. 
16. Blood and urine sampling for clinical laboratory test will be collected at Screening and prior to ITV injection of IP  at Week 12, Week 24, and  Week 36 . Blood and urine 
sampling for clinical laboratory test will also be collected at any time during the visit at Week 52 (EOS visit) or ET visit. Urine samples must be collected  before 
performing FA to avoid false elevations in urine protein values . 
‚Ä¢ Haematology: haemoglobin, haematocrit, platelet count, white blood cell count (total and differential)  
‚Ä¢ Chemistry: sodium, potassium, creatinine, glucose, calcium, phosphorus, total bilirubin, albumin, alanine aminotransferase, aspartate am inotransferas e, alkaline 
phosphatase, lactate dehydrogenase  
‚Ä¢ Urinalysis  (dipstick) :  protein, blood, leucocytes, nitrite, glucose, ketone, pH, specific gravity, bilirubin, urobilinogen  
Blood samples will be analysed in central laboratory and urine samples will be tested in each Investigational site by using a dipstick which will be provided by Sponsor.  
17. Blood sampling for immunogenicity will be collected  prior to ITV injection of IP at Week 0  (Day 1) , Week 4, Week 8, Week 16, Week 24, and Week 36 . Blood 
sampling for imm unogenicity will  also be collected at any time during the visit at Week 1 and Week 52 (EOS visit)  or ET visit. 
18. Blood sampling for PK will be collected in  approximately 40 subjects participating in PK evaluation  (20 subjects  per treatment group). Blood samp ling for PK will 
be collected  prior to ITV injection of IP (C trough) and 24-72 hours after ITV injection  of IP (close to C max) on Week 0  (Day 1) , Week 4, Week 8, Week 16, Week 24, and 
Week 36 . Blood samples for PK will also be collected at any time during the visit at Week 1 and Week 52 (EOS visit).  
19. For women  of childbearing potential , serum pregnancy test must be performed at Screening . The serum samples taken  at Screening will be analysed in central 
laboratory. Additional serum or urine pregnancy test can be performed in each Investigational site  during the study period , if necessary.  
20. Subjects will be administered SB11 or Lucentis¬Æ 0.5 mg via ITV into the study eye every 4 weeks up to Week 48. Dosing visits will be allowed within ¬± 7 days of the 
scheduled  dosing visit date  (except Week 0 (Day 1), visit window not allowed) . If a dose of IP is not given within 7 days of the scheduled dosing visit date, the IP should 
be given within 20 days of the scheduled dosing visit date, but the case will be captured as protocol deviation. Dosing skip is defined when a subject does not receive the 
IP within 20 days after scheduled dosing visit  date. Next scheduled dosing visit date and visit window should not be altered even though previous dosing is not 
performed on the exact scheduled dosing visit date (but, the interval between two doses injected into the study eye should be at least 14 days ) or previous dosing is 
skipped.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 16 of 137 21. The first ITV injection of IP and all other study procedures must be performed at the same day of  randomisation or the following day after randomisation at the latest 
with a proper reason .  
22. Ocular AEs  in the study eye and/or fellow eye  as well as systemic  AEs will be recorded after the written informed consent is obtained from the subject  until Week 5 2 
(EOS visit ) or ET visit. 
23. Any medications including prescription drug, non -prescription drugs  or any therapy (except dietary supplements vitamins , minerals ) received locally (in the study eye 
and/or fellow eye) or systemically within 180 days prior to Scr eening until Week 52 (EOS visit)  or ET visit will be recorded . 
24. End of Treatment (EOT) v isit is defined as the visit for the last ITV injection of SB11 or Lucentis¬Æ during the study period after randomisation . The Sponsor will not 
provide IP (SB11 or Lucent is¬Æ) to subjects after they complete the EOT visit. 
25. End of Study (EOS) visit or Early Termination (ET) visit is defined as 4 weeks (¬± 7 days) after the last ITV injection of SB11 or Lucentis¬Æ. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 17 of 137  
Table 2. Blood Sampling  Schedule for PK, Immunogenicity  and Clinical Laboratory Test  
Visit  Week  
(¬± visit window)  Sampling time  PK sampling  
(Only in subjects participating 
PK evaluation)  Immunogenicity sampling  
(in all randomised subjects)  Clinical laboratory test  
(in all randomised subjects)  
V1 Screening  D-21 to D-1 - - O* 
V2 Week 0  Prior to ITV injection  O O - 
24-72 hr after ITV injection  O - - 
V3 Week 1 (¬± 3  days ) Samples to be collected at any time during the visit  O O - 
V4 Week 4 (¬± 7 days ) Prior to ITV injection  O O - 
24-72 hr  after ITV injection  O - - 
V5 Week 8 (¬± 7 days ) Prior to ITV injection  O O - 
24-72 hr after ITV injection  O - - 
V6 Week 12 (¬± 7 days ) Prior to ITV injection  - - O 
V7 Week 16 (¬± 7 days ) Prior to ITV injection  O O - 
24-72 hr after ITV injection  O - - 
V9 Week 24 (¬± 7 days ) Prior to ITV injection  O O O 
24-72 hr after ITV injection  O - - 
V12 Week 36 (¬± 7 days ) Prior to ITV injection  O O O 
24-72 hr after ITV injection  O - - 
V16 Week 52  (EOS visit)  
 (¬± 7 days ) Samples to be  collected  at any time during the visit O O O 
- ET visit (¬± 7 days)  Samples to be collected at any time during the visit  - O O 
* in all subjects who signed written informed consent  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 18 of 137 LIST OF ABBREVIATIONS  
ADA  Anti-drug Antibody 
AE Adverse Event  
AESI  Adverse Events of Special Interest  
AMD Age-related Macular Degeneration  
BCVA Best Corrected Visual Acuity  
CFT Central Foveal Thickness  
CI Confidence Interval 
CNV  Choroidal  Neovascularisation  
CPT Centre Point Thickness  
CRLT  Central Retinal Lesion Thickness 
CRO  Contract Res earch Organisation  
CSR Clinical Study Report 
CST Central Subfield Thickness  
DA Disc Area  
DME  Diabetic Macular Oedema 
DR Diabetic Retinopathy  
DSMB  Data and Safety Monitoring Board 
eCRF  Electronic Case Report Form  
EMA  European Medicines Agency 
EOS  End of Study 
EOT  End of Treatment  
ET Early Termination  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 19 of 137 ETDRS  Early Treatment Diabetic Retinopathy Study 
FA  Fluorescein Angiography 
FAS Full Analysis Set  
FDA Food and Drug Administration 
FP Fundus Photography 
GCP  Good Clinical Practice  
HUVEC  Human Umbilical Vein Endothelial Cells  
IB Investigator‚Äôs Brochure  
ICF Informed Consent Form 
ICH International Council for  Harmonisation 
IEC Independent Ethics Committee 
ILM Internal Limiting Membrane  
IOL Intraocular Lens 
IOP Intraocular Pressure 
IP Inves tigational Product  
IRB Institutional Review Board  
ITV Intravitreal  
IWRS  Interactive Web Recognition System  
LS mean  Least Squares mean  
MedDRA  Medical Dictionary for Regulatory Activities  
MFDS  Ministry of Food and Drug Safety 
MoA Mechanism of Action  
NAb  Neutralising Antibody 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 20 of 137 NEI VFQ -25 National Eye Institute 25 -Item Visual Function Questionnaire 
OCT  Optical Coherence Tomography  
PDT  Photodynamic Therapy 
PK Pharmacokinetics  
PKS Pharmacokinetic analysis set  
PM Pathologic Myopia 
PPS Per-protocol Set 
QOL  Quality of Life  
RAN  Randomised Set 
RPE Retinal Pigment Epitheli um 
RVO Retinal Vein Occlusion  
SAE  Serious Adverse Event  
SAF Safety Set  
SAP Statistical Analysis Plan  
SD Standard Deviation 
SOP Standard Operation Procedure 
TEAE  Treatment -Emerge nt Adverse Event  
US United States  
VA Visual Acuity  
VEGF  Vascular Endothelial Growth Factor 
WHO- DDE  World Health Organi sation -Drug Dictionary Enhanced 
YAG  Yttrium Alumin ium Garnet 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 21 of 137 TABLE OF CONTENTS  
SYNOPSIS  .................................................................................................................................. 2  
FLOW  CHARTS  ....................................................................................................................... 12  
LIST OF ABBREVIATIONS  ................................................................................................... 18  
TABLE O F CONTENTS  .......................................................................................................... 21  
LIST OF TABLES  .................................................................................................................... 24  
LIST OF FIGURES  .................................................................................................................. 24  
LIST OF STUDY STAFF ......................................................................................................... 25  
1. INTRODUCTION ................................................................................................................. 26  
1.1. Background .................................................................................................................... 26  
1.2. Lucentis¬Æ: Ranibizumab Reference Product  .................................................................. 26  
1.3. SB11: Proposed Ranibizumab Biosimilar  ...................................................................... 30  
1.4. Rationale for the Study  ................................................................................................... 30  
2. STUDY OBJECTIVES  ......................................................................................................... 31  
2.1. Primary Objective  .......................................................................................................... 31  
2.2. Secondary Objective  ...................................................................................................... 31  
3. STUDY DESIGN  .................................................................................................................. 31  
3.1. Overview of Study Design ............................................................................................. 31  
3.2. Rationale f or the Study Design  ...................................................................................... 31  
4. STUDY POPULATION  ....................................................................................................... 33  
4.1. Inclusion Criteria  ............................................................................................................ 33  
4.2. Exclusion Criteria ........................................................................................................... 34  
4.3. Subject Discontinuation from Investigational Product  .................................................. 37  
4.4. Replacement  ................................................................................................................... 39  
5. TREATMENT AND INVESTIGATIONAL PRODUCT  .................................................... 39  
5.1. Treatment of the Subjects  ............................................................................................... 39  
5.1.1. Dosing and Treatment Schedule  ......................................................................... 39  
5.1.2. Withholding Investigational Products  ................................................................. 40  
5.2. Investigational Product  ................................................................................................... 40  
5.2.1. Identity of Investigational Product  ...................................................................... 40  
5.2.2. Assignment of Subject Number  .......................................................................... 41  
5.2.3. Masking  ............................................................................................................... 41  
5.2.4. Unmasking .......................................................................................................... 42  
5.2.5. Investigational Product Treatment Compliance and Accountability  ................... 42  
5.2.6. Investigational Product Administration  .............................................................. 43  
5.3. Prohibited Medication or Therapy  ................................................................................. 43  
5.4. Fellow Eye Treatment  .................................................................................................... 44  
6. STUDY VARIABLES  .......................................................................................................... 45  
6.1. Study Endpoints  ............................................................................................................. 45  
6.1.1. Primary Endpoint  ................................................................................................ 45  
6.1.2. Secondary Endpoints  ........................................................................................... 45  
6.1.3. Exploratory Endpoint  .......................................................................................... 46  
6.2. Efficacy Assessments  ..................................................................................................... 46  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 22 of 137 6.2.1. Best Corrected Visual Acuity  .............................................................................. 46  
6.2.2. Anatomical Parameters  ....................................................................................... 47  
6.3. Safety Assessments  ........................................................................................................ 47  
6.3.1. Adverse Events  .................................................................................................... 47  
6.3.2. Clinical Laboratory Test  ..................................................................................... 47  
6.3.3. Pregnancy Test  .................................................................................................... 48  
6.3.4. Physical Examination .......................................................................................... 49  
6.3.5. Vital Signs  ........................................................................................................... 49  
6.4. Ophthalmic Assessments  ............................................................................................... 49  
6.4.1. Full Ophthalmic Examinations ............................................................................ 49  
6.4.2. Optical Coherence Tomography (OCT)  .............................................................. 50  
6.4.3. Fundus Photography (FP) and Fluorescein Angiography (FA)  .......................... 51  
6.5. Pharmacokinetic Assessment  ......................................................................................... 51  
6.6. Immunogenicity Assessment  ......................................................................................... 52  
6.7. NEI VFQ-25  ................................................................................................................... 52  
7. STUDY PROCEDURES  ...................................................................................................... 53  
7.1. Visit 1 (Screening, D-21 to D-1)  .................................................................................... 53  
7.2. Visit 2 (Week 0/Day 1)  .................................................................................................. 55  
7.3. Visit 3 (Week 1 ¬± 3 days)  .............................................................................................. 56  
7.4. Visit 4 (Week 4 ¬± 7 days)  .............................................................................................. 57  
7.5. Visit 5 (Week 8 ¬± 7 days)  .............................................................................................. 58  
7.6. Visit 6 (Week 12 ¬± 7 days)  ............................................................................................ 59  
7.7. Visit 7 (Week 16 ¬± 7 days)  ............................................................................................ 60  
7.8. Visit 8 (Week 20 ¬± 7 days)  ............................................................................................ 61  
7.9. Visit 9 (Week 24 ¬± 7 days)  ............................................................................................ 62  
7.10. Visit 10 (Week 28 ¬± 7 days) ......................................................................................... 63  
7.11. Visit 11 (Week 32 ¬± 7 days) ......................................................................................... 64  
7.12. Visit 12 (We ek 36 ¬± 7 days) ......................................................................................... 65  
7.13. Visit 13 (Week 40 ¬± 7 days) ......................................................................................... 66  
7.14. Visit 14 (Week 44 ¬± 7 days) ......................................................................................... 67  
7.15. End of Treatment Visit (Visit 15, Week 48 ¬± 7 days)  .................................................. 68  
7.16. End of Study (Visit 16, Week 52 ¬± 7 days) or Early Termination Visit  ...................... 69  
7.17. Early Termination of the Study  .................................................................................... 70  
8. SAFETY MONITORING AND REPORTING  .................................................................... 70  
8.1. Adver se Events ............................................................................................................... 70  
8.1.1. Definition of Adverse Event  ............................................................................... 70  
8.1.2. Period of Observation for Adverse Events  .......................................................... 70  
8.1.3. Reporting Adverse Events  ................................................................................... 71  
8.1.4. Severity Assessment  ............................................................................................ 71  
8.1.5. Causality Assessment  .......................................................................................... 72  
8.1.6. Emergency Unmasking for Safety Reasons  ........................................................ 72  
8.1.7. Expectedness Assessment  ................................................................................... 72  
8.1.8. Withdrawal due to Adverse Events  ..................................................................... 73  
8.2. Serious Adverse Events .................................................................................................. 73  
8.2.1. Definition of Serious Adverse Event  .................................................................. 73  
8.2.2. Reporting Serious Adverse Events  ...................................................................... 75  
8.3. Adverse Events of Special Interest ................................................................................. 76  
8.4. Pregnancy  ....................................................................................................................... 76  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 23 of 137 8.5. Independent Data and Safety Monitoring Board  ............................................................ 76  
9. STATISTICAL MET HODS AND DATA ANALYSIS  ....................................................... 77  
9.1. Analysis Sets  .................................................................................................................. 77  
9.2. Statistical Methods and Analytical Plan ......................................................................... 78  
9.2.1. Demographics and Baseline Characteristics  ....................................................... 78  
9.2.2. Efficacy  ............................................................................................................... 79  
9.2.3. Safety ................................................................................................................... 79  
9.2.4. Pharmacokinetics  ................................................................................................ 80  
9.2.5. Immunogenicity  .................................................................................................. 80  
9.2.6. NEI VFQ-25 ........................................................................................................ 80  
9.3. Determination of Sample Size  ....................................................................................... 81  
10. DATA COLLECTION AND MANAGEMENT  ................................................................ 82  
10.1. Data Confidentiality  ..................................................................................................... 82  
10.2. Monitoring  ................................................................................................................... 82  
10.3. Data Handling and Record Keeping  ............................................................................. 83  
10.4. Database Management and Coding  .............................................................................. 83  
10.5. Quality Control and Quality Assurance  ....................................................................... 84  
11. ETHICAL CONSIDERATIONS AND ADMINISTRATIVE PROCEDURES  ................ 84  
11.1. Institutional Review Boards and Independent Ethics Committees  .............................. 84  
11.2. Ethical Conduct of the Study  ....................................................................................... 85  
11.3. Written Informed Consent  ............................................................................................ 85  
11.4. Investigator Information ............................................................................................... 85  
11.4.1. Investigator Obligations  .................................................................................... 85  
11.4.2. Coordinating Investigator  .................................................................................. 86  
11.4.3. Tra ining of Investigational Site Personnel  ........................................................ 86  
11.4.4. Protocol Signatures  ........................................................................................... 86  
11.5. Financing and Insurance  .............................................................................................. 86  
12. PUBLICATION POLICY ................................................................................................... 87  
13. REFERENCES .................................................................................................................... 88  
APPENDIX A: Grading Scale for Anterior Ch amber Flare  ..................................................... 90  
APPENDIX B: Grading Scale for Anterior Chamber Cells ...................................................... 91  
APPENDIX C: Grading Scale for Anterior Chamber and Vitreal Inflammatory Response  ..... 92  
APPENDIX D: National Eye Institute 25 -Item Visual Function Questionnaire (NEI VFQ-25 
questionnaire)  .................................................................................................................... 93  
PROTOCOL SIGNATURE PAGES  ...................................................................................... 104  
AMENDMENT 1: Sep 01, 2017  ............................................................................................. 107  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 24 of 137 LIST OF TABLES  
Table 1 . Schedule of Acti vities  ...................................................................................................... 13  
Table 2 . Blood Sampling Schedule for PK, Immunogenicity and Clinical Laboratory Test  ......... 17  
Table 3 . Visual Acuity Outcomes at Month 12 and Month 24 in Studies  ..................................... 28  
Table 4 . Visual Acuity Outcomes at Month 6 in Studies  ............................................................... 29  
Table 5 . Visual Acuity Outcomes at Month 24 in Studies  ............................................................. 29  
Table 6 . ‚â•3-step and ‚â•2-step Improvement at Month 24 in Study D-1 and Study D-2  ................. 29  
Table 7 . Investigational Products  ................................................................................................... 41  
Table 8 . Prohib ited Medication and Therapy  ................................................................................. 43  
Table 9 . Parameters for Clinical Laboratory Tests  ........................................................................ 48  
 
LIST OF FIGURES  
Figure 1 . Graphical Study Design .................................................................................................. 12  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 25 of 137 LIST OF STUDY STAFF  
SPONSOR : Samsung Bioepis Co., Ltd.  
107, Ch eomdan-daero, Yeonsu- gu, 
Incheon, 21987 
Republic of Korea  
Tel: +82 (32) 455 3114  
Fax: +82 (32) 455 6799  
 
Clinical Project Manager   
 
  
 
Clinical Research 
Physician   
 
  
 
Clinical Research 
Scientist  
 
 
Clinical Development 
Associate   
 
 
Statistician    
 
  
 
Project Safety Lead   
 
 
 
Safety Physician   
 
 
 

SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 26 of 137 1. INTRODUCTION 
1.1. Backg round  
Age-related  Macular  Degeneration  (AMD) , left untreated, is a leading cause of adult blindness 
in the developed world. Most of severe visual loss of AMD occurs from Choroidal 
Neovascularisation ( CNV) or the neovascular form of AMD. Choroidal neovascul arisation  
can be associated with fibrous replacement of the  retinal photoreceptors and Retinal Pigment 
Epithelium (RPE), as well as atrophy of these portions of the retina in the macula, leading to 
severe visual decline with loss of reading vision, driving vision, and the ability to recognise 
faces. Vascular Endothelial Growth F actor  (VEGF) , a protein growth factor that both 
stimulates angiogenesis and increases vascular permeability, is a major pathogenic factor in 
CNV due to AMD. Counteracting these effec ts of VEGF  can provide significant therapeutic 
benefit to subjects suffering from this disorder. 
In developed countries, AMD is a leading cause of severe visual loss in people 65 years of age 
and older in the US, an estimated 6% of individuals aged 65 to 74, and 20% of those older than 75 are affected with some stage of AMD. Also, among white people aged 40 years and older, AMD is the number one cause of visual impairment and blindness in the US. The pathogenesis of AMD is poorly understood. It is character ised by development of focal 
deposits of long ‚Äìspacing collagen and phospholipid vesicles within and beneath the basement membrane of the RPE, called ‚Äúdrusen‚Äù which can be accompanied by gradual degeneration of photoreceptors and RPE (atrophy), which often results in slow deterioration of central Visual 
Acuity  (VA) . This thickening and degeneration of Bruch‚Äôs membrane can predispose to 
abnormal growth of blood vessels from the choriocapillaris, termed choroidal neovascularization. The occurrence of CNV hera lds the onset of neovascular AMD. Leakage 
from the CNV can cause macular oedema with collection of fluid and blood beneath and within the macula, resulting in loss of vision. Growth of the lesions with accompanying fibrovascular or fibroglial tissue furthe r destroys retinal tissue. Overtime, the CNV promotes 
scarring that damages photoreceptors and the RPE, resulting in permanent vision loss. Neovascular or ‚Äúwet‚Äù AMD accounts for only 10% of cases of AMD yet results in 90% of the severe vision loss. Epidemi ological studies suggest that ‚Äúwet‚Äù AMD will develop in almost 1 
million persons in the US within the next 5 years [ Wu EW  et al., 2014, Macular 
Photocoagulation Study Group. 1991 ]. 
1.2. Lucent is
¬Æ: Ranibizumab Reference Product 
Lucentis¬Æ is approved for indications including neovascular (wet) AMD, visual impairment 
due to D iabetic Macular Oedema (DME) and visual impairment due to macular oedema 
secondary to Retinal Vein Occlusion (branch RVO or central RVO) by both the US FDA and 
EMA. In addition, the FDA approved Lucentis¬Æ for the treatment of Diabetic Retinopathy 
(DR) in subjects with DME and the EMA approved Lucentis¬Æ for the treatment of visual 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 27 of 137 impairment due to CNV secondary to Pathologic My opia (PM)  [Lucentis¬Æ Prescribing 
Information. 2016, Lucentis¬Æ Summary of Product Characteristics. 2016 ] 
Mechanism of Action  
Ranibizumab binds to the receptor bindi ng site of active forms of VEGF -A, including the 
biologically active, cleaved form of this molecule, VEGF 110. VEGF -A has been shown to 
cause neovascularisation  and leakage in models of ocular angiogenesis and vascular occlusion 
and is thought to contribute to pathophysiology of neovascular AMD, macular oedema 
following RVO, DR and DME. The binding of ranibizumab to VEGF- A prevents the 
interaction of VEGF -A with its receptors (VEGFR1 and VEGFR2) on the surface of 
endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation  [Lucentis¬Æ Summary of Product Characteristics. 2016 ]. 
Pharmacodynamics  
Increased retinal thickness (i.e., Centre  Point Thickness [CPT]  or C entral Foveal Thickness 
[CFT]), as assessed by OCT is associated with the activity of  neovascular AMD, macular 
oedema following RVO, and DME. Leakage from CNV  as assessed by FA is also associated 
with the activity of neovascular AMD . 
Microvascular retinal changes  and 
neovascularisation , as assessed by colo ur FP, are associated with diabetic retinopathy 
[Lucentis¬Æ Prescribing Information. 2016].  
Pharmacokinetics  
Following monthly ITV administration of Lucentis¬Æ to pat ients with neovascular AMD, serum 
concentrations of ranibizumab were generally low, with maximum levels (C max) generally 
below the ranibizumab concentration necessary to inhibit the biological activity of VEGF by 
50% (11- 27 ng/ml, as assessed in an in vitr o cellular proliferation assay). C max was dose 
proportional over the dose range of 0.05 to 1.0 mg/eye. Serum concentrations in a limited 
number of DME patients indicate that a slightly higher systemic exposure cannot be excluded compared to those observed in neovascular AMD patients. Serum ranibizumab concentrations 
in RVO patients were similar or slightly higher compared to those observed in neovascular 
AMD patients. 
Based on analysis of population pharmacokinetics and disappearance of ranibizumab from 
serum for patients with neovascular AMD treated with the 0.5 mg dose, the average vitreous elimination half -life of ranibizumab is approximately 9 days. Upon monthly ITV 
administration of Lucentis
¬Æ 0.5 mg/eye, serum ranibizumab C max, attained approximately 1 
day after dosing, is predicted to generally range between 0.79 and 2.90 ng/ml. Serum ranibizumab concentrations are predicted to be approximately 90,000-fold lower than vitreal ranibizumab concentrations [ Lucent is¬Æ Summary of Product Characteristics. 2016 ]. 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 28 of 137 Efficacy  
Neovascular (Wet) Age- Related Macular Degeneration  
The safety and efficacy of L ucentis¬Æ were assessed in three randomis ed, double or single -
masked, sham -or active- controlled studies in subjects with neovascular AMD.  
Table 3. Visual Acuity O utcomes at Month 12 and Month 24 in Studies  
Study: MARINA  
Outcome  Month Sham  
(n = 229) Lucentis¬Æ 0.5 mg  
(n = 230) 
Loss of <15 letters in VA  12 60% 91% 
24 56% 89% 
Gain  of ‚â•15 letters in VA  12 6% 31% 
24 4% 30% 
Mean change in VA (letters)  12 ‚àí11.0 (17.9)  +6.3 (14.1)  
24 ‚àí15.0  (19.7)  +5.5 (15.9)  
Study: ANCHOR  
Outcome  Month Verteporfin PDT  
(n = 141) Lucentis¬Æ 0.5 mg  
(n = 139) 
Loss of <15 letters in VA  12 66% 98% 
24 65% 93% 
Gain of ‚â•15 letters in VA  12 11% 37% 
24 9% 37% 
Mean change in VA (letters)  12 ‚àí8.5 (17.8)  +11.0 (15.8)  
24 ‚àí9.1 (18.7)  +10.9 (17.3)  
Study: FOCUS  
Outcome  Month Verteporfin PDT  
(n = 56) Lucentis¬Æ 0.5 mg+  
Verteporfin PDT  
(n = 105) 
Loss of <1 5 letters in VA  12 68% 91% 
24 75% 88% 
Gain of ‚â•15 letters in VA  12 5% 24% 
24 7% 25% 
Mean change in VA (letters)  12 ‚àí8.2 (16.3)  +4.9 (14.7)  
24 ‚àí7.8 (18.0)  +4.6 (16.7)  
Study: PIER  
Outcome  Month Sham 
(n = 63) Lucentis¬Æ 0.5 mg  
(Quarterly dosing)  
(n = 61) 
Loss of <15 letters in VA  12 49% 90% 
Mean change in VA (letters)  12 ‚àí16.3 ‚àí0.2 
PDT , Photodynamic T herapy  
Source: Lucentis¬Æ Prescribing Information. U. S. Food and Drug Administration. Nov 2016.  
Am J Ophthalmol. 2006;124:1532 -1542.  
Am J Ophthalmol.  2008;145:862- 874. 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 29 of 137 Macular Oe dema Following Retinal Vein Occlusion 
The safety and efficacy of Lucentis¬Æ were assessed in two randomis ed, double- masked, 1 -year 
studies in subjects with macular oedema following RVO.  
Table 4. Vis ual Acuity Outcomes at Month 6 in Studies 
Study: BRAVO  
Outcome  Month Sham  
(n = 131) Lucentis¬Æ 0.5 mg  
(n = 132) 
Gain of ‚â•15 letters in VA  6 29% 61% 
Mean change in VA (letters)  6 +7.3 +18.3  
Study: CRUISE  
Outcome  Month Sham  
(n = 130) Lucentis¬Æ 0.5 mg  
(n = 130) 
Gain of ‚â•15 letters in VA  6 17% 48% 
Mean change in VA (letters)  6 +0.8 +14.9  
Source: Lucentis¬Æ Prescribi ng Information. U. S. Food and Drug Administration. Nov 2016.  
 
Diabetic Macular Oe dema  
The safety and efficacy of Lucentis¬Æ were assessed in two randomis ed, double-masked, 3-
year studies. All enrolled subjects had DR and DME at baseline 
Table 5. Visual Acuity O utcomes at Month 24 in Studies  
Study: RIDE  
Outcome  Month Sham  
(n = 130) Lucentis¬Æ 0.3 mg 
(n = 125) 
Loss of <15 letters in VA  24 92% 98% 
Gain of ‚â•15 letters in VA  24 12% 34% 
Mean change in VA (letters)  24 +2.3 +10.9  
Study: RISE  
Outcome  Month Sham  
(n = 127) Lucentis¬Æ 0.3 mg 
(n = 125) 
Loss of <15 letters in VA  24 90% 98% 
Gain of ‚â•15 letters in VA  24 18% 45% 
Mean change in VA (letters)  24 +2.6 +12.5  
Source: Lucentis¬Æ Prescribing Information. U. S. Food and Drug Administration. Nov 2016.  
 
Diabetic Retinopathy in subjects with Diabetic Macular Oedema  
Efficacy and safety data of Lucentis¬Æ are d erived from studies RIDE  and RISE . 
Table 6. ‚â•3- step and ‚â•2 -step I mprovement at Month 24 in Study D -1 and Study D -2 
Study: RIDE  
Outcome  Month Sham  
(n = 130) Lucentis¬Æ 0.3 mg  
(n = 125) 
‚â•3-step improvement from 
baseline in ETDRS -DRSS  24 2% 17% 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 30 of 137 Study: RIDE  
Outcome  Month Sham  
(n = 130) Lucentis¬Æ 0.3 mg  
(n = 125) 
‚â•2-step improvement from 
baseline in ETDRS -DRSS  24 4% 39% 
Study: RISE  
Outcome  Month Sham  
(n = 127) Lucentis¬Æ 0.3 mg  
(n = 125) 
‚â•3-step improvement from 
baseline in ETDRS -DRSS  24 0% 9% 
‚â•2-step improvement from 
baseline in ETDRS -DRSS  24 7% 37% 
ETDRS -DRSS , Early Treatment Diabetic Retinopathy Study -Diabetic Retinopathy Severity Scale  
Source: Lucentis¬Æ Prescribing Information. U. S. Food and Drug Administration. Nov 2016.  
1.3. SB11 : Proposed Ranibizumab Biosimilar  
Samsung Bioepis Co., Ltd . (Incheon, Republic of Korea) has developed SB11, a proposed 
biosimilar of the  ranibizumab reference product. SB11 is produced by recombinant DNA 
technology in Escherichia coli cells. Extensive characterisation studies including intact mass, 
N- and C-terminal sequencing, peptide mapping, icIEF, CE-SDS (reduced, non-reduced), SE-
HPLC , amino acid composition, disulfide bond, VEGF binding, VEGF neutralisation , and 
Human Umbilical Vein Endothelial Cells ( HUVEC ) anti-proliferation were  performed using 
state-of-the- art techniques. Assays such as CEX -HPLC, UV absorption spectra, free thiol 
group quantification, SEC- MALS, SV -AUC, CD, DSC and FT -IR were  performed for both 
non-clinical and clinical materials.  
After extensive quality similarity studies, a series of in vitro non-clinical studies including 
VEGF binding assay and cell- based assays (HUVEC anti -proliferation assay and VEGF 
neutralizing assay)  were  performed to demonstrate similarity in in vivo  behavio ur between 
SB11 and Lucentis¬Æ.  
1.4. Rationale for the Study  
A biosimilar is a biological medicinal product that is highly similar to an alre ady authorised 
original biological medicinal product (reference medicinal product) in terms of quality, 
tolerability, and efficacy based on a comprehensive comparability exercise 
[EMA/CHMP/BMWP/403543/2010, EMEA/CHMP/437/04 , U. S. Food and Drug 
Administration . 2015] . The EMA  and the US FDA have developed specific guidelines for a 
biologic drug to be approved as a biosimilar [ EMA/CHMP/BMWP/403543/2010, U. S. Food 
and Drug Administration. 2015, EMA/CHMP/BWP/247713/2012] . These guidelines 
recommend a stepwise approach in develop ing a biosimilar starting with extensive 
physicochemical and biological characterisation before initiating clinical studies for the 
comparison of the efficacy, tolerability, pharmacokinetic properties, and immunogenicity of the biosimilar.  The purpose of t his study is to demonstrate the equivalence of efficacy of SB11 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 31 of 137 to Lucentis¬Æ and to evaluate the safety  and immunogenicity in subjects with neovascular 
AMD. In addition, systemic exposure of SB11 to Lucentis¬Æ will also be evaluated  in subjects 
participatin g in PK evaluation. 
2. STUDY OBJECTIVES  
2.1. Primary Objective  
‚Ä¢ To demonstrate the equivalence of efficacy of SB11 to Lucentis¬Æ in subjects with 
neovascular AMD  
2.2. Secondary Objective  
‚Ä¢ To evaluate the safety of SB11 and Lucentis¬Æ 
‚Ä¢ To evaluate the immunogenicity of  SB11 and Lucentis¬Æ 
‚Ä¢       To evaluate the systemic exposure of SB11 and Lucentis¬Æ in subjects participating  in 
PK evaluation  
3. STUDY DESIGN 
3.1. Overview of Study Design 
This is a randomised, double -masked , parallel group, multi centre study to evaluate the 
efficacy, safety, pharmacokinetics and immunogenicity of SB11 compared to Lucentis¬Æ in 
subjects with neovascular AMD. Subjects will be randomised in a 1:1 ratio to receive either 
SB11 or Lucentis¬Æ 0.5 mg via ITV into the study eye every 4 weeks.  
The screening  period is 21 days . IP (SB11 or Lucentis¬Æ) will be given  until 48 weeks and the 
last assessment will be done at Week 52.  
3.2. Rationale for  the Study Design  
The purpose of this study is to demonstrate the equivalence of clinical efficacy of Lucentis¬Æ 
and SB11 i n subjects  with neovascular AMD.  
Although a Phase I comparative PK study comparing the proposed biosimilar product to reference product is a fundamental component in supporting a demonstration of biosimilarity 
[U. S. Fo od and Drug Administration. 2015 ], a Phase I comparative PK study has not been 
necessary to support a demonstration of biosimilarity due to negligible systemic exposure 
following ITV injection of ranibizumab. However, for supporting the assessment of over all 
systemic safety of SB11 relative to Lucentis
¬Æ, systemic exposures will be collected and 
compared in the subgroup population (approximately 40 subjects, 20 subjects per treatment 
group) in Phase III comparative efficacy study.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 32 of 137 Lucentis¬Æ is approved for indications including neovascular AMD, visual impairment due to 
DME and visual impairment due to macular oedema secondary to RVO by both the US FDA 
and EMA. In addition, the US FDA approved Lucentis¬Æ for the treatment of DR in subjects 
with DME and the EM A approved Lucentis¬Æ for the treatment of visual impairment due to 
CNV secondary to PM, respectively.  
Improvements of VA have been reported in the pivotal studies of the various indications. For 
example, at Month 12, the average benefit associated with Lucentis¬Æ over that of sham 
injection or PDT was approximately 13.1 to 20.8 letters, 5.9 or 11.7 letters and 6.2 or 6.6 
letters in subjects with AMD, DME and RVO, respectively . The overall difference in Best 
Corrected Visual Acuity (BC VA) between Lucentis¬Æ treated and control group was the largest 
in subjects with AMD, which indicates that neovascular AMD is the most sensitive indication 
compared to DME  or RVO to show a difference between the treatments [ Lee H , 2014].  In 
addition, neovascular AMD has homogeneous disease progress with fewer compounding 
factors than DME or RVO. For instance, it results in severe visual impairment with an average 
loss of around 4 lines of VA within 2 years of disease onset [ Chakravarthy U  et al. 2010]. 
Although this neovascular form accounts for only approximately 10% to 20% of the AMD cases, it is responsible for 80% to 90% of AMD -associated vision loss [Ferris FL 3rd  et al. 
1984] . Therefore, Subjects with neovascular AMD are the most appropriate target population 
to evaluate the product- related difference between Lucentis
¬Æ and SB11 in this study. 
This study has two different endpoints, depending on regulato ry agency‚Äôs requirements for 
assessing equivalence in efficacy between SB11 and Lucentis¬Æ. 
For US FDA, Korea Ministry of Food and Drug Safety ( MFDS ) or other regulatory agency 
submissions for those who are in favour of the VA, the primary endpoint is the m ean change 
from baseline in BCVA at Week 8. In the pivotal studies for Lucentis¬Æ, the proportion of 
subjects losing < 15 letters was used as primary endpoint to compare the efficacy between Lucentis
¬Æ treatment group and control group. The endpoi nt indicate s the preventive effect of 
the loss of VA, but it includes variability in individual disease progression as well as drug -
induced effect. For example, approximately 90% of the subjects who received Lucentis¬Æ lost 
VA less than 15 letters but 60% of the subje cts who received sham injection (or 
PDT/verteporfin) also lost VA less than 15 letters. Thus, the proportion of subjects losing < 15 letters could not be a sensitive primary endpoint to detect product- related effect between a 
proposed biosimilar product and reference product. On the other hand, change from baseline in VA, gain of letters, can reflect any change (improvement or deterioration) in the disease status , thus  is more sensitive in detecting a difference between the two treatments. To increase 
sensi tivity, evaluation of equivalence will be  conducted at Week 8  before the efficacy plateau 
is reached , as requested by US FDA.  
For EMA  or other regulatory agency submission for those who are in favour of the anatomical 
parameter, the primary objective is t o demonstrate the equivalence of SB11 to Lucentis
¬Æ, in 
terms of the mean change from baseline in CST at Week 4. The evaluation of CST is 
important as it addresses the pharmacodynamics aspects of ranibizumab. Ranibizumab binds 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 33 of 137 with high affinity to all acti ve VEGF -A isoforms (e.g. , VEGF110, VEGF121 and VEGF165) 
on the surface of endothelial cells, thereby preventing binding of VEGF- A to its receptors and 
reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation 
which result in  reduction of CST [Lucentis¬Æ Prescribing Information 2016, Lucentis¬Æ 
Summary of Product Characteristics . 2016]. It indicates that the reduction of CST represents a 
direct effect of ranibizumab based on the M echanism of Action (MoA). Furthermore, it has 
been reported that CST measurements and clinical outcome has a correlation. In OCT -guided, 
variable-dosing study conducted in neovascular AMD subjects, a statisticall y significant 
correlation between the decrease in CST at one month and the subsequent improvement in VA  
seen at two months and three months [ Fung A  et al. 2007] . Similarly in PrONTO study, the 
results indicated that t he initial OCT response is predictor of future VA improvements 
although the strength of the correlation is affected by the fluctuations in macular fluid and the fact that OCT changes are detected before VA is affected. In addition, visual recovery after 
resolution of macular fluid in neovascular AMD likely depends on many variables including 
chronicity of disease, viability of photoreceptors and the RPE, progression of the underlying 
dry AMD (geographic atrophy), as well as the presence of epiretinal membranes, RPE tears, and fibrosis. Despite all these variables, the initial response to ranibizumab characterised by 
resolution of fluid in the macula as assessed by OCT seems to correlate with future VA improvement and may serve as a useful predictor of treatment efficacy  [Lalwani G  et al. 2009 ].   
The study design was consulted and agreed with both EMA and FDA prior to start of this study. 
4. STUDY POPULATION  
Eligibility for participation in this study will be based on the  inclusion/exclusion criteria. Only 
one eye will be designated as the study eye. For subjects who meet eligibility criteria in both 
eyes, the eye with the worse VA will be selected as the study eye. If both eyes have equal VA, the eye with better visual pr ognosis (e.g., clearer lens and ocular media and less amount of 
subfoveal scar or geographic atrophy) will be selected at the Investigator‚Äôs discretion . If there 
is no objective basis for selecting the study eye, factor such as ocular dominance, other ocul ar 
pathology and subject preference should be considered by the Investigator in making the 
selection.  
4.1. Inclusion Criteria  
Subjects must meet all of the following criteria to be eligible for the study:  
1. Age ‚â• 50 years at Screening  
2. Newly diagnosed, * active subfoveal Choroidal Neovascularisation (CNV) lesion 
secondary to AMD  in the study eye  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 34 of 137 * Active CNV indicates presence of leakage and intra- or sub- retinal fluid which 
should be confirmed by central reading centre during Screening 
3. The area of CNV must occupy at least 50% of total lesion in the study eye (confirmed 
by central reading centre during Screening) 
4. Total lesion area ‚â§ 9.0 D isc Areas (DA) in size (including blood, scars and 
neovascularisation) in the study eye (confirmed by central reading centre during 
Screening) 
5. Best Corrected Visual Acuity (BCVA) of 20/40 to 20/200 (letter score of 73 to 34) 
using original series Early Treatment Diabetic Retinopathy Study (ETDRS) chart s or 
2702 series Number char ts in the study eye  at Screening and at Week 0 (Day 1) prior 
to randomisation 
6. Non-childbearing potential female (e.g., permanently sterilis ed, postmenopausal 
[defined as 12 months with no menses without an alternative medical cause prior to 
Screening]) , OR Childbearing potential female subjects or male subjects with their 
(respectively male or female) partners who agree to use at least two forms of 
appropriate contraception method that can achieve a failure rate of less than 1% per year (e.g., established u se of oral, injected, intravaginal, transdermal or implanted 
hormonal contraceptive, placement of an intrauterine device or intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, physical barrier, sexual abstinence) from Screening until 3 months after the last ITV injection of IP  
7. Written  informed consent form must be obtained from the subject prior to any study 
related procedure (If the subject is legal blindness or illiterate, an impartial witness 
should be present during t he entire informed consent discussion ) 
8. Willingness and ability to undertake all scheduled visits and assessments  
4.2. Exclusion Criteria  
Subjects meeting any of the following criteria are not eligible for  the study: 
1. Sub- or intra- retinal h aemorrhage that compri ses more than 50% of the entire lesion in 
the study eye, or presence of subfoveal blood equal to or more than one DA in size 
(confirmed by central reading centre during Screening) 
2. Scar, fibrosis or atrophy involving the centre of the fovea in the study eye  (confirmed 
by central reading centre during Screening)  
3. Presence of CNV in either eye due to other causes, such as ocular histoplasmosis, 
trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture or Pathologic Myopia (PM) (confirmed by central reading centre during Screening)  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 35 of 137 4. Presence of retinal pigment epithelial tears or rips involving the macula in the study 
eye (confirmed by central reading centre during Screening)  
5. Presence of macular hole at any stage in the study eye (confirmed by central reading 
centre during Screening)  
6. Any concurrent macular abnormality other than AMD in the study eye which could 
affect the efficacy of IP including but not limited to epiretinal membrane, macular 
telangiectasia, retinal vascular abnormality, etc.  (confirmed by central reading centre 
during Screening) 
7. History of vitrectomy surgery in the study eye  
8. History of trabecule ctomy or other filtration surgery in the study eye 
9. History of submacular surgery or other surgical intervention for AMD in the study 
eye 
10. Any other intraocular surgery (including cataract sur gery) or periocular surgery in the 
study eye within 90 days  prior to randomisation, except for lid surgery, which may 
not have taken place within 30 days prior to randomisation  
11. Any previous ITV a nti-Vascular  Endothelial Growth F actor ( anti-VEGF) treatment  
(e.g., bevacizumab, aflibercept, ranibizumab) to treat neovascular AMD  in either eye  
12. Any previous systemic anti -VEGF treatment, within 90 days  prior to randomisation, 
and such treatment will not be allowed during the study  period 
13. Any systemic treatment or therapy (including prescribed herbal medication) to treat 
neovascular AMD within 30 days prior to randomisation, and such treatment or therapy will not be allowed during the study period. However, diet ary supplements, 
vitamins or mineral will be allowed  
14. Any intravitreal injection of corticosteroid (e.g., triamcinolone acetonide) or 
intravitreal corticosteroid implant in the study eye within 180 days prior to 
randomisation, and such treatment will not be allowed during the study period 
15. Topical ocular corticosteroids administered for ‚â• 30 consecutive days in the study eye  
within 90 days  prior to randomisation 
16. Spherical equivalent of the refractive error in the study eye demonstrating more than 8 
diopters of myopia. For subjects who have undergone previous refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye must not 
exceed 8 diopters of myopia 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 36 of 137 17. Aphakia or absence of the posterior capsule in the study eye (unless it occurred as a 
result of a Yttrium Alumin ium Garnet [YAG] posterior capsulotomy in association 
with prior posterior chamber I ntraocular Lens [IOL] implantation)  
18. Presence of  scleromalacia in either eye 
19. Current vitreous h aemorrhage in the study eye 
20. Active or recent (within 28 days  prior to randomisation ) intraocular, extraocular and 
periocular inflammation or infection in either eye  
21. History of idiopathic or autoimmune uveitis in either eye  
22. History of retinal detachment in the study eye 
23. History of full -thickness macular hole in the study  eye 
24. History of corneal transplantation surgery  in the study eye  
25. Presence of advanced glaucoma or optic neuropathy that affect or threaten the central 
visual field  in the study eye 
26. Uncontrolled ocular hypertension  (defined as Intraocular Pressure [IOP]  ‚â• 25 mmHg 
despite treatment with anti -glaucoma medication) in the study eye 
27. History of allergy to the fluorescein sodium for injection in angiography 
28. Previous participation in clinical stud ies of ocular investigational products to treat 
neovascular AMD in  either eye or systemic investigational products to treat 
neovascular AMD , and such participation will not be allowed during the study period 
29. Previous participation in any studies of ocular or systemic investigational products 
(excluding dietary supplements , vitamins and minerals) to treat ocular or systemic 
disease other than neovascular AMD within 90 days prior to randomisation, and such 
participation will not be allowed during the study period even if the investigational 
product is dietary supplements, v itamins or minerals  
30. History or clinical evidence of diabetic retinopathy (except for mild non- proliferative 
diabetic retinopathy) or diabetic macular oedema in either eye  
31. Any concurrent ocular condition in the study eye which, in the opinion of the 
Investigator, could either increase the risk to the subject safety or which otherwise 
may interfere with evaluation of efficacy or safety including, but not limited to ocular media opacities such as corneal opacity or cataract  that do not allow proper 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 37 of 137 fundus visuali sation and fundus imaging, and ocular surface abnormalities which 
prevent applanation tonometry during the study period after randomisation  
32. History of other disease, metabolic d ysfunction, physical examination finding, or 
clinical laboratory finding tha t contraindicates the use of an IP  in the opinion of the 
Investigator  
33. Pregnant or lactating women. A serum pregnancy test must be required for women of 
childbearing potential at Screening  
34. Employees of Investigational  sites, individuals directly involved wi th the conduct of 
the study or immediate family members thereof, prisoners, and persons who are 
legally institutionalis ed  
35. Stroke, transient ischemic attacks, or myocardial infarction within 90 days prior to 
randomisation 
36. History of recurrent significant infections and/or current treatment for active systemic 
infection 
37. Known allergic reactions and/or hypersensitivity to ranibizumab or to any ingredients 
of the investigational product  
38. Prior treatment involving macula with photodynamic therapy with verteporfi n, 
transpupillary  thermotherapy , radiation therapy, or retinal laser treatment (e,g ., focal 
laser photocoagulation) in the study eye, and such treatment will not be allowed during the study period 
39. Prior treatment with pan -retinal photocoagulation in the st udy eye, and such treatment 
will not be allowed during  the study period 
40. Current use of systemic medications known to be toxic to the lens, retina or optic 
nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines , vigabatrin  and ethambutol, and such medications will not be allowed 
during the study period  
4.3. Subject Discontinuation from Investigational Product  
The subject must be discontinued from IPs in the event of any of the following: 
‚Ä¢ Consent withdrawal by subject 
- If subjects withdr aw his/her consent, Investigator must inquire the reason s for 
consent withdrawal as to whether it is related to the study (e.g., documented lack 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 38 of 137 of efficacy, AE or pregnancy) ; however, the subject could refuse to provide such 
reason  
- If the main reaso n for  consent withdrawal is considered  related to the study, the 
Investigator may select appropriate reason among the reasons listed below other 
than consent withdrawa l 
‚Ä¢ Rhegmatogenous retinal detachment  or full -thickness macular hole in the study eye 
‚Ä¢ Any n ewly developed or aggravated ophthalmic abnormality other than AMD in the 
study eye which could interfere with evaluation of efficacy or safety of IP including 
but not limited to retinal vascular abnormality 
‚Ä¢ Any AEs in the study eye (e.g., intraocular inflammation, VA  loss, increased IOP , 
subretinal haemorrhage, vitreous haemorrhage, local or systemic infection etc.) 
which in the opinion of the Investigator and/or subject would require IP discontinuation 
‚Ä¢ Intraocular surgery in the study eye (e.g. , cataract operation, vitrectomy, glaucoma 
surgery, etc.) which in the opinion of the Investigator would require IP discontinuation 
‚Ä¢ Protocol deviations which  may adversely affect the subject‚Äôs safety and/or integrity of 
data as agreed by the Investigator and/or upon request from the Sponsor 
‚Ä¢ IP non- compliance  
- A subject  misses any of first two doses (ITV injection of IP at Week 0 (Day 1) 
and Week 4) after randomisation 
- A subject misses two consecutive doses during the study period after 
randomisation 
‚Ä¢ Decision by the Investigator that the subject requires alternate treatment (e.g., other 
anti-VEGF agents such as bevacizumab or aflibercept , PDT , PPV  etc.) to treat 
neovascular AMD in the study  eye 
‚Ä¢ Decision by the Sponsor that IP  discontinuation is in the subject‚Äôs best med ical 
interest or administrative decision for a reason (e.g., a suspicion of fraud, the subject 
enrolling in multiple clinical studies, lack of compliance, etc.) other than that of an AE 
‚Ä¢ Lost to follow -up 
‚Ä¢ Unmasking (except unmasking for the purpose of regulatory reporting) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 39 of 137 ‚Ä¢ Pregnancy  
‚Ä¢ Death of any cause  
Any significant change in the posterior pole (e.g., subretinal haemorrhage, macular hole, 
vitreous haemorrhage or opacity, retinal detachment, etc.) that is detected with fundus 
examination should be confirmed and documented with FP and/or FA. Investigator should 
decide IP discontinuation based on the FP and/or FA.  The images taken at unscheduled visits 
will not be sent to the central reading centre.  
If a subject is prematurely discontinued from IP due to any of the above described reasons 
excluding death, the subject will complete the ET procedures (except for PK sampling) after 4 weeks from the last ITV injection of IP and will be asked to provide continued follow-up and further data collection subsequent to hi s or her ET visit.  
If a subject agrees to continue follow -up for associated clinical outcome information  until 
Week 52 irrespective of IP injection status  (as long as an  additional ICF e.g., withdrawal form 
is signed by the subject for this limited participation in the study), the subject‚Äôs clinical 
outcome information such as BCVA, CST, AE and concomitant medication will be collected  
through non- invasive chart review , if available. 
If a subject does not agree to continue follow-up of associated clinical outcome information, 
the subject will be terminated from the study accordingly. The data and blood samples 
collected on the subject up to ET visit remains in the study database and no further data will be collected.  
In all cases, the reason for IP discontinuation must be recorded in the electronic Case Report 
Form ( eCRF ) and in the subject‚Äôs medical record. 
4.4. Replacement  
Subjects who are discontinued  from IP after randomisation will not be replaced.  
5. TREATMENT AND INVESTIGATIONAL PRODUCT  
5.1. Treatment of the Subjects 
5.1.1.  Dosing and Treatment Schedule  
Subjects will be administer ed SB11 or Lucentis¬Æ 0.5 mg via ITV into the study eye every 4 
weeks up to Week 48 (a total of 13 administrations of IP) unless they are early discontinued 
from IP.  
IP injection will be performed by the Investigator according to delegation of study personnel 
for this study . 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 40 of 137 Dosing visits will be allowed within  ¬± 7 days  of the scheduled dosing visit date (except Week 
0 (Day 1) , visit window not allowed) . If a dose of IP is not given within 7 days of the 
scheduled dosing visit date, the IP  should be given within 20 days of the scheduled dosing 
visit date,  but the case will be captured as protocol deviation. Dosing skip is defined when a 
subject does not receive the IP within 20 days after scheduled dosing visit date.  
Next s cheduled dosing visit  date and visit window should not be altered even though previous 
dosing is not performed on the exact scheduled dosing visit d ate (but, the interval between two 
doses injected into the study eye should be at least 14 days) or previous dosing is skipped.  
5.1.2.  Withholding Investigational Products  
If a subject  experiences an AE in the study eye  and the subject‚Äôs safety or well -being could be 
compromised by ITV injection of IP at  the Investigator‚Äôs discretion , IPs should be withheld 
until the event has resolved . Such events in the study eye include, but are not limited to:  
‚Ä¢ A decrease in BCVA  of ‚â•30 letters compared with the last assessment of VA;  
‚Ä¢ An IOP of ‚â•30 mmHg;  
‚Ä¢ A retinal break;  
Any significant change in the posterior pole (e.g., subretinal haemorrhage, macular hole, 
vitreous haemorrhage or opacity, retinal detachment, etc.) that is detected with fundus 
examination should be confirmed and documented with FP and/or FA. Investigator should 
decide IP withholding based on the FP and/or FA. The images taken at unscheduled visits will 
not be sent to the central reading centre.  
NOTE: If a subject misses any of first t wo dose s or two consecutive doses during the study 
period after randomisation, the subject must be discontinued from IPs according to Section 4.3 .   
5.2. Investigational Product  
5.2.1.  Identity of I nvestigational Product 
Details of the IPs are provided in Table 7. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 41 of 137 Table 7. Investigational Products  
Active pharmaceutical ingredient: ranibizumab  
SB11   
Formulation  Solution for ITV inject ion 
Contents  One ml contains 10 mg ranibizumab  
Storage conditions  Stored in refrigerator (2 -8¬∞C), Do not freeze  
  
US sourced Lucentis¬Æ  
Formulation  Solution for ITV injection  
Contents  One ml contains 10 mg ranibizumab  
Storage conditions  Stored in re frigerator (2 -8¬∞C), Do not freeze  
The IP s will be supplied to Investigat ional  site in one carton containing a single vial. These IP 
vials will be packed and labelled in a double- masked manner for clinical use . The labels for 
carton and vial will contain: the protocol number, unique identifier, Sponsor company name, 
expiry or retest date, storage condition and all other details according to the Good 
Manufacturing Practice (GMP) and other relevant local laws and/or regulations. 
The temperature will be monito red properly during the study period. The IPs should be 
protected from light. The IP should be stored in a secure area and clearly labelled and stored 
away from other IP or medication to prevent confusion (for example in a clearly marked box on a separate shelf of the refrigerator).  
A detailed guideline for IP preparation, administration, storage and destruction will be provided in the Pharmacy Manual.  
5.2.2.  Assignment of Subject Number  
A unique subject number will be assigned to the subject by the Interactive Web  Response 
System (I WRS) at Screening .  
A unique randomisation number will be assigned to the subject number by the IWRS at 
randomisation to ensure that treatment group assignment is unbiased and masked to subjects, Investigators, and other study personnel. The randomisation number is linked to the treatment group assignment, which in turn is linked to IP kit number. 
The assigned  subject number(s) and randomisation number (s) will not be re -used.  
5.2.3.  Masking  
This study is double -masked . Subjects, Investigators, and other study personnel will remain 
masked to the treatment group assignment throughout the study period after randomisation .  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 42 of 137 To ensure the masking of the treatment group assignment, one carton will contain only one IP 
vial (SB11 or Lucentis¬Æ). The ca rton and IP vial will be packed and labell ed in identical 
appearance.  
5.2.4.  Unmasking  
After all subject s complete the procedures at Week 24, or its corresponding visit, a limited 
number of identified individuals of the Sponsor and/or Contract Research Organisat ion (CRO ) 
will be unmasked only for the reporting purpose to regulatory agency.  Available efficacy and 
safety data, pharmacokinetics, and immunogenicity data will be analysed and reported in the 
Main Clinical Study Report ( CSR) . However, subjects, investig ators, and other study 
personnel will remain masked throughout the study period 
After the last subject completes the procedures at Week 52 (EOS  visit) or the corresponding 
visit and database is locked , the treatment group assignment will be unmasked and al l study 
data will be analysed and reported in the Final CSR. 
Emergency unmasking is referred to Section 8.1.6. 
5.2.5.  Investigational Product Treatment Compliance and Accountability  
5.2.5.1.  Investigational Product Treatment Co mpliance 
All IP injection s will be given by the Investigator to ensure compliance. The exact date and 
time of IP injection must be recorded in the source documentation and the eCRF. 
5.2.5.2.  Investigational Product Accountability  
Investigator or designee should mai ntain the documents of IP accountability and record the IP 
kit number administered to subjects. IP accountability and dispensing records must be kept 
and contain the following information:  
‚Ä¢ The identification of the subjects to whom the drug was dispensed. 
‚Ä¢ The date(s) and quantity of the drug dispensed and exact package to the subject . 
‚Ä¢ The dispensing and inventory logs must be available for inspection by the monitor. 
The used IP will be destructed at the Investigational site according to local regulation. Al l 
unused IPs should be returned to the Sponsor or designated vendor unless local destruction 
site is approved by  the Sponsor. If destruction is authorised at the Investigational  site, the 
Investigator must ensure that the materials are destroyed in compliance with all applicable 
environmental regulations, institutional policies and any instructions provided by the Sponsor. Destruction of the IP must be adequately documented.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 43 of 137 5.2.6.  Investigational Product  Administration  
Using aseptic technique, all of the SB11 and Lucentis¬Æ vial contents are withdrawn through a 
blunt filter needle attached to a 1 -cc syringe. The filter needle should be discarded after 
withdrawal of the vial contents and should not be used for ITV injection. The filter needle 
should be replaced with a sterile 30 -gauge x 1/2-inch needle for the ITV injection  of IP . The 
contents should be expelled until the plunger tip is aligned with the line that marks 0.05 mL 
on the syringe.  
The ITV injection procedure should be carried out under controlled aseptic conditions in 
accordance with local practice.  
Each vial should only be used for the treatment of a single eye.  
5.3. Prohibited  Medication or Therapy   
Prohibited medication and therapy during the study period are presented in Table 8. 
Any other medications that are considered necessary for the subject‚Äôs welfare, and that are not 
expected to interfere with the evaluation of the IP may be given at the Investigator‚Äôs discretion.  
Details of a ny medications including both pr escription , non-prescription drugs or any therapy 
(except dietary supplements, vitamins or minerals) received locally (in the study eye and/or  
fellow eye) or systemically within 180 days prior to Screening will be collected until Week 52 (EOS visit) or ET  visit.  Details to be recorded include: name (generic name preferred), dose 
number and unit, frequency of administration, route of administration, start and stop dates, 
and the AE it relates to (if applicable).  
Table 8. Prohibited Medication and Therapy  
Medication or Therapy  Time to be prohibited  Eye to be prohibited  
ITV anti-VEGF treatment  (e.g., 
bevacizumab, aflibercept, 
ranibizumab) to treat neovascular AMD  ‚Ä¢ Prior to Randomisation  ‚Ä¢ Study eye  
‚Ä¢ Fellow eye  
ITV anti-VEGF treatme nt ex cept 
IP (SB11 or Lucentis¬Æ) ‚Ä¢ From Randomisation to EOS/ET visit ‚Ä¢ Study eye  
ITV anti-VEGF treatment (e.g., 
bevacizumab, aflibercept) except ranibizumab  ‚Ä¢ From Randomisation to EOS/ET visit ‚Ä¢ Fellow eye  
NOTE:  If a subject has 
AMD in the fellow eye during the study period 
after randomisation, ONLY Lucentis
¬Æ 
(ranibizumab) will be allowed to treat AMD.  
Systemic Anti -VEGF agents 
(e.g., bevacizumab)  ‚Ä¢  Within 90 days prior randomisation  
‚Ä¢  From Screening  to EOS/ET visit  N/A 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 44 of 137 Medication or Therapy  Time to be prohibited  Eye to be prohibited  
Systemic treatment or therapy  
(including prescribed herbal 
medication) to treat neovascular AMD. However, dietary supplement s, vitamins and 
minerals are allowed.  ‚Ä¢ Within 30 days prior randomisation ‚Ä¢ From Screening  to EOS/ET visit  N/A 
Systemic medications known to 
be toxic to the lens, retina or optic nerve including deferoxamine, chloroquine/hydroxychloroquine , 
tamoxifen, phenothiazines , 
vigabatrin and ethambutol  ‚Ä¢ From Screening to EOS/ET visit  N/A 
Intravitr eal injection of 
corticosteroid (e.g., triamcinolone 
acetonide) or intrav itreal 
corticosteroid implant  ‚Ä¢ Within 180 days prior to 
randomisation  
‚Ä¢  From Screening  to EOS/ET visit  ‚Ä¢ Study eye  
Topical ocular corticosteroids  ‚Ä¢ ‚â• 30 consecutive days within 90 days 
prior to randomisation ‚Ä¢ Study eye  
Treatment involving macula with 
photodynamic therapy with verteporfin, transpupillary  
thermotherapy , radiation therapy, 
or retinal laser treatment (e .g., 
focal laser photocoagulation)  ‚Ä¢ Prior to Screening  
‚Ä¢ From Screening to EOS/ET visit  ‚Ä¢ Study eye  
Treatment with pan -retinal 
photocoagulation  ‚Ä¢ Prior to Screening  
‚Ä¢ From Screening to EOS/ET visit  ‚Ä¢ Study eye  
Ocular investigational products to 
treat neovascular AMD  ‚Ä¢ Prior to Screening  
‚Ä¢ From Screening  to EOS/ET visit  ‚Ä¢ Study eye  
‚Ä¢ Fellow eye  
Systemic investigational products 
to treat neovascular AMD  ‚Ä¢ Prior to Screening  
‚Ä¢ From Screening  to EOS/ET visit  N/A 
Ocular investigational products to 
treat ocular diseases other than 
neovascul ar AMD  ‚Ä¢ Within 90 days prior randomisation ‚Ä¢ From Screening  to EOS/ET visit  ‚Ä¢ Study eye  
‚Ä¢ Fellow eye  
Systemic investigational products (excluding dietary supplement s, 
vitamins and minerals ) to treat 
systemic diseases other than 
neovascular AMD  ‚Ä¢ Within 90 days prior randomisation  
‚Ä¢ From Screening  to EOS/ET visit  
 NOTE:   During the study period, 
investigational products such as dietary 
supplement s, vitamins and minerals  
will be prohibited.  N/A 
N/A, Not applicable  
5.4. Fellow Eye Treatment  
The fellow  eye (non- study eye) will not be considered as an additional study eye. If a subject 
has AMD in the fellow eye, the subject could receive ONLY Lucentis¬Æ and should remain in 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 45 of 137 the study. Lucentis¬Æ for treatment in the fellow eye will be reimbursed or provided by Sponsor 
during the study period after randomisation.  
Fellow eye injection will be performed by the Investigator for this study . However, fellow eye 
visit is not part of study, thus it will be scheduled in accordance with local practice . If a 
subject has both e yes injected on the same day, fellow eye should be injected after completion 
of ITV injection of IP  on the study eye . Ocular adverse events for the fellow eye and systemic 
adverse events will be monitored and recorded after the written informed consent is obtained 
from the subject  until Week 52 (EOS visit) or ET visit.  
6. STUDY VARIABLES  
6.1. Study Endpoints  
6.1.1.  Primary  Endpoint  
For US FDA, Korea MFDS  or other regulatory agency submissions for those who are in 
favour of the VA, the primary endpoint is: 
‚Ä¢ Change from bas eline in BCVA at Week 8  
For EMA  or other regulatory agency submission for those who are in favour of the anatomical 
parameter , the primary endpoint is: 
‚Ä¢ Change from baseline in CST  at Week 4 (based on assessment by  central reading centre ) 
6.1.2.  Secondary Endpoint s 
The secondary efficacy endpoints are: 
‚Ä¢ Change from baseline in BCVA over time up to Week 24 and Week 52  
‚Ä¢ Proportion of subjects who lost fewer than 15 letters in BCVA compared to baseline at  
Week 24 and Week 52  
‚Ä¢ Proportion of subjects who gained 15 letters or more in BCVA compared to baseline at 
Week 24 and Week 52  
‚Ä¢ Change from baseline in CST and Central Retinal Lesion Thickness (CRLT) at  Week 24 
and Week 52 (based on assessment by central reading centre)  
‚Ä¢ Change from baseline in total CNV size at Week 24 and  Week 52 (based on assessment 
by central reading centre)  
‚Ä¢ Proportion of subjects with active CNV leakage at Week 24 and Week 52 (based on 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 46 of 137 assessment by central reading centre)  
The safety endpoints are:  
‚Ä¢ Incidence of ocular AEs or serious ocular adverse event s 
‚Ä¢ Incidence of systemic AEs or serious systemic adverse event s 
The pharmacokinetic endpoints are:  
Blood sampling for PK will be collected in approximately  40 subjects participating in PK 
evaluation (20 subjects per treatment group) . 
‚Ä¢ Systemic exposure measu red pre-dose (C trough) and 24 to 72 hours post-dose (close to 
Cmax)  
The immunogenicity endpoints are:  
‚Ä¢ Incidence of A nti-Drug Antibodies (ADAs) to ranibizumab 
‚Ä¢ Incidence of N eutralising Antibodies (NAbs) to ranibizumab  
6.1.3.  Exploratory Endpoint  
‚Ä¢ Proportion of su bjects with out intra- or sub- retinal fluid  at Week 24 and Week 52 (based 
on assessment by central reading centre)  
The Quality of Life (QOL) is assessed using National Eye Institute 25 -Item Visual Function 
Questionnaire ( NEI VFQ -25). 
‚Ä¢ Change from baseline in  subscale scores and composite scores of NEI  VFQ -25 at Week 
24 and Week 52 
6.2. Efficacy  Assessments  
6.2.1.  Best Corrected Visual Acuity  
VA will be assessed in both the study eye and fellow eye (non- study eye)  at Screening and 
prior to ITV injection of IP at each  visit until Week 48 . VA will also be assessed in both the 
study eye and fellow eye (non -study eye) at any time during the visit at Week 52 (EOS visit) 
or ET visit.  
VA will be assessed using original series ETDRS chart s or 2702 series Number charts at a 
starti ng distance of 4 meters, and then repeated at a distance of 1 meter , if necessary. Subject 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 47 of 137 must use the same chart consistently from Screening to Week 52 (EOS visit)  or ET visit . VA 
testing must be performed before dilation of pupils and  FP/FA  and OCT assessment.  
VA examiners and VA lanes at Investigational sites must be certified to ensure consistent 
measurement of BCVA  prior to start of study .  
A detailed protocol for conducting VA testing and refraction will be provided in the VA  
Testing Manual . 
A decrease in VA of ‚â• 15 letters from the last assessment of VA should be reported as AEs/ 
Serious Adverse Events ( SAEs ) as appropriate.  
If the event  meets one or more of the following criteria, it should be reported as SAE.  
‚Ä¢ A decrease in VA of ‚â• 30 letters from  the last assessment of VA 
‚Ä¢ A decrease in VA to the level of Light Perception or worse  
6.2.2.  Anatomical Parameters  
The average retinal thickness in the central 1 -mm area in the ETDRS grid  (CST; central 
subfield thickness) , retinal thickness between Internal Limiting M embrane (ILM) and the base 
of RPE  (CRLT; central retinal lesion thickness) and other lesion characteristics will be 
evaluated using OCT on the study eye  at Screening and prior to ITV injection of IP until 
Week 48. OCT will also be performed at any time during the visit at Week 52 (EOS visit) or 
ET visit.   
Lesion characteristics such as CNV size and presence of leakage or haemorrhage will also be evaluated using F P/FA  on the study eye at Screening and prior to ITV injection of IP Week 24 . 
FP/FA  will also be performe d at any time during the visit at  Week 52 (EOS visit)  or ET visit . 
6.3. Safety  Assessments  
6.3.1.  Adverse Events  
All AEs including ocular AEs in the study eye and/or fellow eye as well as systemic AEs will 
be recorded from the written informed consent is obtained from the subject  until Week  52 
(EOS  visit ) or ET visit . AEs should be elicited from subjects using non-leading questions such 
as ‚ÄòHow are you feeling?‚Äô. Further information on AE monitoring and reporting is presented 
in Section  8. 
6.3.2.  Clinical Laboratory Test  
Blood and urine sampling for clinical laboratory test will  be collected at Screening and prior 
to ITV injection of IP at Week 12, Week 24, and Week 36. Blood and urine sampling for 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 48 of 137 clinical laboratory test will also  collected at any time during the visit at Week 52 (EOS visit) 
or ET visit  (Table 2). Urine samples must be collected before performing FA to avoid false 
elevations in urine protein values.  
Blood samples will be analysed in central laboratory and urine samples will be tested in each 
Investigational site by using a dipstick which will be provided by Sponsor. A detailed process 
for clinical laboratory sampling, handling, storage and shipping will be provided in the 
Central Laboratory Manual for safety lab testing . 
The parameters for clinical laboratory tests are listed in Table 9. 
Table 9. Parameters for Clinical Laboratory Tests  
Haematology  Chemistry  Urinalysis1 
ÔÇû Haemoglobin  
ÔÇû Haematocrit  
ÔÇû Platelet count  
ÔÇû White blood cell count 
(total and differential)  ÔÇû Sodium  
ÔÇû Potassium  
ÔÇû Creatinine  
ÔÇû Glucose  
ÔÇû Calcium  
ÔÇû Phosphorus  
ÔÇû Total bilirubin  
ÔÇû Albumin  
ÔÇû Alanine aminotransferase  
ÔÇû Aspartate aminotransferase  
ÔÇû Alkaline phosphatase  
ÔÇû Lactat e dehydrogenase  ÔÇû Protein  
ÔÇû Blood  
ÔÇû Leucocytes  
ÔÇû Nitrite  
ÔÇû Glucose  
ÔÇû Ketone  
ÔÇû pH 
ÔÇû Specific gravity  
ÔÇû Bilirubin,  
ÔÇû Urobilinogen  
1 Urinalysis will be tested using a  dipstick which will be provided by Sponsor.  
The Investigator  will check any laboratory values which have potential significance in 
subject‚Äôs safety  during the study  period. The Investigator will also evaluate any change in 
laboratory values. Each out of range result should be assessed  as not clinically significant or 
clinically significant by Investigator . All lab oratory abnormalities that require intervention 
(e.g., IP withholding, IP discontinuation, concomitant medication) should be assessed  as 
clinically significant and the clinically significant abnormalities should be recorded as  AEs .  
Clinical l aboratory tes t including haematology, clinical chemistry, and urinalysis  can be 
repeated during the study period at the Investigator‚Äôs discretion .  
Deleted  laboratory test results with technical problems, such as handling error, sampling error, 
or tube breakage, should be followed by re- test. Result of re- test will be considered as that of 
an initial.  
6.3.3.  Pregnancy Test  
For women of childbearing potential , serum pregnancy test must be performed at Screening. 
The serum samples taken at Screening will be analysed in central laboratory.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 49 of 137 Additional serum or urine pregnancy test can be performed in each Investigational site during 
the study period, if necessary (at the Investigator‚Äôs discretion).  
Deleted pregnancy test result at Screening  with technical problems, such as handling error, 
sampling error or tube breakage, should be followed by re- test. Result of re- test will be 
considered as that of an initial.  
6.3.4.  Physical Examination 
Physical examination will be performed  at Screening and Week 52 (EOS visit) or ET visit . 
The physical e xamination will include an assessment of the subject‚Äôs general appearance, skin, 
head, neck, throat, lymph nodes, cardiovascular, neurological, thyroid, musculoskeletal/extremities, respiratory systems and the subject‚Äôs abdomen. Abnormal 
findings will be d ocumented on the source document , and a ny clinically significant 
abnormality or worsening of a previously noted abnormality should be recorded as an AE. 
Body weight will be recorded at Screening and Week 52 (EOS  visit ) or ET visit, but height 
will be measu red only at Screening.  
6.3.5.  Vital Signs 
Vital signs include blood pressure, heart rate and body temperature. Vital signs will be 
assessed at Screening and prior to ITV injection of IP at each visit until Week 48. Vital signs 
will also be assessed at any time du ring the visit at Week 52 (EOS visit) or ET visit ( Table 1).  
The Investigator should assess all vital signs and any clinically significant abnormalities 
should be reported as AE. 
6.4. Ophthalmic Assessments  
6.4.1.  Full Ophtha lmic Examinations 
The full ophthalmic examination will consist of an external examination of the eye and adnexa 
routine screening for eyelid/pupil responsiveness (including but not limited to blepharoptosis, 
abnormal pupil shape, unequal pupils, abnormal reaction to light, and afferent pupillary defect), slit lamp biomicroscopy, IOP measurements and indirect ophthalmoscopy . 
The posterior segment should be examined with the slit lamp and indirect ophthalmoscopy. Careful evaluation of the macula, optic nerve, retinal vessels, peripheral retina and vitreous should be included.  
Grading scales for slit lamp biomicroscopy and indirect ophthalmoscopy are provided in Appendix A , B and C . 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 50 of 137 Slit lamp biomicroscopy  
The slit lamp examination (cornea, lens, iris, aqueous rea ction [cells and flare]) will be 
performed in both the study eye and fellow eye at Screening and prior to ITV injection of IP at 
each visit until Week 48 , irrespective of whether or not the fellow eye has AMD . Slit lamp 
examination will also be performed at any time during the visit at Week 52 (EOS visit) or ET 
visit.  If the fellow eye is not diagnosed with AMD, it will be followed to determine whether or 
not AMD develops.  
Both the anterior segment and posterior segment will be assessed with the slit lamp.  
The posterior segment will be examined  after dilation of pupil with 2 -3 drops of 
phenylephrine-tropicamid (or any other mydriatic drug) applied topically to the eye.  
Intraocular pressure (IOP) measurement  
IOP will be measured on the study eye at Screening and prior to ITV injection of IP and 30-60 
minutes after ITV injection of IP  at each visit until Week 48. When IOP is measured before 
ITV injection of I P, IOP should be measured after OCT and FP/FA are completed to avoid 
corneal erosion. IOP will also be measured at any time during the visit at Week 52 (EOS visit) 
or ET visit.  
IOP should be measured using Goldmann applanation tonometry. Th e same method o f IOP 
measurement must be used in each subject from Screening to Week 52 (EOS visit) or ET visit.  
Indirect ophthalmoscopy  
Indirect ophthalmoscopy using in a standard way (i.e., usually using a head-mounted light 
source and a 20- 30 dpt lens) will be perform ed on the study eye  (including evaluation of 
posterior segment abnormalities of the vitreous, optic nerve, peripheral retina and retinal 
vasculature, as well as retinal pigment epithelium detachment, ischemic events including 
cotton wool spots and microane urysms)  at Screening and prior to ITV injection of IP and 0-15 
min after ITV injection of IP  at each visit until Week 48. Indirect ophthalmoscopy will also be 
performed at any time during the visit at Week 52 (EOS visit) or ET visit.   
6.4.2.  Optical Coherence Tomography (OCT) 
OCT will be performed on the study eye at Screening and prior to ITV injection of IP at each 
study visit  until Week 48. OCT will also be performed at any time during the visit at Week 52 
(EOS visit) or ET visit.  
Site staffs who will perform O CT scans in this study must be certified by the central reading 
centre before study starts.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 51 of 137 OCT devices registered in an Investigational site should be all from the same manufacture and 
meet the minimum software requirement. The subject should use the OCT device s registered 
by central reading centre during the study period.  
All original OCT images will be kept in the Investigational site and copies will be sent to the 
central reading centre for analysis and archiving. A detailed protocol for OCT image 
acqu isition and transmission will be provided in the Image Handbook. 
6.4.3.  Fundus Photography  (FP) and Fluorescein Angiography (FA)  
FP/FA will be performed on the both  eyes at Screening and those images taken from the both 
eyes will be sent to the central reading centre.   
FP/FA will also be performed on the study eye prior to ITV injection of IP at Week 24  and at 
any time during the visit at Week 52 (EOS visit) or ET visit . Those images taken from the 
study eye will be sent to the central reading centre.  
Site staffs who will perform FA/FP  in this study must be certified by the central reading centre 
before study starts.  
Only FP/FA device certified by central reading centre is allowed to be used in this study. If 
one or more FP/FA  devices are certified in an Investiga tional s ite, a subject must use the same  
FP/FA device consistently from Screening to Week 52  (EOS visit)  or ET visit .  
All original FP/FA images will be kept in the  Investigational  site and copies will be sent to the 
central reading centre for analysis and  archiving.  A detailed protocol for FP/FA  image 
acquisition and transmission will be provided in the Image Handbook. 
If any significant change in the posterior pole ( e.g., subretinal haemorrhage, macular hole, 
vitreous haemorrhage or opacity, retinal detac hment, etc .) is detected with fundus examination, 
additional FP and/or FA can be performed at the Investigat or‚Äôs discretion , but the images will 
not be sent to the central reading centre.  
6.5. Pharmacokinetic  Assessment  
Blood sampling for PK will be collected in approximately 40 subjects (20 subjects per 
treatment group) participating in PK evaluation.  The Investigational sites which are interested in taking part in PK sub -study and are also fully 
equipped as per study requirement (e.g.,  - 70 ¬∞C deep freezer for PK  sample storage and 
temperature controlled centrifuge) will be selected before the study starts. The selected 
Investigational sites will be defined as PK Investigational sites which are registered in the 
IWRS.   
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 52 of 137 Subjects screened at PK Investigational  sites will be asked to participate in PK sub -study. If 
subject  consents to the PK blood sampling, the subject will be enrolled in this study. Subjects 
enrolled  at PK Investigational sites will be ‚ÄúPK subjects‚Äù participating in  PK evaluation  until 
the expe cted number of PK subjects is reached. Once the expected number of PK subjects is 
reached, the following  subjects enrolled at  PK Investigational sites will be ‚Äúnon -PK subjects‚Äù 
for whom blood sampling for PK will not be performed.  
Blood sampling for PK wi ll be collected  prior to ITV injection of IP (C trough) and 24-72 hours 
after ITV injection of IP (close to C max) at Week 0  (Day 1) , Week 4, Week 8, Week 16, Week 
24, and Week 36. Blood sampling for PK will also be collected  at any time during the visit at 
Week 1 and Week 52 (EOS  visit)  (Table 2).  
The exact date and time of sample collection must  be recorded in the source documentation 
and the eCRF. A detailed process for PK  sampling, handling, storage and shipping will be 
provided in the Central Laboratory Manual for PK and Immunogenicity.   
6.6. Immunogenicity  Assessment  
Blood sampling for immunogenicity will be collected  in all randomis ed subjects.  
Blood sampling for immunogenicity  will be collected  prior to ITV inject ion of IP at Week 0  
(Day 1) , Week 4, Week 8, Week 16, Week 24, and Week 36. Blood sampling for 
immunogenicity will also be collected  at any time during the visit at Week 1 and Week 52 
(EOS visit) or ET visit ( Table 2). 
The exact date and time of sample collection must be recorded in the source documentation 
and the eCRF.  A detailed process for immunogenicity sampling, handling, storage and 
shipping will be provided in the Central Laboratory Manual for PK and Immunogenicity . 
If a subject has an unresolved adverse event that is possibly related to ADA formation, he or 
she could be asked to return for immunogenicity blood sampling after Week 52 ( EOS  visit)  or 
ET visit until the antibody titres return to baseline or stabilise at a level acceptable to the 
Investigator and Sponsor . 
6.7. NEI VFQ -25 
Vision -related QOL will be assessed using NEI VFQ -25. NEI VFQ -25 should be performed at 
Week 0 (Day 1) after randomisation. Then, NEI VFQ-25 should be performed before dilation of pupil at Week 0 (Day1), Week 24  and Week 52 (EOS visit) or ET visit.  
All questionnaires will be administered in the local language. Investigator or delegated site 
staff will conduct a questionnaire survey with the subject in a quiet room. The results of the 
questionnaire will be recorded in a paper questionnaire and then entered into the eCRF. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 53 of 137 7. STUDY PROCEDURES  
During this study, efficacy, safety, pharmacokinetic and immunogenicity assessments will be 
performed. All results should be recorded in the source documents along with the date and 
time the procedures were performed . Such assessments must be performed at the times 
outlined in Table 1. 
7.1. Visit 1 (Screening, D -21 to D -1) 
Screening should be performed within 21 days before randomisation excluding the day of 
randomisation.  
‚Ä¢ Written i nformed consent 
Investigator must  discuss the study with the subject and obtain written informed consent  from 
the subject prior to any study related procedures. If the subject is not randomi sed within 21 
days after Screening, the subject should be screen failed . Once the subject is screen failed , he 
or she should not be re -screened.  
The following procedures should be performed: 
‚Ä¢ Demographic data  
‚Ä¢ Medical & ophthalmic history 
‚Ä¢ Physical examinatio n (including body weight and height) 
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Pregnancy test  for women of childbearing potential ( serum ) 
‚Ä¢ Blood and urine sampling for clinical laboratory tests  
- Urine samples must be collected before performing FA to avoid false elevation in 
urine protein values 
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA and OCT assessment ) 
- Subject must use the same chart consist ently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy 
‚Ä¢ Indirect ophthalmoscopy 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 54 of 137 ‚Ä¢ OCT  (images should be sent to central reading centre ) 
‚Ä¢ FP & FA (images should be sent to central reading centre) 
‚Ä¢ IOP using Goldmann applanation tonometry  
‚Ä¢ Adverse event monitoring 
‚Ä¢ Concomitant and previous medication or therapy 
‚Ä¢ Evaluate subject compliance with all inclusion and exclusion criteria 
Investigators are advised to send OCT and FP/ FA images to central reading centre as soon as 
possible for review as this could take more time than the other procedures, in order to avoid 
exceeding the allowed 21 days. If the subject is screen failed due to any reasons before the 
Investigator send OCT and/or FP/FA images to central reading centre, the Investigator does 
not have to send the subject‚Äôs OCT and/or FP/FA images to central reading centre.  
Central reading centre will send central review results confirming  the subject‚Äôs eligibility to 
the Investigational site. If a subject is confirmed as ineligible from  centra l reading centre due 
to poor quality of images, but the investigator still considers the subject eligible for the study, 
the Investigator may be allowed to send a second set of images to the central reading centre. In this case, only FP/FA  or OCT  (and not all other screening procedures) have to be repeated 
within screening period of 21 days and the subject will retain the subject number initially 
assigned . 
Once the subject is confirmed eligible for the study, the subject will be advised on study restriction s such as contraception, prohibited medications and other study requirements if any. 
NOTE  
ÔÉò The most critical assessment will be at Week 4 and Week 8 as these are the visits 
for primary endpoint assessment. Thus, every effort should be made to adhere 
to the visit schedule for the subjects.    
ÔÉò A decrease in VA of ‚â• 15 letters (compared with the last assessment of 
VA) should be reported as AEs/SAEs as appropriate.  
ÔÉò Intraocular inflammation should be recorded based on the location  of 
inflammation (e.g., ‚Äúiritis‚Äù, ‚Äúvitritis‚Äù or ‚Äúiridocyclitis‚Äù rather than ‚Äúuveitis‚Äù) 
ÔÉò Grading scales for slit lamp biomicroscopy and indirect ophthalmoscopy are 
provided in Appendix A, B and C. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 55 of 137 7.2. Visit 2  (Week 0 /Day 1) 
Before randomisation 
‚Ä¢ Evaluate subject compliance with all inclusion and exclusion criteria 
‚Ä¢ Investigator must confirm that the subject can read between 34 letters and 73 letters 
using original series ETDRS chart s or 2702 series Number chart s (before dilation of 
the pupils and FP/FA or OCT assessment ) prior to  randomisation (Please see 
inclusion criteria #5) . Subject must use the same chart consistently from Screening to 
Week 52 (EOS visit) or ET visit  
Randomisation 
‚Ä¢ After a subject ‚Äôs eligibility is confirmed by the central reading centre and Investigator, 
subject should be randomised to either SB11 or Lucentis¬Æ treatment group 
‚Ä¢ The first ITV injection of IP and all other study procedures must be performed at the 
same day of randomisa tion or the following  day after  randomisation at the latest with 
a proper reason  
After randomisation  
ÔÉº Before ITV injection of IP  
‚Ä¢ NEI VFQ -25 ( prior to dilation of pupil after randomisation) 
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood sampl ing for immunogenicity  
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation  
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 56 of 137 ‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant and previous medication or therapy 
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye. 
ÔÉº After ITV injection  of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation  (24 - 
72 hours post-dose) 
‚Ä¢ Adverse event m onitoring  
7.3. Visit 3  (Week 1  ¬± 3 days) 
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood sampling for immunogenicity 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation  
‚Ä¢ Pregnancy test (serum or urine) at the Investiga tor‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series  ETDRS chart s or 2702 series Number 
chart s (before dilation  of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 57 of 137 ‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
7.4. Visit 4  (Week 4 ¬±  7 da ys) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood sampling for immunogenicity  
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation   
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äô s discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit)  or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry  
‚Ä¢ Adverse event monitoring 
‚Ä¢ Review of concomitant medication  or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye. 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 58 of 137 ‚Ä¢ Blood sampling for pharmacokinetics for subjects partici pating in PK evaluation (24 - 
72 hours post-dose) 
‚Ä¢ Adverse event monitoring  
7.5. Visit 5  (Week 8 ¬±  7 days) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood sampling for immunogenicity  
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation   
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series  ETDRS chart s or 2702 series Number 
chart s (before dilation  of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry  
‚Ä¢ Adverse event monitoring 
‚Ä¢ Review of concomitant medication  or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 59 of 137 ‚Ä¢ IOP using Goldmann ap planation tonometry (30-60 min post-dose) 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation  (24 - 
72 hours post-dose) 
‚Ä¢ Adverse event monitoring  
7.6. Visit 6 ( Week 12 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, bl ood pressure and pulse rate)  
‚Ä¢ Blood and urine sampling for clinical laboratory tests 
- Urine samples must be collected before performing FA to avoid false elevation in 
urine protein values 
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocula r assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry  
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given in the study eye. 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 60 of 137 ‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Adverse event monitoring  
7.7. Visit 7 ( Week 16 ¬±  7 days ) 
ÔÉº Before ITV injectio n of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood sampling for immunogenicity  
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation   
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular ass essments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be  given  in the study eye. 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 61 of 137 ‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluati on (24 - 
72 hours post-dose) 
‚Ä¢ Adverse event monitoring  
7.8. Visit 8 ( Week 20 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry  
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the st udy eye  
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 62 of 137 ‚Ä¢ Adverse event monitoring  
7.9. Visit 9 ( Week 24 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ NEI VFQ -25 (be fore dilation of pupil ) 
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood and urine sampling for clinical laboratory tests  
- Urine samples must be collected before performing FA to avoid false elevation in 
urine protein values 
‚Ä¢ Blood sampling for immunogenicity   
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation   
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series  ETDRS chart s or 2702 series Numbe r 
chart s (before dilation of the pupils and FP/FA or OCT assessment) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy 
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ FP & F A (images should be sent to central r eading centre)  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 63 of 137 ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation  (24 - 
72 hours post-dos e) 
‚Ä¢ Adverse event monitoring  
7.10. Visit 10 (Week 28 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using origina l series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given in the study eye 
ÔÉº After ITV inject ion of IP  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 64 of 137 ‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Adverse event monitoring  
7.11. Visit 11 (Week 32 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood press ure and pulse rate)  
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series  ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject mu st use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 65 of 137 ‚Ä¢ Adverse event monitoring  
7.12. Visit 12 (Week 36 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Blood and urine sampling for clinical laboratory tests  
- Urine samples must be collected before performing FA to avoid false elevation in 
urine protein values 
‚Ä¢ Blood sampling for immunogenicity 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation   
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given in the study eye 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 66 of 137 ‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Blood sampling for pharmacokinetics for subjects participating in PK evaluation  (24 - 
72 hours post-dose) 
‚Ä¢ Adverse event monitoring 
7.13. Visit 13 (Week 40 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examinatio n using original series  ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring 
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye. 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 67 of 137 ‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Adverse event monitoring  
7.14. Visit 14 (Week 44 ¬±  7 days ) 
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperatu re, blood pressure and pulse rate) 
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessm ent) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse ev ent monitoring 
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given  in the study eye. 
ÔÉº After ITV injection of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Adverse event monitoring  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 68 of 137 7.15. End of Treatment Visit ( Visit 15 , Week 48 ¬± 7 days)  
End of Treatment Visit (EOT ) is defined as the visit for the last ITV injection of SB11 or 
Lucentis¬Æ. The Sponsor will not provide IP (SB11 or Luc entis¬Æ) to subjects after they 
complete the EOT visit.  
ÔÉº Before ITV injection of IP  
‚Ä¢ Vital signs (temperature, blood pressure and pulse rate)  
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s (before dilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry  
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
ÔÉº ITV injection of IP  
‚Ä¢ IP (SB11 or Lucentis¬Æ) will be given in the study eye 
ÔÉº After ITV injection  of IP  
‚Ä¢ Ocular assessments:  
‚Ä¢ Indirect ophthalmoscopy (0-15 min post-dose) 
‚Ä¢ IOP using Goldmann applanation tonometry (30-60 min post-dose) 
‚Ä¢ Adverse event monitoring  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 69 of 137 7.16. End of Study (Visit 16, Week 52 ¬± 7 days) or Early Termination Visit  
End of study ( EOS ) or E arly Termination (ET) visit is defined as 4 weeks (¬± 7 days) after the 
last ITV injection of SB11 or Lucentis¬Æ. For ET visit, PK sampling will be excluded from the 
following procedures. 
‚Ä¢ NEI VFQ -25 ( before dilation of pupil ) 
‚Ä¢ Vital signs (temperature, blood pr essure and pulse rate)   
‚Ä¢ Physical examination (only body weight)  
‚Ä¢ Blood and urine sampling for clinical laboratory tests  
- Urine samples must be collected before performing FA to avoid false elevation in 
urine protein values 
‚Ä¢ Blood sampling for immunogenicity 
‚Ä¢ Blood sampling for systemic exposure for subjects participating  in PK evaluation   
‚Ä¢ Pregnancy test (serum or urine) at the Investigator‚Äôs discretion  
‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series ETDRS chart s or 2702 series Number 
chart s(before d ilation of the pupils and FP/FA or OCT assessment ) 
- Subject must use the same chart consistently from Screening to Week 52 (EOS 
visit) or ET visit  
‚Ä¢ Slit lamp biomicroscopy  
‚Ä¢ Indirect ophthalmoscopy  
‚Ä¢ FP & FA (images should be sent to central reading centre)  
‚Ä¢ OCT (images should be sent to central reading centre)  
‚Ä¢ IOP using Goldmann applanation tonometry   
‚Ä¢ Adverse event monitoring  
‚Ä¢ Review of concomitant medication or therapy  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 70 of 137 7.17. Early Termination of the Study  
The study can be terminated at any time for any reason by the Sponsor. Investigator may be 
informed of additional procedures to be followed in order to assure that adequate consideration is given to the protection of the subject‚Äôs interests. Investigator will be 
responsible for informing Independent Ethics Committees (IECs) of the early termination of 
the study. 
8. SAFETY MONITORING AND REPORTING  
8.1. Adverse Events  
8.1.1.  Definition of Adverse Event  
An AE is any untoward medical occurrence in a subject or clinical investigation subject administered a medicinal (investigational) pr oduct or other protocol-imposed intervention and 
which does not necessarily have to have a causal relationship with this treatment or 
intervention. An AE can therefore be an unfavourable and unintended sign (including an 
abnormal laboratory finding), sympt om, or disease temporally associated with the use of any 
dose of a medicinal (investigational) product or other protocol-imposed intervention, 
regardless of attribution.  
All AEs including ocular AEs in the study eye and/or fellow eye as well as systemic A Es will 
be collected from the written informed consent is obtained from the subject  until Week 52 
(EOS visit) or ET visit.  If the AMD is diagnosed in the fellow eye during the study period, the 
event should be also reported as an AE.  
Pre-existing conditions and any abnormal findings from assessments at the time of Screening 
which are not related to protocol-imposed intervention should not be reported as AEs, however pre- existing conditions which worsen (i.e., change in severity) that meets the 
definition of an AE during the study period are to be reported as AEs. 
Diagnostic and therapeutic non -invasive and invasive procedures, such as surgery, should not 
be reported as AEs. However, the medical condition for which the procedure was performed 
should be report ed if it meets the definition of an AE. For example, an acute appendicitis that 
begins during the AE reporting period should be reported as an AE and the resulting 
appendectomy should be recorded as treatment of the AE.  
The AE that emerge during the treatment with an IP (i.e., T reatment -Emergent Adverse Event 
[TEAE] ) will be analysed for the purposes of safety analyses.  
8.1.2.  Period of Observation for Adverse Events  
All AEs (ocular or systemic) will be recorded from the written informed consent is obtained 
from the subject  until Week 52  (EOS visit) or ET visit.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 71 of 137 SAEs  that occurred at or before Week 52 ( EOS visit) or ET  visit must be reported to Sponsor 
or its designated representative via eCRF SAE report form  at least within 24 h ours of the 
Investigator becoming aware of the event.  
SAEs that are considered to be related to the IP can be collected regardless of the study 
period. SAEs that occurred after Week 52 (EOS visit) or ET visit and that are considered to 
be related to the IP must be reported to Sponsor or i ts designated representative using the 
paper SAE report form at least within 24 h ours of the Investigator becoming aware of the 
event (see Section 8.2.2.).   
Date and time (wherever possible) of Investigator becoming aware of the SAE will be 
recorded in the SAE form and source document properly. 
Unresolved AEs should be followed up until the Week 52 ( EOS  visit) or ET visit and 
follow-up information will be recorded in the eCRF. The I nvestigator should provide prop er 
monitoring of subject‚Äôs status and related AEs for appropriate medical care of the subject  
until AE resolution or stabilisation.  
Unresolved  SAE at Week 52 (EOS visit) or ET visit will be followed until event resolution or 
stabilisation (see Section  8.2.2.).   
8.1.3.  Reporting Adverse Events 
AEs are to be reported and reviewed by Investigator. When reporting an AE, a diagnosis 
(when possible and appropriate) rather than each individual signs and symptom s should be 
reported. 
Each AE is to be assessed to determine if it meets the criteria of an SAE (see Section  8.2. for 
SAE definition). If an AE is classed as an SAE, it must be reported to Sponsor, or its 
designated representa tive, promptly according to the timeline specified in Section  8.2.2.  
For a n SAE, a diagnosis with a description of signs and symptoms as well as other supporting 
information that led to the diagnosis should be described in the SAE report form and reported 
to the Sponsor, or its designated representative, according to the procedures described in Section  8.2.2.  
8.1.4.  Severity Assessment  
Investigator is responsible for assessi ng and reporting the severity of AEs. The following 
classification should be used to classify AEs:  
‚Ä¢ Mild events are usually transient and do not interfere with the subject‚Äôs daily activities.  
‚Ä¢ Moderate events introduce a low level of inconvenience or concern to the subject and  
may interfere with daily activities.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 72 of 137 ‚Ä¢ Severe events interrupt the subject‚Äôs usual daily activity.  
8.1.5.  Causality Assessment  
Investigator is responsible for assigning a causal relationship to each AE. The causal 
relationship between the IP and  the AE should be defined as not related (no) or related (yes).  
Events should be classified as ‚Äúrelated‚Äù if there is a reasonable possibility that the IP caused the AE. This means that there are facts (evidence) or arguments to suggest a causal 
relationshi p. 
Events should be classified as ‚Äúnot related‚Äù if there is no reasonable possibility that the IP 
caused the AE.  
8.1.6.  Emergency Unmasking for Safety Reasons  
Unmasking  should be considered only when knowledge of the treatment group assigned to 
subject  is deemed essential for the subject‚Äôs safety by Investigator. Emergency unmasking 
may be performed by Investigator through IWRS system if deemed necessary during the study period after randomisation.  
If the treatment group assigned to subject is unmasked , Investigat or should promptly 
document and explain to the Sponsor about any premature unmasking (e.g., accidental 
unmasking, unmasking due to a serious adverse event) of the investigational product(s) which is treated to the subject .  
Pertinent information regarding the circumstances of unmasking of a subject‚Äôs treatment 
group must be documented in the subject‚Äôs source documents. This includes who performed 
the unmasking, the subject(s) affected, the reason for the unmasking , the date of the 
unmasking  and the relevant IP information.  
After unma sking (except unmasking  for the purpose of pre-planned regulatory reporting in 
Section 5.2.4.), subjects will be discontinued from the IP (Refer to Section  4.3.).  
8.1.7.  Expectedness Assessment  
Expectedness of AEs will be assessed by referring to the safety information in the 
Investigator‚Äôs Brochure ( IB) of the relevant safety section. More detailed information on 
expectedness assessment will be explained in the IB. The latest SmPC of Lucentis
¬Æ, Annex I 
of EPAR Product Information posted on EMA website, will be used to assess the 
expectedness for the AEs. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 73 of 137 8.1.8.  Withdrawal due to Adverse Events  
Subject withdrawal from the IP due to an AE should be distinguished from withdrawal due to 
personal reasons. Subjects withdrawn due to an AE will be followed up until the time point 
specified in the protocol  (refer to Section  4.3.). If s ubjects cannot be followed, the reasons will 
be documented by the I nvestigator (e.g. , lost to follow -up, refusal to be followed up). When a 
subject withdraws from the IP due to an SAE, the SAE must be reported and followed in 
accordance with the requirements outlined in Section 8.2.2.  
Subjects who are discontinue d from  IPs because of serious or significant safety issues should 
be followed closely until the events are fully and permanently resolved or stabilised.  
8.2. Serious Adverse Events  
8.2.1.  Definition o f Serious Adverse Event  
An SAE is any untoward medical occurrence at any dose that:  
‚Ä¢ Results in death   
‚Ä¢ Is life -threatening  
‚Ä¢ Requires inpatient hospitalisation or prolongation of existing hospitalisation 
‚Ä¢ Results in persistent or significant disability/incapacity  
‚Ä¢ Results in congenital anomaly/birth defects  
‚Ä¢ Is medically important  
Life-threatening  
The term ‚Äúlife -threatening‚Äù in the definition of ‚Äúserious‚Äù refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to  an event which 
hypothetically might have caused death if it were more severe.  
Hospitalisation  
AEs reported from clinical studies associated with hospitalisation or prolongation of existing 
hospitalisation are considered serious. 
Any admission to a healthc are facility more than 24 hours meets these criteria. Admission also 
includes transfer within the hospital to an acute/intensive care unit (e.g., from the medical 
floor to a coronary care unit, neurological floor to a tuberculosis unit). Staying at the observation unit in the emergency room for more than 24 hours qualifies for hospitalisation. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 74 of 137 Any events leading to a subsequent emergency ro om visit or inpatient hospitalis ation for less 
than 24 hours may be regarded as medically important for its seriousness criteria, at the 
discretion of the Investigator based on medical judgement. 
Hospitalis ation or prolongation of existing hospitalis ation in the absence of an AE is not in 
itself an SAE. Examples include:  
‚Ä¢ Admission for treatment of a pre- existing (prior to ICF signed) condition not 
associated with the development of a new AE or with a worsening of the pre- existing 
condition 
‚Ä¢ Diagnostic admission (e.g., for work-up of persistent pre- treatment laboratory 
abnormality) 
‚Ä¢ Social admission (e.g., study subject has no place to sleep)  
‚Ä¢ Administrative admission (e.g., for a regular check -up) 
‚Ä¢ Protocol-specified admission during a clinical study (e.g., for a procedure required by 
the study protocol) 
‚Ä¢ Elective admission not associated with an AE (e.g., for elective cosmetic surgery)  
‚Ä¢ Pre-planned treatments or surgical procedures  
: Pre-planned treatments or surgical procedures should be noted in the relevant source 
document for the individual subject.  
Medical and scientific judgement should be exercised in deciding whether expe dited reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life -threatening or result in death or hospitalisation. However, if it is determined 
that the event may jeopardise the subject and may require intervention to prevent one of the 
other outcomes listed in the definition above, the important medical event should be reported as serious. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dy scrasias or convulsions that do not result in hospitalisation 
or development of drug dependency or drug abuse. 
The term ‚Äúsevere‚Äù is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This is not the same as ‚Äúserious,‚Äù which is based on subject/event outcome or action criteria usually associated with events that pose a threat to a subject‚Äôs life or functioning. 
In addition, sight -threatening ocular adverse event will be reported as SAE if it meets one or 
more of the following criteria:   
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 75 of 137 ‚Ä¢ A decrease in VA of ‚â• 30 letters from  the last  assessment of VA 
‚Ä¢ A decrease in VA to the level of Ligh t Perception or worse  
‚Ä¢ Requirement of surgical intervention (e.g., conventional surgery, vitreous tap or 
biopsy with ITV injection of anti-biotics , laser  treatment, ITV gas injection,  or retinal 
cryopexy) to prevent permanent loss of vision  
‚Ä¢ Severe intraocu lar inflammation ( e.g., 4+ anterior chamber cell/flare or 4+ vitritis).  
‚Ä¢ In the investigator‚Äôs opinion, medical  intervention may be required to prevent 
permanent loss of vision. 
8.2.2.  Reporting Serious Adverse Events  
SAEs  that occurred at or before Week 52 ( EOS visit) or ET visit must be reported to Sponsor 
or its designated representative via eCRF SAE report form  at least within 24 h ours of the 
Investigator becoming aware of the event.  
SAEs that occurred after Week 52 (EOS visit) or ET visit and that are considered to be related 
to the IP must be reported to Sponsor or its designated representative using the paper SAE 
report form at least within 24 h ours of the Investigator becoming aware of the event.  
Date and time (wherever possible) of Investigator becoming aware of the SAE will be 
recorded in the SAE form and source document  properly. 
In particular, if the SAE is fatal or life -threatening, Sponsor must be notified immediately, 
irrespective of the extent of available SAE information. This timeframe also appli es to 
additional (follow -up) information that becomes available on previously forwarded SAE 
reports. Sponsor will then follow expedited reporting procedures according to local and 
international regulations as appropriate. 
The Investigator is obligated to p ursue and provide information to Sponsor on all SAEs in 
accordance with the timeframes for reporting specified above. In addition , Investigator may be 
requested by Sponsor to obtain specific additional follow- up information in an expedited 
fashion. In general, this will include a description of the SAE, which should be provided in 
sufficient detail so as to allow for a complete medical assessment of the case and independent 
determination of possible causality. Information on other possible causes of the event, such as 
concomitant medications and illnesses must be provided. In the case of a subject death, a summary of available autopsy findings must be submitted as soon as possible to Sponsor or its designated representative.  
All SAEs will be followed until event resolution or stabilisation (for chronic events), if possible, even when a subject is discontinued from IP. For chronic events that does not fully 
resolve until years later, the outcome should be reported as ‚Äúresolved with sequelae‚Äù as soon 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 76 of 137 as the event has stabilised or returned to baseline. Follow -up information for the SAE should 
be actively sought and submitted as the information becomes available.  
8.3. Adverse Events of Special Interest  
The following AEs in  the study eye will be class ified as  Adverse Events of Special Interests 
(AESIs ) in this study:  
‚Ä¢ Any case of new onset IOP of > 21 mm Hg that does not respond to treatment, except 
the transient pressure rise observed within an hour  after ITV injection  of IP  
‚Ä¢ Any case of IOP ‚â• 35 mmHg , at any time, that required treatment 
‚Ä¢ Any case of intraocular infection such as endophthalmitis 
‚Ä¢ Any case of intraocular inflammation  such as iritis, vitritis and iridocyclitis  
‚Ä¢ Iatrogenic traumatic cataract  
‚Ä¢ Arterial thromboembolic events defined as nonfatal stroke, nonfatal myocardial 
infarction, or vascular death (including deaths of unknown as cause) 
8.4. Pregnancy  
Any pregnancy, including those of female partners of male subjects treated with the IP, should 
be reported to the Sponsor. If the female partner of a male subject becomes pregnant, a written 
informed consent must be obtained from the female partner before collecting any pregnancy-
related data. All pregnancies associated with the subject, from the time the subject receives the 
first ITV injection of IP  until either Week 52 (EOS visit)  or ET visit, should be reported to the 
Sponsor. Pregnancy reports should be submitted to the Sponsor within 24 hours  from when  
the Investigator became aware of the pregnancy , using the Pregnancy Report Form. 
Although pregnancy is not an AE, all pregnancies must be followed up every 2 months until 
6-8 weeks after the outcome of the pregnancy becomes available,  unless the subject is lost to 
follow-up. The pregnancy outcome should be notified to the Sponsor by submitting a follow-
up Pregnancy Report Form. If the outcome of the pregnancy meets the SAE criteria then the Investigator should report this case according to the SAE reporting process ( Section  8.2.2. ). 
8.5. Independent Data and Safety Monitoring Board  
An independent D ata and Safety Monitoring B oard (DSMB) will be assigned for this study. 
The DSMB will consist of external experts (e.g., physician, clinical pharmacologists or 
biostatisticians) and will revie w the safety and tolerability data from the study at pre- specified 
intervals. The details of the safety data and time points for review will be described in the 
DSMB Charter and in the DSMB Statistical Analysis Plan (SAP).  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 77 of 137 In addition, an ongoing masked  review of AEs, including clinical laboratory data will be 
continuously undertaken by the Sponsor medical monitor and pharmacovigilance team. 
9. STATISTICAL METHODS AND DATA ANALYSIS  
Further information on the statistical methods to be used in this study will be provided in the 
SAP, which will be finalised prior to the database lock for reporting the main  CSR . 
Statistical analysis and reporting will be performed as follows:  
‚Ä¢ Interim safety analysis for independent DSMB  meeting:  
A DSMB SAP, describing the methodol ogy and presentation of results and access to 
results will be prepared as a separate document  and included in the DSMB Charter . The 
safety reports for the DSMB data review meetings will be prepared according to the 
DSMB SAP.  
The statistical analysis will be performed by an independent statistical reporting team and 
the results will be communicated to the DSMB directly by an independent unmasked 
statistician.  
‚Ä¢ Main CSR:  
The main  analysis will take place once all  subjects complete the procedures at Week 24, 
or its corresponding visit . Available efficacy and safety data, pharmacokinetics, and 
immunogenicity data  will be analysed and reported . 
At the time of this reporting,  a limited number of identified individuals of the Sponsor or 
CRO  will be un masked for rep orting purpose. However, s ubjects, I nvestigators, and 
other study personnel will remain masked  throughout the entire study period. 
‚Ä¢ Final CSR:  
The final analysis will take place after the last subject completes the procedures at Week 
52 or the corresponding  visit. All study data will be analysed and reported for final CSR. 
9.1. Analysis Sets 
The following sets will be used for the analyses performed in the study: 
‚Ä¢ Randomised S et (RAN) consists of all subjects who receive a randomisation number 
at the randomis ation  visit .  
‚Ä¢ Full Analysis Set (FAS) consists of all subjects who are randomi sed at the 
randomis ation visit. Following the intent- to-treat principle, subjects will be analysed 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 78 of 137 according to the treatment group they are assigned to at randomis ation. However, 
subjects who do not qualify for randomisation and are inadvertently randomis ed into 
the study will be excluded from the FAS, provided these subjects do not receive IP 
during the study period. The FAS will be the primary analysis set for BCVA  
‚Ä¢ Per-Protocol S et for BCVA (PPS- BCVA) consists of all FAS subjects who have first 
two IP injections and complete the procedures at Week 8 without any major protocol 
deviations that have impact on the BCVA assessment. Major protocol deviations that will lead to exclusion from this set will be pre -defined prior to unmasking the 
treatment group assignment for analyses. 
‚Ä¢ Per-Protocol S et for CST (PPS- CST) consists of all FAS subjects who have the first  
IP injection at Week 0 (Day 1 ) and complete the procedures at Week 4 without a ny 
major protocol deviations that have impact on the CST  assessment. This PPS -CST 
will be the primary analysis set for CST. Major protocol deviations that will lead to 
exclusion from this set will be pre-defined prior to unmasking the treatment codes for 
analyses . 
‚Ä¢ Safety Set (SAF) consist s of all subjects who receive at least one IP during the study 
period after randomisation. Subjects will be analysed according to the IP received . 
‚Ä¢ Pharmacokinetic Analysis S et (PKS)  consist s of all subjects in the SAF who 
participate  in PK  evaluation  at PK Investigational sites (PK subjects) and have at least 
one PK  sample analysed .  
9.2. Statistical Methods and Analytical Plan  
9.2.1.  Demographics and Baseline Characteristics 
Subject demographics and baseline characteristics will be sum marised by treatment group for 
the RAN and PKS. Continuous variables (e.g., age, weight, height) will be summarised with descriptive statistics (n, mean, SD, median, minimum, maximum)  and c ategorical variables 
(e.g., gender, race, ethnicity) will be summarised with frequency and percentage.  
Comparison between  treatment groups in baseline characteristics will be performed using the 
chi-square test or F -test as appropriate. The results of these tests will be provided including 
the p- value only for descriptiv e purposes and will not be used as a formal basis to determine 
the factors to be included in primary or secondary efficacy analysis models. If baseline 
imbalances are detected for any of the factors, additional analyses may be performed to adjust for these  baseline differences.  
Relevant medical history will be summarised by treatment group for the RAN. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 79 of 137 Duration of exposure to IP and number of injections will be summarised by treatment group 
with descriptive statistics for the SAF. Prior and concomitant medications and significant non-
drug therapies will be summarised by treatment group with frequency and percentage.  
9.2.2.  Efficacy  
For US FDA, Korea MFDS or other regulatory agency submissions for those who are in 
favour of the VA, t he primary efficacy analysis will be performed for the FAS with the 
change from baseline of BCVA at Week 8 using an analysis of covariance model with the 
baseline BCVA as a covariate and region (or pooled centres) and treatment group as factors. 
The equivalence in BCVA will be declared if  the two -sided 90 % Confidence I nterval (CI) of 
the difference in terms of  BCVA Least Squares mean ( LS mean ) changes from baseline at 
Week 8 between SB11 and Lucentis¬Æ lies within the pre -defined equivalence margin of [‚àí 3 
letters, 3 letters].  
For EMA or other regulatory agency submissions for those who are in favour of the 
anatomical parameter, the primary efficacy analysis will be performed for the per -protocol set 
(PPS- CST)  with the change from baseline of  CST at Week  4 using an analysis of covariance 
model with baseline CST as a covariate and region (or pooled centres) and treatment group as 
factors . The equivalence in CST will be declared if the two -sided 95% CI of the difference of 
the CST LS mean changes from basel ine in Week 4 between SB11 and Lucentis¬Æ lies within 
the pre -defined equivalence margin of [‚àí36 Œºm, 36 Œºm]. 
No formal adjustment of Type I error rates will be performed. 
For the primary analysis with the FAS for BCVA, missing data will be imputed for subjects 
who drop out for the study prior to the primary analysis time-point. A missing- at-random 
approach will assume that subjects who withdraw from a study had missing values similar to similar subjects who completed the study in that treatment group. This approach ensures that evidence of lack of equivalence is not diluted when there are missing d ata. For the 
components of BCVA, the missing letter will be imputed by multiple imputation method with 
the assumption of monotone missing pattern and regression method. For the sensitivity 
analyses, available case analysis and last observation carried forward analysis will be performed.  
All other secondary efficacy measurements will be summarised descriptively by treatment 
group and visit, and analysed using analysis of covariance model for continuous outcomes or 
Cochran- Mentel -Haenszel method for categori cal outcomes unless otherwise specified . 
9.2.3.  Safety 
All reported terms for AEs (ocular and systemic) will be coded using Medical Dictionary for 
Regulatory Activities ( MedDRA
¬Æ). For all AE and SAE tables, subjects will be counted once 
for each preferred term an d each system organ class.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 80 of 137 A TEAE will be defined as any AE with an onset date on or after the date of the first ITV 
injection of  IP. AEs which are already present before the first ITV injection of  IP and increase 
in severity after the first ITV injection  of IP will be considered as TEAEs. Pre- existing AEs 
before the first ITV injection of  IP with no increase in severity after the first ITV injection of 
IP will not be considered as TEAEs.  
All TEAEs and SAEs will be summarised  respectively for study eye (o cular TEAE), fellow 
eye (ocular TEAE) and others (systemic TEAE) by the frequency and percentage of subjects 
experiencing events by system organ class, preferred term and treatment group. SAEs leading 
to IP discontinuation and TEAEs by causality and severi ty will be summarised similarly. All 
AEs including those pre- existing before the first ITV injection of IP  will be listed by subject.   
In addition, systemic TEAEs will also be summarised without subjects who received 
Lucentis¬Æ in the  fellow eye due to AMD during the study  period after randomisation.  
Changes in vital signs and clinical laboratory parameters will be summarised descriptively by 
treatment group and visit . Other safety variables will be summarised unless otherwise 
specified, and all safety vari ables will be listed.  
All safety analyses will be performed using the SAF.  
9.2.4.  Pharmacokinetics  
Blood sampling for PK will be collected in approximately 40 subjects participating in PK 
evaluation ( 20 subjects per treatment group). The systemic exposure will be summarised 
descriptively by treatment group and visit.  
If fellow eye received Lucentis¬Æ due to AMD during the study period after randomisation, the 
concentration measured after treatment for the fellow eye will be listed, but excluded from the 
summary statistics.  
9.2.5.  Immunogenicity  
The number and proportion of subjects with ADA and NAb results (e.g., ‚Äúpositive‚Äù or 
‚Äúnegative‚Äù) will be summarised by treatment group and visit.  
If fellow eye received Lucentis¬Æ due to AMD during the study period after randomisat ion, the 
ADA and NAb results obtained after treatment for the fellow eye will be listed, but excluded 
from the summary statistics.  
9.2.6.  NEI VFQ -25 
Subscale scores (general health, general vision, ocular pain, near activities, distance activities, 
vision -specifi c social functioning, vision- specific mental health, vision -specific role 
difficulties, vision -specific dependency, driving, colour vision, and peripheral vision) and the 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 81 of 137 composite score, which represent overall visual function, will be calculated, and the change 
from baseline will be summarised by treatment group and visit. 
In addition, the subscale scores and composite score of NEI  VFQ -25 will be also summarised 
without subjects who received Lucentis¬Æ in the fellow eye due to AMD during the study 
period a fter randomisation. 
9.3. Determination of Sample Size  
For the calculation of the equivalence margin  for BCVA, the mean changes in VA were 
referred from two studies of Lucentis¬Æ in subjects with neovascular AMD. In MARINA study, 
the mean change of VA at Week 24 (SD) were ‚àí6.6 (13.31) letters and 6.5 (12.00) letters for 
placebo and 0.5 mg Lucentis¬Æ treatment groups, respectively. In FOCUS study, the mean 
change (SD) of VA at Week 24 were ‚àí5.0 (16.14) letters and 4.0 (14.41) letters for placebo 
and 0.5 mg Lucentis¬Æ treatment groups , respectively.  
A fixed -effect meta- analysis of the above two studies estimates a weighted mean change in 
VA of 12.41 letters with a 95% CI [10.34 letters; 14.48 letters]. The derived equivalence limit 
from meta -analysis is 4.9 letters at Week 24, but by the agency recommendation the 
equivalence limit at Week 8 will be 3 letters for the comparison with the 90% CI of mean 
difference between treatment groups.  
With the given equivalence margin of [‚àí 3 letters, 3 letters], 334 subjects per treatment groups 
was calculated with the assumptions of the mean difference of 0.5 letters and pooled standard deviation (SD)  of 12.5 letters at the overall 5% significance level. Assuming a 5% loss from 
randomised subjects after  8 weeks , a sample size of 352 subjects per treatment groups (overall 
sample size of 704) will give 334 completers per treatment group after 8 weeks, which is 
estimated to give 80% power to detect the equivalence within the margin of 3 letter s. 
For the calculation of the equivalence margin  for CST, the mean changes in CST were 
referred from two studies of Lucentis
¬Æ in subjects with neovascular AMD. In MARINA study, 
the mean change of CST  at Week 4 (SD) was 8.1 (58.1) Œºm and ‚àí106 (122.5) Œºm for placebo 
and 0.5 mg Lucentis¬Æ treatment groups, respectively. In PIER study, the mean change (SD) of 
CST at Week 4 were 15 (94.9) Œºm and ‚àí90 (140.9) Œºm for placebo and 0.5 mg Lucentis¬Æ 
treatment groups , respectively.  
A fixed -effect meta- analysis of the above two studies estimates a weighted mean change in 
CST of ‚àí109.6 Œºm with a 95% CI [‚àí146.45 Œºm; ‚àí72.65 Œºm]. The derived equivalence limit 
from meta -analysis is 36 Œºm at Week 4. 
With the given equivalence margin of [‚àí36 Œºm, 36 Œºm], 290 subjects per treatment group was 
calculated with the assumptions of the mean difference of 0 between treatment groups, common SD  of 133.3 Œºm at the overall 5% significance level. Assuming a 10% loss from 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 82 of 137 FAS, a sample size of 323 per arm (overall sam ple size of 646) will give 80% power to detect 
the equivalence within the pre -defined margin. 
Therefore, the sample size of 704 allows enough power to detect the equivalence between 
treatment groups in both situations.  
10. DATA COLLECTION AND MANAGEMENT  
10.1. Data C onfidentiality  
Information about study subjects will be kept confidential. Subject identification information will be labelled with a code number, and will not include the subject‚Äôs name or other 
information that could identify them. A list linking the cod e and the subject‚Äôs name will be 
kept in the Investigational site files as required by International Council for Harmonisation 
(ICH) Guideline for Good Clinical Practice (GCP) to protect the subject‚Äôs confidentiality.  
The coded information will be sent to the Sponsor (or designee) who will analyse it and report the study results both to regulatory and ethical authorities. The Sponsor may also place data 
on public websites or publish journal articles based upon these results. Subject names or other directly identifiable information will not appear on any reports, publications, or other 
disclosures of clinical study outcomes. Care will be taken to prevent subjects being identified through these publications. In addition, data may be shared with other companies or 
researchers to aid further research into AMD . Such data sharing practices will be covered by 
confidentiality agreements. No -one outside the Investigat ional site will have access to subject -
identifiable information. 
10.2. Monitoring  
The Sponsor has engaged the services of a CRO to perform all monitoring functions within 
this clinical study. The monitors will work in accordance with the CRO Standard Operation Procedures ( SOPs) and have the same rights and responsibilities as monitors from the Sponsor 
organisation. Monitors will establish and maintain regular contact between the Investigator and the Sponsor. 
Monitors will evaluate the competence of each Investigational site and inform the Sponsor 
about any problems relating to facilities, technical equipment or m edical staff. During the 
study period, monitors will check that written informed consent has been obtained correctly 
from all subjects and that data are recorded correctly and completely. Monitors will also perform source data verification by comparing ent ries in the eCRF with corresponding source 
data and informing the Investigator of any errors or omissions. Monitors will verify adherence to the protocol at the Investigational site. All protocol deviations will be reported to the 
Sponsor via the Monitoring Visit Reports. Monitors will arrange for the supply of IP and ensure appropriate storage conditions are maintained.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 83 of 137 Monitoring visits will be conducted at regular intervals according to  ICH  GCP. The monitor 
will provide written reports to the Sponsor on each occasion they make contact with the 
Investigator regardless of whether it is by phone or in person. 
Further details on the monitoring processes and the level of source data verification to be 
performed will be outlined in the monitoring plan. 
10.3. Data Han dling and Record Keeping  
The Investigator must maintain essential study documents including protocol and protocol 
amendments, completed eCRFs, signed written ICFs  and its revisions/updates, completed 
eCRFs, other  relevant correspondence according to ICH GCP and other relevant study 
requirements (if applicable) until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years af ter the formal termination of clinical 
development of the IP or 15 years from completion of the study , or whichever longer 
according to the relevant local laws and/or regulations. These documents should be retained for a longer period if required by the applicable regulatory requirements or the Investigational 
site, institution or private practice in which the study is being conducted. Subject identification codes (subject names and corresponding study numbers) will be retained for the 
same period of time. These documents may be transferred to another responsible party, 
deemed acceptable by the Sponsor, and who agrees to abide by the retention policies. Written 
notification of transfer must be submitted to the Sponsor. The Investigator must contact the Sponsor prior to disposing of any study records and obtain written permission to do so. 
10.4. Database Management and Coding 
Data generated within this clinical study will be handled according to the relevant SOPs of the 
data management of the Sponsor (or an appropriate company designated by the Sponsor to perform these activities). The study eCRF is the primary data collection instrument for the study. Subject data will be captured in an eCRF and reviewed by the monitor in order to check 
adherence to the protocol and to detect any data inconsistency or discrepancy  from source 
document. 
The Investigator must ensure that the clinical data required by the study protocol are carefully 
reported in the eCRF. He/she must also check that the data reported in the eCRF correspo nd to 
those in the medical records. The investigator will sign all collected data in eCRF.  
Forms should be available during periodic visits by study monitors to enable review for completeness and acceptability. Any correction to the data entered into the eCRF must be carried out by the Investigator or a designated member of staff. These changes may be made either on the initiative of the Investigational site staff or in response to monitoring or data 
queries. Any changes to written data must be made using I CH GCP corrections and any 
change to electronic data should be made in a system which can provide an audit trail. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 84 of 137 Monitors and clinical data managers will review the eCRF for accuracy and can generate 
queries to the investigational staff for resolution. Co rrections will be recorded in an audit trail 
that records the old information, the new information, and identification of the person making the changes, date of correction made and reason for change. The Investigator must sign and 
date the eCRF pages as in dicated. 
Medical/surgical history and underlying diseases and AEs will be coded using MedDRA
¬Æ. 
Concomitant medications will be coded using the World Health Organi sation -Drug Dictionary 
Enhanced (WHO- DDE). The versions of coding dictionaries used will be st ated in the clinical 
study report.  
10.5. Quality Control and Quality Assurance 
During the conduct of the study, Sponsor or its agent will conduct periodic monitoring visits 
to ensure that the protocol and ICH GCP are being followed. The monitors may review sourc e 
documents to confirm that the data recorded on the eCRFs are accurate. The Investigator and 
institution will allow the domestic and foreign regulatory authorities, sponsor‚Äôs monitors and 
auditors‚Äô direct access to source documents to perform this verific ation. The Investigational 
site may be subject to review by the IEC, and/or to quality assurance audits performed by Sponsor, and/or to inspection by appropriate regulatory authorities. It is important that 
Investigator s and their relevant personnel are available during the monitoring visits and 
possible audits or inspections and that sufficient time is devoted to the process.
 
11. ETHICAL CONSIDERATIONS AND ADMINISTRATIVE 
PROCEDURES  
11.1. Institutional Review Boards and Independent Ethics Committees  
The Investigator and the Sponsor will follow all local laws and regulations relating to conta ct 
with and approvals from the I nstitutional Review Board (IRB)/IEC.  
The Investigator must provide the Sponsor with documentation of IRB/IEC approval of the 
protocol and written in formed consent before the study may begin at the Investigat ional s ite. 
The Investigator will supply documentation to the Sponsor relating to the annual renewal of the protocol from the IRB/IEC and any approvals of revisions to the ICF or amendments to the protocol.  
The Investigator will report promptly to the IRB/IEC any new information that may adversely 
affect the safety of subjects or the conduct of the study. Similarly, the Investigator will submit 
written summaries of the study status to the IRB/IEC on a regular basis and in accordance with the timelines required locally. Upon completion of the study, the Investigator will provide the ethics committee with a report on the outcome of the study if required by local regulations.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 85 of 137 11.2. Ethical Conduct of the Study  
This study will be conducted in compliance with the protocol, the ICH GCP, the Declaration 
of Helsinki (2013) and other relevant laws and/or regulations. 
11.3. Written Informed Consent  
The written informed consent  will be used to explain the risks and benefit s of study 
participation to the subject in simple terms prior to any study related procedures . The written 
informed consent contains a statement that the consent is freely given, that the subject is 
aware of the risks and benefits of entering the study, an d that the subject is free to withdraw 
from the study at any time. Written consent must be given by the subject after the receipt of detailed information on the study.  
The Investigator is responsible for ensuring that informed consent is obtained from each 
subject  and for obtaining the appropriate signatures and dates on the written informed consent 
prior to the performance of any protocol procedures and prior to the first ITV injection of IP . 
The Investigator will provide each subject  with a copy of the s igned and dated written 
informed consent and this will be documented in the subject‚Äôs source notes.  
If the subject is legal  blindness or illiterate , an impartial witness should be present during the 
entire informed consent discussion. After the written in formed consent and any other written 
information to be provided to subjects is read and explained to the subject, and after the 
subject  has orally consented to the subject‚Äôs participation in the study, and, if capable of doing 
so, has signed and personally dated the  written informed consent , the witness should sign and 
personally date the written informed consent . By signing the written informed consent , the 
witness attests that the information in the written informed consent and any other written 
information was accurately explained to the subject  and apparently understood by the subject, 
and that written informed consent  was freely given by the subject.  
11.4. Investigator Information  
11.4.1.  Investigator Obligations  
This study will be conducted in accordance with the IC H GCP (1997), ICH GCP E6 R2 
(2016), the ethical principles that have their origin in the Declaration of Helsinki (2013) and other local laws and /or regulations. 
The Investigator is the qualified physician who is responsible for ensuring that the study is 
conducted according to the signed Investigator statement, the study protocol and applicable 
regulations; for protecting the rights, safety and welfare of subjects under the Investigator‚Äôs 
care; and for the control of drugs under investigation. The Investigator must obtain the written informed consent of each subject to whom IP will be  administered. The Investigator is also 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 86 of 137 responsible for supervising any individual or party who conducts study- related duties at 
Investigational site to ensure the integrity.  
11.4.2.  Coordinating Investigator  
Sponsor will designate a Coordinating Investigator among the Investigators who participate in 
the study. The roles of the Coordinating Investigator are defined as following: 
‚Ä¢ Provid e scientific and medical advice and/or inputs on cur rent medical practice, 
protocol development and Investigational site selection  
‚Ä¢ Review ongoing study activities with Interpretation and presentation of final analyses 
‚Ä¢ Review clinical study reports  
‚Ä¢ Involved in development of publication strategy 
‚Ä¢ The designat ed Coordinating Investigator will sign the signature page of CSR as a  
representative of other Investigators.  
11.4.3.  Training of Investigational Site Personnel  
Before the first subject is enrolled into the study, a Sponsor representative will review and 
discuss t he requirements of the Clinical Study Protocol and related documents with the 
investigational staff and will also train them in any study -specific procedures.  
The Investigator will ensure that appropriate training relevant to the study is given to all Investigational site staff and that any new information relevant to the performance of this 
study is forwarded to the staff involved.  
The Investigator will maintain a record of all individuals involved in the study (medical, nursing and other staff). 
11.4.4.  Protocol Signatures  
The Investigator must sign the Investigator Signature Page of this protocol prior to enrolling 
subjects in  the study. By signing the protocol signature page, the Investigator attests  in writing 
that he or  she has read, underst ood, and will condu ct the study in accordance with the study 
protocol, ICH GCP and  other relevant local laws and/or regulations.  
11.5. Financing and Insurance  
Samsung Bioepis Co., Ltd. is the Sponsor of this study and will support the financ ial aspects 
for the study conduct at the Investigational site.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 87 of 137 Details of financial agreements are provided in the Clinical Study Agreements with the 
Investigat ional  sites. The Sponsor has obtained suitable insurance for this study. The 
insurance details may be provided to the Investigational s ites and/or the Investigators who are 
responsible for providing the IRB/IEC with these details according to local requirements if 
any.  
12. PUBLICATION POLICY 
The Sponsor supports the efforts of health authorities to increase the transparency of medical 
resear ch conducted in human subjects. The Sponsor will register and maintain the information 
of clinical studies on a public registry program such as www.ClinicalTrials.gov. The Sponsor will comply with the guidelines of regulatory authorities with regards to public registration and disclosure of clinical study data. 
The clinical study data collected during the study are confidential and proprietary to the 
Sponsor. Sponsor shall have the right to delete any confidential or proprietary information 
contained in any proposed abstract or presentation. 
Any publications from this study should be approved by the Sponsor prior to publication or 
presentation. The rights of the Investigator with regard to publication of this study are described in the Clinical Study Agreement. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 88 of 137 13. REFERENCES  
Chakravarthy U, Wong T, Fletcher A, et al. Clinical risk factors for age- related macular 
degeneration: a systematic review and  meta -analysis. BMC Ophthalmology . 2010;10(31)  
Ferris FL 3rd, Fine SL, Hyman L. Age -related macular degeneration and blindness due to 
neovascular maculopathy. Arch Ophthalmol . 1984;102(11):1640-2. 
Fung A, Lalwani G, Rosenfeld P et al. An Optical Coherence Tomography -Guided, Variable 
Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age- related 
Macular Degeneration. Am J Ophthalmol . 2007;143(4):566‚Äì83. 
Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference 
product. U. S. Food and Drug Administration. (Apr 2015). Retrieved Dec 29, 2016 from 
http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guid
ances/UCM291128.pdf  
Guideline on similar biological medicinal products. EMEA . (Oct  2005). 
EMEA/CHMP/437/04. Retrieved Dec 29, 2016 from 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500003517.pdf  
Guideline on similar biological medicinal products containing biotechnology-derived proteins 
as active substance: quality issues (revision 1). EMEA . (Dec  2014). 
EMA/CHMP/BWP/247713/2012. Retrieved Dec 29, 2016 
from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/
WC500167838.pdf  
Guideline on similar biological medicinal products containing monoclonal ant ibodies ‚Äì non-
clinical and clinical issues. EMEA. (Dec  2012). EMA/CHMP/BMWP/403543/2010. Retrieved 
Dec 29, 2016 from 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/
WC500128686.pdf  
Lalwani G, Rosenfeld P, Fung A et al. Variable- dosing Regimen with Intravitreal 
Ranibizumab for Neovascular Age- related Macular Degeneration: Year 2 of the PrONTO 
Study. Am J Ophthalmol. 2009;148(1):43‚Äì58. 
Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate 
for biosimilars ?. AAPS J . 2014;16(1):22-26. 
Lucentis¬Æ Prescribing Information. U. S. Food and Drug Administration. (Nov 2016). 
Retrieved  Dec 29, 2016 
from http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125156s112lbl.pdf  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 89 of 137 Lucentis¬Æ Summary of Product Characteristics. EMEA. (Dec  2016). Retrieved Dec 29, 2016 
from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000715/WC500043546.pdf  
Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age -related macular 
degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. 
Arch Ophthalmol . 1991;109:1242. 
Wu EW, Schaumberg DA, Park SK. Environme ntal cadmium and lead exposures and age-
related macular degeneration in U.S. adults: the National Health and Nutrition Examination 
Survey 2005 to 2008. Environmental research . 2014;133:178-184. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 90 of 137 APPENDIX A: Grading Scale for Anterior Chamber Flare  
Grading Scale for Anterior Chamber Flare  
Flare   
0 No protein is visible in the anterior chamber when viewed by an experienced 
observer using slit lamp biomicroscopy; a small, bright, focal slit-beam of 
white light; and high magnification.  
Trace  Trace amount of protein detectable in the anterior chamber. This protein is 
visible only with careful scrutiny by an experienced observer using slit lamp 
biomicroscopy; a small, bright, focal slit-beam of white light; and high 
magnification. 
1+ Mild amount of protein det ectable in the anterior chamber. The presence of 
protein in the anterior chamber is immediately apparent to an experienced observer using slit lamp biomicroscopy and high magnification, but such protein is detected only with careful observation with the na ked eye and a 
small, bright, focal slit-beam of white light. 
2-3+ Moderate amount of protein detectable in the anterior chamber. These grades 
are similar to 1+ but the opacity would be readily visible to the naked eye of an observer using any source of a focused beam of white light, This is a 
continuum of moderate opacification, with 2+ being less apparent than 3+. 
4+ A large (severe) amount of protein is detectable in the anterior chamber. 
Similar to 3+, but the density of the protein approaches that of the lens. 
Additionally, frank fibrin deposition is frequently seen in acute circumstances.  
It needs to be noted that because fibrin may persist for a period of time after 
partial or complete restoration of the blood- aqueous barrier, it is possible to 
have  resorbing fibrin present with lower numeric assignations for flare (e.g., 
1+ flare with fibrin).  
Reference: The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of Uveitis Nomenclature for Reporting Clinical Data: Results of t he First 
International Workshop. American journal of ophthalmology . 2005;140(3): 509-516. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 91 of 137 APPENDIX B: Grading Scale for Anterior Chamber Cells  
Grading scale for anterior chamber cells  
The intensity of the cellular reaction in the anterior chamber is graded according to the 
number of inflammatory cells seen in a 1 x 3 mm high- powered beam at full intensity at a 
45¬∞-60¬∞ ang le. 
Cells   
0 No inflammatory cells. 
Trace  < 5 cells . 
1+ 5 ‚Äì 9 cells . 
2+ 10 ‚Äì 19 cells . 
3+ 20 ‚Äì 29 cells . 
4+ ‚â• 30 cells, c ells too numerous to count . 
Reference: Bloch -Michel E., Nussenblatt RB. International Uveitis Study Group 
recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol . 
1987; 103(2):234 -5. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 92 of 137 APPENDIX C: Grading Scale for Anterior Chamber and Vitreal 
Inflammatory Response  
Grading scale for anterior chamber and vitreal inflammatory response 
Cells in Retro -illuminated Field  Description  Grade  
0-1 Clear  0+ 
2-20 Few opacities  Trace  
21-50 Scattered opacities  1+ 
51-100 Moderate opacities  2+ 
101-250 Many opacities  3+ 
> 250 Dense opacities  4+ 
Reference: Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal 
inflammatory activity in intermediate and posterior uveitis. Ophthalmology . 1985;92:467-71. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 93 of 137 APPENDIX D: National Eye  Institute 25-Item Visual Function 
Questionnaire (NEI VFQ -25 questionnaire)  
 
National Eye Institute  
Visual Functioning Questionnaire - 25 
(VFQ -25) 
 
version 2000  
 
  
(INTERVIEWER ADMINISTERED FORMAT)  
 
  
 
 
 
January 2000 
  
 
  
RAND hereby grants permission to use the "National Eye Institute Visual Functioning Questionnaire 25 (VFQ -25) July 1996, in 
accordance with the following conditions which shall be assumed by all to have been agreed to as a consequence of accepting a nd 
using this document:  
 1.  Changes to the NEI VFQ- 25 - July 1996 may be made without the written permission of RAND.  However, all such changes 
shall be clearly identified as having been made by the recipient.  
 2.  The user of this NEI VFQ -25 - July 1996 accepts full responsibility, and agrees  to hold RAND harmless, for the accuracy of 
any translations of the NEI VFQ -25 Test Version - July 1996 into another language and for any errors, omissions, 
misinterpretations, or consequences thereof.  
 
3.  The user of this NEI VFQ -25 - July 1996 accepts f ull responsibility, and agrees to hold RAND harmless, for any consequences 
resulting from the use of the NEI VFQ -25. 
 4.  The user of the NEI VFQ -25 - July 1996 will provide a credit line when printing and distributing this document or in 
publications of results or analyses based on this instrument acknowledging that it was developed at RAND under the sponsorship 
of the National Eye Institute.  
 5.  No further written permission is needed for use of this NEI VFQ -25 - July 1996.  
 
7/29/96  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 94 of 137 Instructions: 
I‚Äôm g oing to read you some statements about problems which involve your vision or feelings 
that you have about your vision condition.  After each question I will read you a list of 
possible answers.  Please choose the response that best describes your situation . 
Please answer all the questions as if you were wearing your glasses or contact lenses (if any).  
Please take as much time as you need to answer each question.  All your answers are confidential.  In order for this survey to improve our knowledge about vision problems and how they affect your quality of life, your answers must be as accurate as possible.  Remember, 
if you wear glasses or contact lenses for a particular activity, please answer all of the 
following questions as though you were wearing them. 
   
 
   
 
    
 
 
    
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 95 of 137 Visual Functioning Questionnaire - 25 
 
 PART 1 - GENERAL HEALTH AND VISION  
  
1. In general , would you say your overall health
 is*:  
 
 (Circle One)  
READ CATEGORIES:  Excellent  ......................................   1 
 Very Good ...................................   2 
 Good ............................................   3 
 Fair ...............................................   4 
 Poor ..............................................   5 
 
 
  
2. At the pr esent time, would you say your eyesight using both eyes (with glasses or 
contact lenses, if you wear them) is excellent , good, fair , poor, or very poor
 or are 
you completely blind ? 
 
 (Circle One)  
READ CATEGORIES:  Excellent  ......................................   1 
 Good ............................................   2 
 Fair ...............................................   3 
 Poor ..............................................   4 
 Very Poor .....................................   5 
 Completely Blind  .........................   6 
 
 
  
 
 
 
 
 
__________________________________________________________________________ 
* Skip Question 1 when the VFQ -25 is administered at the same time as the SF -36 or RAND 36- Item 
Health Survey 1.0  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 96 of 137  
3. How much of the time do you worry  about your eyesight?  
 
 (Circle One)  
READ CATEGORIES:  None of the time  .......................................   1 
 A little of the time  .....................................   2 
 Some of the time .......................................   3 
 Most of the time  ........................................   4 
 All of the time?  .........................................   5 
 
4. How much pain or discomfort  have you had in and around your eyes  (for example, 
burning, itching, or aching)?  Would you say it is: 
 
 (Circle One)  
READ CATEGORIES:  None .............................................   1 
 Mild  ..............................................   2 
 Moderate ......................................   3 
 Severe, or  .....................................   4 
 Very severe?  ................................   5 
 
 
 
PART 2 - DIFFICULTY WITH ACTIVITIES  
 
The next questions are about how much difficulty, if any, you have doing certain activities 
wearing your glasses or contact lenses if you use them for that activity.  
 
5. How much difficulty do you have reading ordinary print in newspapers ?  Would you 
say you have:   
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 97 of 137  
6. How much difficulty do you have doing work or hobbies that require you to see well up 
close , such as cooking, sewing, fixing things around the house, or using hand tools? 
Would you say: 
 (READ CATEGORIES AS NEEDED)  
  (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
 
 
7. Because of your eyesight, how much difficulty do you have 
finding something on a 
crowded shelf ? 
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
 
 
8. How much difficulty do you have reading street signs or the names of stores
?    
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 98 of 137  
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or 
curbs in dim light or at night?  
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
  
10. Because of your eyesight, how much difficulty do you have 
noticing objects off to the 
side while you are walking along ? 
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme  difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  
interested in doing this ...............................................................   6 
  
11. Because of your eyesight, how much difficulty do you have 
seeing how people react to 
things  you say?  
(READ CAT EGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  
interested in doing this ...............................................................   6 
 
 
 
 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 99 of 137 12. Because of your eyesight, how much difficulty do you have picking out and matching 
your own clothes ? 
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  
interested in doing this ...............................................................   6 
 
 
13. Because of your eyesight, how much difficulty do you have visiting with people in their 
homes, at parties, or in restaurants ? 
(READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme difficulty  ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
  14. Because of your eyesight, how much difficulty do you have 
going out to see movies, 
plays, or sports events ? 
 (READ CATEGORIES AS NEEDED)  
 (Circle One)  
 No difficulty at all  ......................................................................   1 
 A little difficulty .........................................................................   2 
 Moderate difficulty  ....................................................................   3 
 Extreme diffic ulty ......................................................................   4 
 Stopped doing this because of your eyesight .............................   5 
 Stopped doing this for other reasons or not  interested in doing this ...............................................................   6 
  
 
 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 100 of 137 15. Now, I‚Äôd like to ask about driving a car .  Are you currently driving , at least once in a 
while?  
 
 (Circle One)  
 
 Yes .................................  1 Skip To Q 15c  
 No ..................................  2 
 
15a. IF NO, ASK:  Have you never  driven a car or have you given up driving ? 
 
 (Circle One)  
 
 Never drove ‚Ä¶‚Ä¶‚Ä¶‚Ä¶ 1       Skip To Part 3, Q 17  
 Gave up ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶2 
 
15b. IF GAVE UP DRIVING:  Was that mainly because of your eyesight , main ly for 
some other reason , or because of both your eyesight and other reasons ? 
 
 (Circle One)  
 
 Mainly eyesight ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..1                Skip To Part 3, Q 17  
 Mainly other reasons‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...2                Skip To Part 3, Q 17  
 Both eyesight and other reasons‚Ä¶‚Ä¶..3               Skip To Part 3, Q 17  
 
15c. IF CURRENTLY DRIVING:  How much difficulty do you have driving during 
the daytime in familiar places ?  Would you say you have: 
 
 (Circle One)  
 
 No difficulty at all  ............................................   1 
 A little difficulty  ..............................................   2 
 Moderate difficulty  ..........................................   3 
 Extreme difficulty  ............................................   4 
 
 
 
 
 
 
 
  
 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 101 of 137  
16.     How much difficulty do you have driving at night ?  Would you say you have: (READ 
CATEGORIES AS NEEDED)  
 
 (Circle One)  
 No difficulty at all  ..................................................   1 
 A little difficulty  ....................................................   2 
 Moderate difficulty  ................................................   3 
 Extreme difficulty  ..................................................   4 
 Have you stopped doing this because 
of your eyesight .....................................................   5 
 Have you stopped doing this for other  
reasons or are you not interested in  doing this ................................................................   6 
 
 
 
16a. How much difficulty do you have 
driving in difficult conditions, such as in bad 
weather, during rush hour, on the freeway, or in city traffic?  Would you say 
you have:  
(READ CATEGORIES AS NEEDED)  
 
 (Circle One)  
 No difficulty at all  ..................................................   1 
 A little difficulty  ....................................................   2 
 Moderate difficulty  ................................................   3 
 Extreme difficulty  ..................................................   4 
 Have you stopped doing this because  
of your eyesight .....................................................   5 
 Have you stopped doing this for other  
reasons or are you not interested in  doing this ...............................................................   6 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 102 of 137  
PART 3:  RESPONSES TO VISION PROBLEMS  
 
The next questions are about how things you do may be affected by your vision. For each one, I‚Äôd like you to tell me if this is true for you all, most , some , a little , or none
 of the time.  
 
 (Circle One On Each Line)  
 
READ CATEGORIES:  All of the 
time 
 Most of 
the time  
 Some of 
the time  
 A little of 
the time  
 None of 
the time  
 
17. Do you  accomplish  
less than you would  
like because of your vision?  .....  1 2 3 4 5 
 
18. Are you limited  in how long you 
can work or do other activities 
because  
of your vision? ..........................   1 2 3 4 5 
 
19. How much does pain or 
discomfort in or around your 
eyes, for example, burning, 
itching, or aching, keep you from doing what you‚Äôd like to 
be doing?  Would you say:  .......  1 2 3 4 5 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 103 of 137  
For each of the following statements, please tell me if it is definitely true, mostly true, mostly 
false, or definitely false for you or you are no t sure.  
 
 (Circle One On Each Line)  
 
  Definitely 
True Mostly 
True Not  
Sure Mostly 
False  Definitely 
False  
 
       
20. I stay home most of the time  because 
of my eyesight  ................................ ......  1 2 3 4 5 
       
21. I feel frustrated  a lot of the time 
because of my eyesight  ...................   1 2 3 4 5 
       
22. I have much less control  over what I 
do, because of my eyesight  .............   1 2 3 4 5 
       
23. Because of my eyesight, I have 
to rely too much on what other 
people tell me  ................................ ..  1 2 3 4 5 
       
24. I need a lot of help  from others 
because of  my eyesight  ...................   1 2 3 4 5 
       
25. I worry about doing things that will 
embarrass myself or others , because 
of my eyesight  ................................ .  1 2 3 4 5 
  That‚Äôs the end of the interview.  Thank you very much for your time and your help.  
 
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 106 of 137  
SIGNATURE PAGE  
Declaration of the Principa l Investigator  
Protocol T itle: A Phase III Randomised, Double- masked , Parallel Group, Multicentre Study to 
Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 
(proposed ranibizumab biosimilar) and Lucentis¬Æ in Subject with Neovascular Age-r elated 
Macular  Degeneration  
This clinical study protocol was subjected to critical review. The information it contains is consistent with current knowledge of the risks and benefits of the investigational medicinal product, as well as with the moral, ethical and scienti fic principles governing clinical research 
as set out in the Declaration of Helsinki, 20 13 and the guidelines on Good Clinical Practice 
applicable to this clinical study.  
Principal Investigator  
Name:   
Institution:   
Signature:  Date:   
   (MMM DD, YYYY)  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 107 of 137 AMENDMENT 1: Sep 0 1, 2017 
 
Section Affected  Original Content  Amended/New Content  Rationale  
Synopsis -Inclusion 
criteria  
 
4.1. Inclusion Criteria  2.  
* Active CNV indicates presence of leakage as 
evidenced by Fluorescein Angiography (FA) and intra- 
or sub -retinal fluid as evidenced by Optical Coherence 
Tomography (OCT) which should be confirmed by 
central reading centre  during Screening  2.  
* Active CNV indicates presence of leakage as 
evidenced by Fluorescein A ngiography (FA)  and 
intra- or sub -retinal fluid as evidenced  by Optical 
Coherence T omography (OCT)  which should be 
confirmed by central reading centre  during Screening  Per central reading 
centre‚Äôs practice, images used for assessment will 
be selected at the reader‚Äôs best knowledge.  
4. Total lesion a rea ‚â§ 9.0 Disc Areas (DA) in size 
(including blood, scars and neovascularisation)  as 
assessed by FA in the study eye (confirmed by central 
reading centre during Screening) 4. Total lesion area ‚â§ 9.0 Disc Areas (DA) in size 
(including blood, scars and neova scularisation)  as 
assessed by FA  in the study eye (confirmed by central 
reading centre during Screening) Per central reading 
centre‚Äôs practice, images 
used for assessment will 
be selected at the 
reader‚Äôs best knowledge.  
5. Best Corrected Visual Acuity (B CVA) of 20/40 to 
20/200 (letter score of 73 to 3 4) using Early Treatment 
Diabetic Retinopathy Study (ETDRS) chart or 2702 Number chart in the study eye  at Screening and at 
Week 0 (Day 1) prior to randomisation 5. Best Corrected Visual Acuity (BCVA) of 20/4 0 to 
20/200 (letter score of 73 to 3 4) using original series  
Early Treatment Diabetic Retinopathy Study (ETDRS) chart s or 2702 series Number  chart s in the study eye  at 
Screening and at Week 0 (Day 1) prior to 
randomisation  Clarification for charts 
used in this study  
6. Non-childbearing potential female (e.g., permanently 
steriliz ed, postmenopausal [defined as 12 months with 
no menses without an alternative medical cause prior to Screening]) , 
OR Childbearing potential female subjects 
or male subjects with their (respectively male or 
female) partners who agree to use at least two forms of 
appropriate contraception method that can achieve a failure rate of less than 1% per year (e.g., established use of oral, injected, intravaginal, transdermal or implanted h ormonal contraceptive, placement of an 
intrauterine device or intrauterine hormone -releasing 6. Non-childbearing potential female (e.g., 
permanently steriliz ed sterilis ed, postmenopausal 
[defined as 12 months with no menses without an alternative medical cause prior to Screening]), 
OR 
Childbearing potential female subjects or male subjects 
with their (respectively male or female) partners who 
agree to use at least two forms of appropriate contraception method that can achieve a failure rate of less than 1% per year (e.g., established use of oral, injected, intravaginal, transdermal or implanted 
hormona l contraceptive, placement of an intrauterine Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 108 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
system, bilateral tubal occlusion, vasectomised partner, 
physical barrier, sexual abstinence) from Screening 
until 3 months after the last  ITV injection of IP  device or intrauterine hormone -releasing system, 
bilateral tubal occlusion, vasectomised partner, physical barrier, sexual abstinence) from Screening 
until 3 months after the last  ITV injection of IP  
Synopsis -Exclusion 
criteria  
 4.2. Exclusion Criteria  1. Sub- or intra -retinal haemorrhage that comprises 
more than 50% of the entire lesion in the  
study eye, or presence of subfoveal blood equal to or more than one DA in size as assessed by  
FA (con firmed by central reading centre during 
Screening)  1. Sub- or intra -retinal haemorrhage that comprises 
more than 50% of the entire lesion in the  
study eye, or presence of subfoveal blood equal to or more than one DA in size 
as assessed by  
FA (confirmed by central reading centre during 
Screening)  Per central reading 
centre‚Äôs practice, images used for assessment will be selected at the reader‚Äôs best knowledge.  
2. Scar, fibrosis or atrophy involving the centre of the 
fovea in the study eye as assessed by FA  
(confirmed by central reading centre during Screening)  2. Scar, fibrosis or atrophy involving the centre of the 
fovea in the study eye as assessed by FA  
(confirmed by central reading centre during Screening)  Per central reading 
centre‚Äôs practice, images used for assessment will 
be selected at the 
reader‚Äôs best knowledge.  
3. Presence of CNV in either eye due to other causes, 
such as ocular histoplasmosis, trauma,  
multifocal choroiditis, angioid streaks, history of 
choroidal rupture or Pathologic Myopia  
(PM) as assessed by FA (confirmed by central reading 
centre during Screening)  3. Presence of CNV in either eye due to other causes, 
such as ocular histoplasmosis, trauma,  
multifocal choroiditis, angioid streaks, history of choroidal rupture or Pathologic Myopia  
(PM) as assessed by FA
 (confirmed by central reading 
centre during Screening)  Per central reading 
centre‚Äôs practice, images 
used for assessment will 
be selected at the 
reader‚Äôs best knowledge.  
4. Presence of retinal pigment epithelial tears or rips 
involving the macula in the study eye as  
assessed by FA (confirmed by central reading centre during Screening)  4. Presence of retinal pigment epithelial tears or rips 
involving the macula in the study eye as 
assessed by FA (confirmed by central reading centre 
during Screening)  Per central reading 
centre‚Äôs practice, images used for assessment will be selected at the 
reader‚Äôs best knowledge.  
6. Any concurrent macular abnormality other than 
AMD in the study eye which, in the opinion of Investigator, could affe ct the efficacy of IP including 
but not limited to epiretinal membrane, macular 
telangiectasia, retinal vascular abnormality, etc  6. Any concurrent macular abnormality other than 
AMD in the study eye which , in the opinion of 
Investigator, could affect the efficacy of IP including 
but not limited to epiretinal membrane , macular 
telangiectasia, retinal vascular abnormality, etc This criterion will be 
assessed  by central 
reading centre. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 109 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
(confirmed by central reading centre)  
10. Any other intraocular surgery (including cataract 
surgery and laser photocoagulation) or periocular 
surgery in the study eye within 90 days prior to 
randomisation, except for lid surgery, which may not 
have taken place within 30 days prior to randomisation  10. Any other intraocular sur gery (including cataract 
surgery and laser photocoagulation ) or periocular 
surgery in the study eye within 90 days prior to randomisation, except for lid surgery, which may not 
have taken place within 30 days prior to randomisation  Error correction. Laser 
photocoagulation is not 
included in the category 
of surgery . 
13. Any systemic treatment or therapy (including 
prescribed herbal medication) to treat neovascular 
AMD within 30 days prior to randomisation, and such treatment or therapy will not be allowed during the 
study period. However, dietary supplementary, vitamins or mineral will be allowed.  13. Any systemic treatment or therapy (including 
prescribed herbal medication) to treat neovascular AMD within 30 days prior to randomisation, and such treatment or therapy will not be allowed during the 
study period. However, dietary 
supplementary supplements , vitamins or 
mineral will be allowed.  Editorial change  
14. Any ITV sustained drug delivery  implant in the 
study eye   (e.g., intravitreal corticosteroid implant) 
within 180 days prior to randomisation, and such treatment will not be allowed during the study period
 14. Any ITV intravitreal  injection of corticosteroid 
(e.g., triamcinolone acetonide) or sustained drug 
delivery  implant in the study eye (e.g.,  intravitreal 
corticosteroid implant ) in the study eye  within 180 
days prior to randomisation, and such treatment will 
not be allowed during the study period  Prohibited medication is 
added . 
16. Spherical equivalent of the refractive error in the 
study eye de monstrating more than 8 diopters of 
myopia  16. Spherical equivalent of the refractive error in the 
study eye demonstrating more than 8 diopters of myopia . For subjects who have undergone previous 
refractive or cataract surgery in the study eye, the 
preoperative refractive error in the study eye must  
not exceed 8 diopters of myopia  Clarification for subjects 
who have undergone 
refractive or cataract surgery in the study eye  
21. History of idiopathic or autoimmune -associated 
uveitis in either eye  21. History of idiopathic or autoimmune -associated  
uveitis in either eye  Editorial change  
24. History of corneal transplant in the study eye  24. History of corneal transplant ation surgery  in the 
study eye  Editorial change  
25. Presence of advanced glaucoma or o ptic 
neuropathy that involve or threaten the central visual 25. Presence of advanced glaucoma or optic 
neuropathy that involve  affect  or threaten the central Editorial change  
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 110 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
field visual field in the study eye  Target eye is specified . 
29. Previous part icipation in any studies of  ocular or 
systemic  investigational products (excluding dietary 
supplementary, vitamins and minerals) to treat ocular 
or systemic disease other than neovascular AMD 
within 90 days  prior to randomisation, and such 
participation wi ll not be allowed during the study 
period even if the investigational product is dietary 
supplementary, vitamins and minerals  29. Previous participation in any studies of  ocular or 
systemic  investigational products (excluding 
dietary supplementary  supplements , vitamins and 
minerals) to treat ocular or systemic disease other than 
neovascular AMD within 90 days  prior to 
randomisation, and such participation will not be 
allowed during the study period even if the investigational product is dietary 
supplementar y supplements , vitamins and 
minerals  Editorial change  
30. History or clinical evidence of diabetic retinopathy 
(except for mild non -proliferative diabetic retinopathy) , 
diabetic macular oedema  or any retinal vascular disease 
other than AMD in either eye  30. History or clinical evidence of diabetic retinopathy 
(except for mild non -proliferative diabetic retinopathy) , 
or diabetic macular oedema or any retinal vascular 
disease other than AMD  in either eye  Retinal vascular disease 
that affects macula will be excluded from 
exclusion criterion #6.  
31. Any concurrent ocular condition in the study eye 
which, in the opinion of Investigator, could either 
increase the risk to the subject safety or which 
otherwise may interfere with evaluation of efficacy or 
safety including, but not limited to  corneal opacities, 
cataract, ocular media that do not allow proper fundus visuali sation and  fundus  imaging, and ocular surface 
abnormalities which prevent applanation tonometry during the  study period  after randomisation  31. Any concurrent ocular condition in the study eye 
which, in the opinion of the Investigator, could either 
increase the risk to the subject safety or which 
otherwise may interfere with evaluation of efficacy or 
safety including, but not limited to  ocular medi a 
opacities such as  corneal opacities,  opacity or 
cataract , ocular media  that do not allow proper fundus 
visuali sation and  fundus  imaging, and ocular surface 
abnormalities which prevent applanation tonometry 
during the  study period  after randomisation  Editorial change  
33. Pregnant or lactating women. A serum pregnancy 
test must be  required for  all women at Screening  33. Pregnant or lactating women. A serum pregnancy 
test must be  required for  all women of childbearing 
potential  at Screening  Pregnancy test will be 
performed only for childbearing potential 
female subjects.  
Not applicable  35. Stroke, transient ischemic attacks, or 
myocardial infarction within 90 days prior to Exclusion criterion is 
added as per Korea 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 111 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
randomisation  MFDS‚Äôs request . 
Not appli cable  36. History of recurrent significant infections and/or 
current treatment for active systemic infection  Exclusion criterion  is 
added as per Korea 
MFDS‚Äôs request . 
Not applicable  37. Known allergic reactions and/or hypersensitivity 
to ranibizumab or to any ingredients of the 
investigational product  Exclusion criterion is 
added as per Korea 
MFDS‚Äôs request . 
Not applicable  38. Prior treatment involving macula with 
photodynamic therapy with verteporfin, 
transpupillary  thermotherapy , radiation therapy, or  
retinal laser treatment (e,g ., focal laser 
photocoagulation) in the study eye , and such 
treatment will not be allowed during the study 
period  Exclusion criterion is 
added as per Korea MFDS‚Äôs request
. 
Not applicable  39. Prior treatment with pan -retinal 
photocoagulation in the study eye , and such 
treatment will not be allowed during the study 
period  Exclusion criterion  is 
added as per Korea MFDS‚Äôs request .
 
Not applicable  40. Current use of systemic medications known to 
be toxic to the lens, retina or opt ic nerve, including 
deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, vigabatrin  and 
ethambutol, and such medications will not be 
allowed during the study period  Exclusion criterion is 
added as per Korea MFDS‚Äôs request .
 
Synopsis - 
Primary endpoints  
 6.1.1. Primary Endpoint  For US Food and Drug Administration (FDA), Korea 
Ministry of Food and Drug Safety (MFDS) or other 
regulatory agency submissions for those who are in favour of  VA , 
the primary endpoint  is: 
Change from baseline in BC VA at Week 8  
For European Medicines Agency (EMA) or other 
regulatory agency submissions for those who are in For US Food and Drug Administration (FDA), Korea 
Ministry of Food and Drug Safety (MFDS) or other regulatory agency submissions for those who are in favour of the VA, the primary endpoint is:  
Change from baseline in BCVA at Week 8  
For European Medicines Agency (EMA) or other 
regulatory agency submissions for those who are in Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 112 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
favour of anatomical parameter, the primary endpoint 
is: 
Change from baseline in Central Subfield Thickness 
(CST) at Week 4 (based on assessment by  central 
reading centre)  favour of the anatomical parameter, the primary 
endpoint is:  
 Change from baseline in Central Subfield Thickness 
(CST) at Week 4 (based on assessment by central  
reading centre)  
Synopsis -
Secondary endpoints  
 6.1.2. Secondary 
Endpoints  The secondary efficacy endpoints are:  
Proportion  of subjects with out intra - or sub -retinal fluid  
at Week 24 and Week 52 (based on assessment by 
central reading cent re) The secondary efficacy endpoints are:  
Proportion  of subjects with out intra - or sub -retinal 
fluid  at Week 24 and Week 52 (based on assessment 
by central reading centre)  To move exploratory 
endpoint section. The 
endpoint has few clinical meaning with hig h 
variability.  
The pharmacokinetic endpoints are:  
PK sampling will be collected in approximately 120 subjects participating in PK evaluation (60 subjects per treatment group).  The pharmacokinetic endpoints are:  
PK sampling  Blood sampling for PK will be 
collected in approximately 12040 subjects participating 
in PK evaluation ( 6020 subjects per treatment group). Number of subjects 
participating  in PK 
evaluation  is changed as 
per US FDA‚Äôs request.  
Synopsis -
Exploratory endpoint  
 6.1.3. Exploratory 
Endpoint  The exploratory endpoint is:  
 
The Quality of Life (QOL) is assessed using National 
Eye Institute 25 -Item Visual Function Questionnaire 
(NEI VFQ -25). 
Change from baseline in subscale scores and composite scores of NEI -VFQ- 25 at Week 24 and Week 52  The explor atory endpoint s is are : 
 
Proportion  of subjects with out intra - or sub -retinal 
fluid  at Week 24 and Week 52 (based on assessment 
by central reading centre)  
The Quality of Life (QOL) is assessed using National 
Eye Institute 25 -Item Visual Function Questionnaire 
(NEI VFQ -25). 
Change from baseline in subscale scores and composite scores of NEI -VFQ- 25 at Week 24 and Week 52  To move exploratory 
endpoint section. The endpoint has few clinical meaning with high variability.  
Synopsis - 
Statistical Methods: Efficacy  analysis  
 9.2.2. Efficacy The primary efficacy analysis will be performed for the 
FAS with the change from baseline of BCVA at Week 8 using an analysis of covariance model with the 
baseline BCVA as a covariate and region (or pooled 
centres) and treatment group as factors.  For US FDA, Korea MFDS or other regulatory 
agency submissions for those who are in favour of  
the VA, The the primary efficacy analysis will be 
performed for the FAS with the change from baseline of BCVA at Week 8 using an analysis of cova riance 
model with the baseline BCVA as a covariate and 
region (or pooled centres) and treatment group as Clarification for primary 
efficacy endpoint analysis for BCVA  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 113 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
factors.  
The other primary efficacy analysis will be performed 
for the FAS  and Per -Protocol Set (PPS -CST) with the 
change from baseline of CST at Week 4 using an 
analysis of covariance model with baseline CST as a 
covariate and region (or pooled centres) and treatment 
group as factors.  The other primary efficacy analysis will be 
performed for the FAS and Per -Protocol Set (PPS -
CST)  For EMA or other regulatory agency 
submissions for those who are in favour of the 
anatomical parameter, the primary efficacy analysis 
will be performed for the per- protocol set (PPS -
CST)  with the change from baseli ne of CST at Week 4 
using an analysis of covariance model with baseline CST as a covariate and region (or pooled centres) and 
treatment group as factors.  Clarification for primary 
efficacy endpoint analysis for CST  
For the sensitivity analysis, missing d ata will be 
imputed using the Last Observation Carried Forward (LOCF) or other multiple imputation methods for the FAS.  For the sensitivity analysis, missing data will be 
imputed using the Last Observation Carried 
Forward (LOCF) or other multiple imputatio n 
methods for the FAS.  For the primary analysis with 
the FAS for BCVA, missing data will be imputed for subjects who drop out for the study prior to the 
primary analysis time -point. A missing -at-random 
approach will assume that subjects who withdraw 
from a  study had missing values similar to similar 
subjects who completed the study in that treatment group. This approach ensures that evidence of lack of equivalence is not diluted when there are missing 
data. For the components of BCVA, the missing 
letter wil l be imputed by multiple imputation 
method with the assumption of monotone missing pattern and regression method. For the sensitivity analyses, available case analysis and last 
observation carried forward analysis will be 
performed.  Clarification for missi ng 
imputation method  
Synopsis - 
Statistical Methods:  Blood sampling for PK will be collected in 
approximately 120 subjects participating in PK Blood sampling for PK will be collected in  
approximately 12040 subjects participating in PK Number of subjects 
participating in PK 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 114 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Pharmacokinetic 
analysis  evaluation (60 subjects per treatment group).  evaluation ( 6020 subjects per treatment group).  evaluation  is changed as 
per US FDA‚Äôs request.  
Synopsis - 
Statistical Methods: 
NEI VFQ- 25 
analyses  
 Subscale scores (ge neral health, general vision, ocular 
pain, near activities, distance activities, vision -specific 
social functioning, vision -specific mental health, 
vision -specific role difficulties, vision -specific 
dependency, driving, colour vision, and peripheral vision ) and the composite score, which represent 
overall visual function, will be calculated, and the change from baseline will be summarized by treatment 
group and visit.  Subscale scores (general health, general vision, ocular 
pain, near activities, distance activities, vision -specific 
social functioning, vision -specific mental health, 
vision -specific role difficulties, vision -specific 
dependency, driving, colour vision, and peripheral vision) and the composite score, which represent overall visual function, wil l be calculated, and the 
change from baseline will be 
summarized  
summarised  by treatment group and visit.  Editorial change  
Table 1. Schedule 
of Activities  NEI VFQ -25: 
Week 0, Week 12, Week 24, Week 36, Week 52 
(EOS/ET)  NEI VFQ -25: 
Week 0, Week 12,  Week 24 , Week 36,  Week 52 
(EOS/ET)  Frequency of NEI VFQ -
25 is changed as per US 
FDA‚Äôs request.  
Table 1  
Footnote  
  
 
 3. Physical examination will be performed at Screening 
and Week 52 (EOS visit) or ET visit. Body weight will be measured and recorded at Screenin g and Week 52 
(EOS visit) or ET visit, but height will be measured 
and recorded only at Screening.  3. Physical examination will be performed at Screening 
and Week 52 (EOS visit) or ET visit. The physical 
examination will include an assessment of the 
subjec t‚Äôs general appearance, skin, head, neck, 
throat, lymph nodes, cardiovascular, neurological, thyroid, musculoskeletal/extremities, respiratory 
systems and the subject‚Äôs abdomen. Body weight 
will be measured and recorded at Screening and Week 
52 (EOS visit)  or ET visit, but height will be measured 
and recorded only at Screening.  Clarification for physical 
examination (systems and organs)  
6. Visual acuity will be assessed in both the study eye 
and fellow (non- study) eye at Screening and prior to 
ITV inject ion of IP at each visit until Week 48. Visual 
acuity will also be assessed at any time during the visit at Week 52 (EOS visit) or ET visit. Subject must use either ETDRS chart or 2702 Number chart (at a starting 
distance of 4 meters) consistently from Scre ening to 6. Visual acuity will be assessed in both the study eye 
and fellow (non- study) eye at Screening and prior to 
ITV injection of IP at each visit until Week 48. Visual acuity will also be assessed at any time during the visit at Week 52 (EOS visit) or ET visit. Subject must use 
either original series  ETDRS chart s or 2702 series  
Number  chart s (at a starting distance of 4 meters) Clarification for charts 
used in this study 
    
 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 115 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Week 52 (EOS visit) or ET visit. Visual acuity testing 
must be performed before dilation of pupils and FP/FA 
and OCT assessment. A decrease in visual acuity of > 15 letters (compared with the last assessment of VA) 
should be reported as AEs/Seriou s Adverse Events 
(SAEs) as appropriate. If there is a decrease in VA of > 
30 letters (compared with the last assessment of VA) lasting > 1 hour or if there is a decrease in VA to the level of Light Perception or worse lasting > 1 hour, it 
should be reporte d as SAE.  consistently from Screening to Week 52 (EOS visit) or 
ET visit. Visual acuity testing must be performed 
before dilation of pupils and FP/FA and OCT assessment. A decrease in visual acuity of ‚â•
> 15 
letters (compared with  from  the last assessment of 
VA) should be reported as AEs/Serious Adverse 
Events (SAEs) as appropriate. If there is a decrease in VA of ‚â•
> 30 letters (compared with  from  the last 
assessment of VA ) lasting > 1 hour  or if there is a 
decrease in VA to the level of Light Perception or 
worse lasting > 1 hour , it should be reported as SAE.   
  Error correction  
   SAE criteria are 
changed . 
7. Investigator must confirm that the subject c an read 
between 34 letters to 73 letters using ETDRS chart or 2702 Number chart at Week 0 (Day1) prior to 
randomisation  7. Investigator must confirm that the subject can read 
between 34 letters to 73 letters using original series  
ETDRS chart s or 2702 series  Number chart s at Week 0 
(Day1) prior to randomisation  Clarification for charts 
used in this study 
8. Visit at Week 8 is the most critical as the visit is for 
the primary endpoint assessment for US FDA, Korea 
MFDS or other regulatory agency submissions for 
those who are in favour of VA. Thus, every effort 
should be made to adhere to the visit schedule for the 
subjects.  8. Visit at Week 8 is the most critical as the visit is for 
the primary endpoint assessment for US FDA, Korea 
MFDS or other regulatory ag ency submissions for 
those who are in favour of  the VA. Thus, every effort 
should be made to adhere to the visit schedule for the 
subjects.  Editorial change  
9. OCT will be performed only in the study eye at 
Screening and prior to ITV injection of IP at each visit 
until Week 4 8. OCT will also be performed at any time 
during the visit at Week 52 (EOS visit) or ET visit.  
Only OCT devices registered and certified by central reading centre are allowed to be used in this study. If one or more OCT devices are registered and certified in an Investigational site, a subject should use the same 
OCT device consistently from Screening to Week 52 
(EOS visit) or ET visit.  OCT images will be sent to the 
central reading centre.  9. OCT will be performed only in on the study  eye at 
Screening and prior to ITV injection of IP at each visit until Week 48 . OCT will also be performed at any time 
during the visit at Week 52 (EOS visit) or ET visit.  
Site staffs who will perform OCT scans in this study must be certified by the central reading centre before study starts. OCT devices registered in an Investigational site should be  all from the same 
manufacture and meet the minimum software 
requirement . Only OCT devices registered and 
certified by central reading centre are allowed to b e Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 116 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
used in this study. If one or more OCT devices are 
registered and certified in an Investigational site, a 
subject should use the same OCT device 
consistently  The subject should use the OCT device 
registered by the central reading centre from 
Screening to  Week 52 (EOS visit) or ET visit.  
10. Visit at Week 4 is the most critical as the visit is for 
the primary endpoint assessment for EMA or other 
regulatory agency submissions for those who are in favour of anatomical parameter. Thus, ever y effort 
should be made to adhere to the visit schedule for the 
subjects.  10. Visit at Week 4 is the most critical as the visit is for 
the primary endpoint assessment for EMA or other regulatory agency submissions for those who are in favour of the anatomi cal parameter. Thus, every effort 
should be made to adhere to the visit schedule for the 
subjects.  Editorial change  
11. FP/FA will be performed only in the study eye at 
Screening and prior to ITV injection of IP at Week 24. FP/FA will also be performed a t any time during the 
visit at Week 52 (EOS visit) or ET visit. Only FP/FA device certified by central reading centre is allowed to 
be used in this study. If one or more FP/FA devices are 
certified in an Investigational site, a subject must use the same FP/FA device consistently from Screening to Week 52 (EOS visit) or ET visit. FP/FA images will be sent to the central reading centre. If any significant change in the posterior pole (i.e. subretinal 
haemorrhage, macular hole, vitreous haemorrhage or 
opacity,  retinal detachment, etc.) is detected with 
fundus examination, additional FP and/or FA can be performed at Investigator‚Äôs discretion, but the images will not be sent to the central reading centre.  
 11. FP/FA will be performed only in on the study  both  
eyes at Screening and those images taken from the 
both eyes will be sent to the central reading centre. 
FP/FA will also be performed on the study eye  prior 
to ITV injection of IP at Week 24 and. FP/FA will 
also be performed  at any time during the visit at Wee k 
52 (EOS visit) or ET visit. Those images taken from 
the study eye will be sent to the central reading 
centre. Site staffs who will perform FA/FP in this study must be certified by the central reading centre 
before study starts. Only FP/FA device certifie d by 
central reading centre is allowed to be used in this 
study. If one or more FP/FA devices are certified in an Investigational site, a subject must use the same FP/FA device consistently from Screening to Week 52 (EOS visit) or ET visit. 
FP/FA images wi ll be sent to the 
central reading centre. If any significant change in 
the posterior pole (i.e. subretinal haemorrhage, macular hole, vitreous haemorrhage or opacity, retinal 
detachment, etc.) is detected with fundus examination, According to exclusion 
criteria #3, FP/FA images taken from the both eyes should be sent to the central reading 
centre at Screening. 
 
Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 117 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
additional FP and/or FA ca n be performed at the 
Investigator‚Äôs discretion, but the images will not be 
sent to the central reading centre.  
12. Indirect ophthalmoscopy using a standard way (i.e., 
usually using a head -mounted light source and a 20- 30 
lens) will be performed only in the study eye at Screening and prior to ITV injection of IP and within 15 minutes after ITV injection of IP at each visit until Week 48. Indirect ophthalmoscopy will also be 
performed at any time during the visit at Week 52 
(EOS visit) or ET visit.  12. Indirect ophthalmoscopy using a standard way (i.e., 
usually using a head -mounted light source and a 20- 30 
lens) will be performed only in on the study eye at 
Screening and prior to ITV injection of IP and within 
15 minutes after ITV injection of IP at each visit until Week 48. Indirect ophthalmoscopy will also be 
performed at any time during the visit at Week 52  
(EOS visit) or ET visit.  Editorial change  
 
14. Intraocular Pressure (IOP) will be measured using 
Goldmann applanation tonometry only. The same 
method of IOP measurement must be used in each subject from Screening to Week 52 (EOS visit) or ET visit. IOP will be measured only in the study eye at 
Screening and prior to ITV injection of IP and 30- 60 
minutes after ITV injection of IP at each visit until 
Week 48.  14. Intraocular Pressure (IOP) will be measured using 
Goldmann applanation tonometry  only. The sa me 
method of IOP measurement must be used in each 
subject from Screening to Week 52 (EOS visit) or ET visit. IOP will be measured 
only in on the study eye at 
Screening and prior to ITV injection of IP and 30- 60 
minutes after ITV injection of IP at each vis it until 
Week 48.  Editorial change  
 
15. NEI VFQ -25 should be performed at Week 0 
(Day1) after randomisation, but prior to starting any other study procedures. Then, NEI VFQ -25 should be 
performed before starting any other study procedures at Week 12, Week 24, Week 36 and Week 52 (EOS visit) or ET visit.  15. NEI VFQ -25 should be performed at Week 0 
(Day1) after randomisation , but prior to starting any 
other study procedures . Then, NEI VFQ -25 should be 
performed before starting any other study 
procedures  dilation of pupil  at Week 0 (Day 
1), Week 12, Week 24 , Week 36  and Week 52 (EOS 
visit) or ET visit.  Frequency of NEI VFQ -
25 is changed as per US 
FDA‚Äôs request.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 118 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
16. Blood and urine sampling for clinical laboratory 
test will be collected at Screening and prior to ITV 
injection of IP at Week 12, Week 24, and Week 36. Blood and urine sampling for clinical laboratory test 
will also be collected at any time during the visit at 
Week 52 (EOS visit) or ET visit. Urine samples must be collected before performing FA to avoid false elevations in urine protein values.  
‚Ä¢ Haematology: haemoglobin, haematocrit, platelet 
count, white blood cell count (total and differential)  
‚Ä¢ Chemistry: sodium, potassium, creatinine, glucose, 
calcium, phosphorus, total bilirubin, albumin, alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase  
‚Ä¢ Urinalysis (dipstick):  protein, blood, leucocytes, 
nitrite, glucose, ketone, pH, specific gravity, bilirubin, 
urobilinogen  16. Blood and urine sampling for  clinical laboratory 
test will be collected at Screening and prior to ITV injection of IP at Week 12, Week 24, and Week 36. Blood and urine sampling for clinical laboratory test 
will also be collected at any time during the visit at 
Week 52 (EOS visit) or ET visit. Urine samples must 
be collected before performing FA to avoid false elevations in urine protein values.  
‚Ä¢ Haematology: haemoglobin, haematocrit, platelet 
count, white blood cell count (total and differential)  
‚Ä¢ Chemistry: sodium, potassium, creat inine, glucose, 
calcium, phosphorus, total bilirubin, albumin, alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase  
‚Ä¢ Urinalysis (dipstick):  protein, blood, leucocytes, 
nitrite, glucose, ketone, pH, specific gr avity, bilirubin, 
urobilinogen  
Blood samples will be analysed in central laboratory 
and urine samples will be tested in each Investigational site by using a dipstick which will be 
provided by Sponsor.  Clarification for central 
laboratory test  
18. Blood s ampling for PK will be collected only in 
approximately 120 subjects participating in PK evaluation (60 subjects per treatment group).  18. Blood sampling for PK will be collected only in 
approximately 12040 subjects participating in PK 
evaluation ( 6020 subjects per treatment group).  Number of subjects 
participating in PK 
evaluation  is changed as 
per US FDA‚Äôs request.  
19. For all women , serum pregnancy test must be 
performed at Screening. Serum or urine pregnancy test 
may be performed after randomisation at  Investigator‚Äôs 
discretion.  19. For all women  of childbearing potential , serum 
pregnancy test must be performed at Screening. The 
serum samples taken at Screening will be analysed 
in central laboratory. Additional  Sserum or urine 
pregnancy test may can be performed after 
randomisation at Investigator‚Äôs discretion  in each 
Investigational site during the study period, if Pregnancy test will be 
performed only for 
childbearing potential 
female subjects.  
 
Clarification for 
pregnancy test  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 119 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
necessary.  
20. Subject s will be administered SB11 or Lucentis¬Æ 
0.5 mg via ITV into the study eye every 4 weeks up to 
Week 48. Dosing visits will be allowed within ¬± 7 days of the scheduled dosing visit date (except Week 0 (Day 1), visit window not allowed). If a dose of IP is n ot 
given within 7 days of the scheduled dosing visit date, the IP should be given within 2 1 days of the scheduled 
dosing visit date, but the case will be captured as protocol deviation. Dosing skip is defined when a subject does not receive the IP within 2 1 days (3 
weeks) after scheduled dosing visit date. Next 
scheduled dosing visit date and visit window should not be altered even though previous dosing is not performed on the exact scheduled dosing visit date (but, the interval between two doses injected into the study eye should be at least 14 days) or previous dosing 
is skipped.  20. Subjects will be administered SB11 or Lucentis¬Æ 
0.5 mg via ITV into the study eye every 4 weeks up to Week 48. Dosing visits will be allowed within ¬± 7 days of the scheduled dosing visit date (except Week 0 (Day 
1), visit window not allowed). If a dose of IP is not 
given within 7 days of the scheduled dosing visit date, 
the IP should be given within 
21 20 days of the 
scheduled dosing visit date, but the case will be captured as protocol deviation. Dosing skip is defined when a subject does not receive the IP within 
21 20 
days (3 weeks) after scheduled dosing visit date. Next 
scheduled dosing visit date and visit window should not be altered even though previous dosing is not performed on the exact scheduled dosing visit date 
(but, the interval between two doses injected into the study eye should be at least 14 days) or previous dosing 
is skipped.  Error correction  
21. The first ITV injection of IP should be performed at 
the sam e day of randomisation or the following day 
after randomisation at the latest with a proper reason.  21. The first ITV injection of IP and all other study 
procedures  should  must be performed at the same day 
of randomisation or the following day after 
random isation at the latest with a proper reason.  Editorial change  
Background  Age-related Macular Degeneration, left untreated, is a 
leading cause of adult blindness in the developed world. Most of severe visual loss of AMD occurs from 
CNV or the neovascular fo rm of AMD  
 
 
‚Ä¶as well as atrophy of these portions of the retina in Age-related Macular Degeneration (AMD) , left 
untreated, is a l eading cause of adult blindness in the 
developed world. Most of severe visual loss of AMD 
occurs from Choroidal Neovascularisation ( CNV ) or 
the neovascular form of AMD  
 
‚Ä¶ as well as atrophy of these portions of the retina in Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 120 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
the macula, leading to severe visual decline with loss of 
reading vision, driving vision, and the ability to 
recognize faces. Vascular endothelial growth factor, a 
protein growth factor tha t both stimulates angiogenesis 
and increases vascular permeability,‚Ä¶  
  
The pathogenesis of AMD is poorly understood. It is characterized by development of focal deposits of long 
‚Äìspacing collagen and phospholipid vesicles within and 
beneath the basement membrane of the RPE, called 
‚Äúdrusen‚Äù which can be accompanied by gradual degeneration of photoreceptors and RPE (atrophy), which often results in slow deterioration of central 
visual acuity (VA).  the macula, leading to severe v isual decline with loss of 
reading vision, driving vision, and the ability to 
recognize  recognise faces. Vascular Eendothelial 
Ggrowth Ffactor (VEGF), a protein growth factor that 
both stimulates angiogenesis and increases vascular permeability,‚Ä¶  
 The path ogenesis of AMD is poorly understood. It 
is characterized
 characterised  by development of 
focal deposits of long ‚Äìspacing collagen and 
phospholipid vesicles within and beneath the basement membrane of the RPE, called ‚Äúdrusen‚Äù which can be accompanied by gr adual degeneration of 
photoreceptors and RPE (atrophy), which often results 
in slow deterioration of central Visual Acuity (VA).  
1.2. Lucentis¬Æ: 
Ranibizumab Reference Product  Neovascular (Wet) Age -Related Macular Degeneration  
The safety a nd efficacy of Lucentis¬Æ were assessed in 
three randomized, double or single -masked, sham -or 
active -controlled studies in subjects with neovascular 
AMD.  
Macular Oedema Following Retinal Vein Occlusion  
The safety and efficacy of Lucentis¬Æ were assessed in 
two randomized, double -masked, 1- year studies in 
subjects with macular oedema following RVO.  Neovascular (Wet) Age -Related Macular Degeneration  
The safety and efficacy of Lucentis¬Æ were assessed in 
three randomized  randomised , double or single -
masked, sham -or active -controlled studies in subjects 
with neovascular AMD.  
Macular Oedema Following Retinal Vein Occlusion  
The safety and efficacy of Lucentis¬Æ were assessed in 
two randomized  randomised , double -masked, 1 -year 
studies in subjects with macular oedema fo llowing 
RVO.  Editorial change  
1.3. SB11: 
Proposed Ranibizumab 
Biosimilar  Extensive characterization studies including intact 
mass, N - and C -terminal sequencing, peptide mapping, 
icIEF, CE- SDS (reduced, non -reduced), SE -HPLC, 
amino acid composition, disulfide bond, VEGF 
binding, VEGF neutralization,  Extensive characterization  characterisation  studies 
including intact mass, N - and C -terminal sequencing, 
peptide mapping, icIEF, CE -SDS (reduced, non -
reduced), SE -HPLC, amino acid composition, disulfide 
bond, VE GF binding, VEGF neutralization  
neutralisation , Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 121 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
1.4. Rationale for 
the Study A biosimilar is a biological medicinal product that is 
highly similar to an already authorized original 
biological medicinal product ‚Ä¶  
These guidelines recommend  a stepwise approach in 
developing a biosimilar starting with extensive physicochemical and biological characterization before initiating clinical studies for the comparison of the efficacy,‚Ä¶  A biosimilar is a biological medicinal product that is 
highly si milar to an already  authorized authorised 
original biological medicinal product ‚Ä¶ 
These guidelines recommend a stepwise approach in 
developing a biosimilar starting with extensive 
physicochemical and biological characterization 
characterisation  before 
initiating clinical studies for the comparison of the 
efficacy,‚Ä¶  Editorial change  
3.2 Rationale for 
the Study Design  However, for supporting the assessment of overall 
systemic safety of SB11 relative to Lucentis¬Æ, systemic 
exposures will be collected and compared in the subgroup population (approximately 120 subjects, 60 subjects per treatment group) in Phase III comparative 
efficacy study.  However, for supporting the assessment of overall 
systemic safety of SB11 relative to Lucentis¬Æ, systemic 
exposures will be collected and compared in the 
subgroup population (approximately 12040 
subjects, 6020 subjects per treatment group) in Phase 
III comparative efficacy study.  Number of subjects 
participating in PK evaluation is changed as per US FDA‚Äôs request.  
For US F DA, Korea MFDS or other regulatory agency 
submissions for those who are in favour of VA,‚Ä¶  
For EMA or other regulatory agency submission for those who are in favour of anatomical parameter,‚Ä¶  
Ranibizumab binds with high affinity to all active VEGF -A isoforms  (e.g. VEGF110, VEGF121 and 
VEGF165) on the surface of endothelial cells, thereby preventing binding of VEGF -A to its receptors and 
reducing endothelial cell proliferation,‚Ä¶  For US FDA, Korea Ministry of Food and Drug 
Safety (MFDS)  or other regulatory agency submissions 
for those who are in favour of the VA,‚Ä¶  
For EMA or other regulatory agency submission for those who are in favour of the anatomical parameter,‚Ä¶  
Ranibizumab binds with high affinity to all active VEGF -A isoforms (e.g. , VEGF110, VEGF121 and 
VEGF165) on the surface of endothelial cells, thereby 
preventing binding of VEGF -A to its receptors and 
reducing endothelial cell proliferation,‚Ä¶  Editorial change  
4.3. Subject 
Discontinuation from 
Investigational Not applicable  ‚Ä¢ Any newly develope d or aggravated ophthalmic 
abnormality other than AMD in the study eye which could interfere with evaluation of efficacy or safety 
of IP including but not limited to retinal vascular Subject discontinuation 
from IP criterion was added as per In dia 
regulatory agency‚Äôs 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 122 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Product  abnormality  request  
5.1.1. Dosing and 
Treatment 
Schedule  Dosing visits will be allowed within ¬± 7 days of the 
scheduled dosing visit date (except Week 0 (Day 1), visit window not allowed). If a dose of IP is not given within 7 days of the sche duled dosing visit date, the IP 
should be given within 21 days of the scheduled dosing visit date, but the case will be captured as protocol deviation. Dosing skip is defined when a subject does not receive the IP within 21 days (3 weeks) after 
scheduled d osing visit date.  Dosing visits will be allowed within ¬± 7 days of the 
scheduled dosing visit date (except Week 0 (Day 1), visit window not allowed). If a dose of IP is not given within 7 days of the scheduled dosing visit date, the IP 
should be given within 
21 20 days of the scheduled 
dosing visit date, but the case will be captured as 
protocol deviation. Dosing skip is defined when a subject does not receive the IP within 
21 20 days (3 
weeks) after scheduled dosing visit date.  Error correction  
5.1.2. Wit hholding 
Investigat ional 
Products  If a subject experiences an AE in the study eye and the 
subject‚Äôs safety or well -being could be compromised 
by ITV injection of IP at Investigator‚Äôs discretion, IPs could be withhold until the event has resolved. Such even ts in the study eye include, but are not limited to:  
‚Ä¢ A decrease in BCVA of ‚â•30 letters compared with 
the last assessment of VA;  
‚Ä¢ An IOP of ‚â•30 mmHg;  
‚Ä¢ A retinal break;  
‚Ä¢ A subretinal haemorrhage involving the centre of the 
fovea, or, if the size of t he haemorrhage is ‚â•50%, of the 
total lesion area;  If a subject experiences an AE in the study eye and the 
subject‚Äôs safety or well -being could be compromised 
by ITV injection of IP at the Investigator‚Äôs discretion, 
IPs should could be withhold  withheld until the event 
has resolved. Such events in the study eye include, but are not limited to:  
‚Ä¢ A decrease in BCVA of ‚â•30 letters compared with 
the last assessment of VA;  
‚Ä¢ An IOP of ‚â•30 mmHg;  
‚Ä¢ A retinal break;  
‚Ä¢ A subretinal haemorrhage involving the centr e of 
the fovea, or, if the size of the haemorrhage is 
‚â•50%, of the total lesion area;  Editorial change  
      
 
  As per SmPC  and usual 
practice from sites  
5.2.1. Identity of 
Investigational 
Product  The IPs will be supplied to Investigational site in one 
carton containing a single vial of 3.0 mg of 
ranibizumab in 0.3 mL solution.  The IPs will be supplied to Investigational site in one 
carton containing a single vial . of 3.0 mg of 
ranibizumab in 0.3 mL solution.  Editorial change  
Table 7. 
Investigational 
Prod ucts [Contents]  
3.0 mg of ranibizumab in 0.3 mL solution  [Contents]  
3.0 mg of ranibizumab in 0.3 mL solution  
One ml contains 10 mg ranibizumab  Editorial change  
5.2.6. 
Investigational Using aseptic technique, all of the SB11 and Luc entis¬Æ 
vial contents are withdrawn through a 19 -gauge filter Using aseptic technique, all of the SB11 and Lucentis¬Æ 
vial contents are withdrawn through a 19-gauge  blunt Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 123 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Product 
Administration  needle attached to a 1 -cc syringe.  filter needle attached to a 1 -cc syringe.  
Table 8. Prohibited 
Medication and 
Therapy  [Medication or Therapy]  
ITV anti-VEGF treatment  (e.g., bevacizumab, 
aflibercept, ranibizumab) to treat neovascular AMD  
[Time to be prohibited]  
‚Ä¢ Prior to Screening Randomisation  
‚Ä¢ From Screening to EOS/ET visit 
[Eye to be prohibited]  
‚Ä¢ Study eye  
‚Ä¢ Fellow eye  
NOTE: If a subject has AMD in the fellow eye during the study period after randomisation, ONLY Lucentis
¬Æ 
(ranibizumab) will be allowed to treat AMD.  
 [Medication or Therapy]  
ITV anti-VEGF treatment  (e.g., bevacizumab, 
aflibercept, ranibizumab) to treat neovascular AMD  
[Time to be prohibited]  
‚Ä¢ Prior to Screening  Randomisation 
‚Ä¢ From Screening to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ Study eye  
‚Ä¢ Fellow eye  
NOTE: If a subject has AMD in the fellow eye 
during the study period after randomisation, ONLY 
Lucentis¬Æ (ranibizumab) will be allowed to treat 
AMD.  Editorial change  
Not applicable  
 [Medication or Therapy]  
ITV anti -VEGF treatment except IP (SB11 or 
Lucentis¬Æ)  
[Time to be prohibited]  
‚Ä¢ From Randomisa tion to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ Study eye  Prohibited ITV anti -
VEGF treatment is 
specified for the study 
eye. 
Not applicable  
 [Medication or Therapy]  
ITV anti -VEGF treatment (e.g., bevacizumab, 
aflibercept) except ranibizumab  
[Time to be p rohibited]  
‚Ä¢ From Randomisation to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ Fellow eye  
 
NOTE: If a subject has AMD in the fellow eye 
during the study period after randomisation, ONLY Prohibited ITV anti -
VEGF treatment is 
specified for the fellow eye. 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 124 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Lucentis¬Æ (ranibizumab) will be allowed to treat 
AMD.  
[Medication or Therapy]  
Systemic treatment or therapy (including prescribed 
herbal medication) to treat neovascular AMD. However, dietary supplementary, vitamins and minerals are allowed  
[Time to be prohibite d] 
‚Ä¢ Within 30days prior to randomisation ‚Ä¢  From Screening to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ N/A [Medication or Therapy]  
Systemic treatment or therapy (including prescribed herbal medication) to treat neovascular AMD. However, dietary supplementar y
 supplements , 
vitamins and minerals are allowed  
[Time to be prohibited]  
‚Ä¢ Within 30days prior to randomisation ‚Ä¢  From Screening to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ N/A Editorial change  
Not applicable  [Medication or Therapy]  
Systemic medications k nown to be toxic to the lens, 
retina or optic nerve including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, vigabatrin and ethambutol  
[Time to be prohibited]  
‚Ä¢ From Screening to EOS/ET visit  
[Eye to be prohibited]  
N/A Prohibited medication or 
therapy is added as per Korea MFDS‚Äôs request.  
[Medication or Therapy]  
ITV sustained drug delivery implant (e.g., ITV corticosteroid implant)  
[Time to be prohibited]  
‚Ä¢ Within 180 days prior to randomisation 
‚Ä¢  From Screening to EOS/ET visit   
[Eye to be prohibited]  
‚Ä¢ Study eye  [Medication or Therapy]  
ITV Intravitreal injection of corticosteroid (e.g., 
triamcinolone acetonide) or sustained drug delivery 
implant (e.g., ITV  intravitreal corticosteroid implant ) 
 [Time to be prohibited]  
‚Ä¢ Within 1 80 days prior to randomisation 
‚Ä¢ From Screening to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ Study eye  Prohibited medication or 
therapy is revised 
according to updated exclusion criteria #15.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 125 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Not applicable  [Medication or Therapy]  
Treatment involving macula with photodynamic 
therapy with verteporfin, transpupillary 
thermotherapy, radiation therapy, or retinal laser 
treatment (e.g., focal laser photocoagulation)  
[Time to be prohibited]  
‚Ä¢ Prior to Screening  
‚Ä¢ From Screening to EOS/ET visit  
[Eye to be prohibi ted] 
‚Ä¢ Study eye  Prohibited medication or 
therapy is added as per 
Korea MFDS‚Äôs request.  
Not applicable  [Medication or Therapy]  
Treatment with pan- retinal photocoagulation  
[Time to be prohibited]  
‚Ä¢ Prior to Screening  
‚Ä¢ From Screening to EOS/ET visit  
[Eye to be prohibited]  
‚Ä¢ Study eye  Prohibited medication or 
therapy is added as per Korea MFDS‚Äôs request.  
[Medication or Therapy]  
Systemic investigational products (excluding dietary supplementary, vitamins and minerals ) to treat 
systemic diseases other tha n neovascular AMD  
[Time to be prohibited]  
‚Ä¢ Within 90 days prior to randomisation 
‚Ä¢  From Screening to EOS/ET visit  
NOTE :  During the study period, investigational 
products such as dietary supplementary , vitamins and 
minerals  will be prohibited.  
[Eye to b e prohibited]  
‚Ä¢ N/A [Medication or Therapy]  
Systemic investigational products (excluding 
dietary supplementary  supplements , vitamins and 
minerals ) to treat systemic diseases other than 
neovascular AMD  
[Time to be prohibited]  
‚Ä¢ Within 90 days prior to randomisation  
‚Ä¢  From Screening to EOS/ET visit  
NOTE :  During the study period, investigational 
products such as dietary supplementary  supplements , 
vitamins and minerals  will be prohibited.  
[Eye to be prohibited]  
‚Ä¢ N/A Editorial change  
5.4. Fellow Eye 
Treatme nt Lucentis¬Æ for treatment in the fellow eye will be 
reimbursed or provided by Sponsor.  Lucentis¬Æ for treatment in the fellow eye will be 
reimbursed or provided by Sponsor during the study Period of providing 
Lucentis  for fellow  eye 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 126 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
period after randomisation . treatment  is specified.  
Fellow eye injection will be performed by the 
Investigator for this study. However, fellow eye visit is 
not part of study, thus it will be scheduled in accordance with local practice.  Fellow eye injection will be performed b y the 
Investigator for this study. However, fellow eye visit is not part of study, thus it will be scheduled in accordance with local practice. If a subject has both 
eyes injected on the same day, fellow eye should be 
injected  after completion of ITV injec tion of IP on 
the study eye.  To provide guideline for 
fellow eye injection  
6.2.1. Best 
Corrected Visual Acuity  VA will be assessed using ETDRS chart or 2702 
Number charts (only for subjects who are not familiar with alphabet or subjects with illiteracy) at a starting distance of 4 meters, and then repeated at a distance of 
1 meter, if necessary.  VA will be assessed using original series  ETDRS 
chart s or 2702 series Number  charts (only for subjects 
who are not familiar with alphabet or subjects with 
illiter acy) at a starting distance of 4 meters, and then 
repeated at a distance of 1 meter, if necessary.  Clarification for charts 
used in this study 
VA examiners and VA lanes at Investigational sites 
must be certified to ensure consistent measurement of BCVA p rior to start of study. VA examiners should be 
masked to the subject‚Äôs treatment group and should not 
perform any other study procedures.  VA examiners and VA lanes at Investigational sites 
must be certified to ensure consistent measurement of BCVA prior to  start of study. 
VA examiners should 
be masked to the subject‚Äôs treatment group and 
should not perform any other study procedures.  Requirement is changed.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 127 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
A decrease in VA of > 15 letters (compared with the 
last assessment of VA) should be reported as AE s/ 
SAEs as appropriate. If there is a decrease in VA of > 
30 letters (compared with the last assessment of VA) or 
there is a decrease in VA to the level of Light 
Perception or worse, VA should be re -assessed after at 
least 1 hour.  
If the event meets one or  more of the following criteria, 
it should be reported as SAE.  
‚Ä¢ A decrease in VA of > 30 letters (compared with the last assessment of VA) lasting > 1 hour  
‚Ä¢ A decrease in VA to the level of Light Perception or worse lasting > 1 hour  A decrease in VA of > ‚â•15 letters (compared with  
from the last assessment of VA) should be reported as 
AEs/  Serious Adverse Events ( SAEs ) as 
appropriate. If there is a decrease in VA of > 30 
letters (compared with the last assessment of VA) or 
there is a decrease in VA to the level of Light 
Perception or worse, VA should be re -assessed after 
at least 1 hour.  
If the event meets one or more of the following criteria, 
it should be reported as SAE.  
‚Ä¢ A decrease in VA of > ‚â• 30 letters  (compared 
with from the last assessment of VA ) lasting > 1 hour  
‚Ä¢ A decrease in VA to the level of Light Perception or 
worse lasting > 1 hour  Error correction  
   
 
    
SAE criteria are 
changed . 
6.2.2. Anatomical 
Parameters  The average retinal thickness in the central 1 -mm area 
in the ETDRS grid (CST; c entral subfield thickness), 
retinal thickness between Internal Limiting Membrane 
(ILM) and the base of RPE (CRLT; central retinal lesion thickness) and other lesion characteristics will be evaluated using OCT only in the study eye at Screening and prior to ITV injection of IP until Week 48. OCT 
will also be performed at any time during the visit at Week 52 (EOS visit) or ET visit.  
Lesion characteristics such as CNV size and presence of leakage or haemorrhage will also be evaluated using FP/FA only in the study eye at Screening and prior to ITV injection of IP Week 24. FP/FA will also be 
performed at any time during the visit at Week 52 
(EOS visit) or ET visit.  The average retinal thickness in the central 1 -mm area 
in the ETDRS grid (CST; central subfield th ickness), 
retinal thickness between Internal Limiting Membrane 
(ILM) and the base of RPE (CRLT; central retinal lesion thickness) and other lesion characteristics will be evaluated using OCT 
only in on the study eye at 
Screening and prior to ITV injection of IP until Week 
48. OCT will also be performed at any time during the 
visit at Week 52 (EOS visit) or ET visit.  
Lesion characteristics such as CNV size and presence of leakage or haemorrhage will also be evaluated using FP/FA only in
 on the study eye at Screening and prior 
to ITV injection of IP Week 24. FP/FA will also be 
performed at any time during the visit at Week 52 
(EOS visit) or ET visit.  Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 128 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
6.3.2. Clinical 
Laboratory Test  Clinical laboratory test including haematology, clinical 
chemistry, urinalysis and pregnancy test can be 
repeated ‚Ä¶.  Clinical laboratory test including haematology, clinical 
chemistry,  and urinalysis and pregnancy test  can be 
repeated ‚Ä¶.  Pregnancy test will be 
provided in the separate 
section.  
Table 9. Parameters 
for Clinical 
Laboratory Tests  [Others]  Pregnancy test2 at Screening (serum)2   
2 Serum or urine pregnancy test s may be performed after 
randomisation at Investigator‚Äôs discretion.  [Others]  Pregnancy test2 at Screening (serum)2   
2 Serum or urine pregnancy t ests may be performed after 
randomisation at Investigator‚Äôs discretion.  Pregnancy test will be 
provided in the separate 
section.  
6.3.3. Pregnancy 
Test Not applicable  For women  of childbearing potential , serum 
pregnancy test must be performed at Screening.  
The serum samples taken at Screening will be analysed in central laboratory.  
Additional serum or urine pregnancy test can be 
performed in each Investigational site during the 
study period, if necessary (at the Investigator‚Äôs 
discretion). 
Deleted pregnancy  test result at Screening with 
technical problems, such as handling error, 
sampling error or tube breakage, should be 
followed by re -test. Result of re- test will be 
considered as that of an initial.  Clarification for 
pregnancy test  
6.3.4. Physical 
Examina tion Physical examination will be performed at Screening 
and Week 52 (EOS visit) or ET visit. Abnormal findings will be documented on the source document, and any clinically significant abnormality or worsening 
of a previously noted abnormality should be r ecorded 
as an AE.  Physical examination will be performed at Screening 
and Week 52 (EOS visit) or ET visit. The physical 
examination will include an assessment of the 
subject‚Äôs general appearance, skin, head, neck, 
throat, lymph nodes, cardiovascular, neuro logical, 
thyroid, musculoskeletal/extremities, respiratory 
systems and the subject‚Äôs abdomen.  Abnormal 
findings will be documented on the source document, 
and any clinically significant abnormality or worsening of a previously noted abnormality should be r ecorded 
as an AE.  Clarification for physical 
examination (systems and organs)  
6.4.1. Full The examination of the anterior segment is performed The examinati on of the anterior segment is Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 129 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Ophthalmic 
Examinations  
- Slit lamp 
biomicroscopy  only with the slit lamp without any additive drugs or 
lenses.  
 
The posterior segment should be examined with the slit 
lamp and the appropriate lens. For this examination the 
pupil of the eye must be dilated with 2 -3 drops of 
phenylephrine -tropicamid (or any other mydriatic) 
applied topically to the eye.  performed only with the slit lamp without any 
additive drugs or lenses. Both the anterior segment 
and posterior segment will be assessed with the slit lamp.  
The posterior segment should  will be examined after 
dilation of pupil with the slit lamp and the 
appropriate lens. For this examination the pupil of 
the eye must be dilated  with 2 -3 drops of 
phenylephrine -tropicamid (or any other mydriatic 
drug ) applied topically to the eye.  
6.4.1. Full 
Ophthalmic Examinations  
- Intraocular 
pressure (IOP) 
measurement  IOP will be measured only in the study eye at 
Screening and prior to ITV injection of IP and 30- 60 
minutes after ITV injection of IP at each visit until 
Week 48.  IOP will be measured only in on the study eye at  
Screening and prior to ITV injection of IP and 30- 60 
minutes after ITV injection of IP at each visit until 
Week 48.  Editorial change  
IOP should be measured using Goldmann applanation 
tonometry only.  IOP should be measured using Goldmann applanation 
tonometry  only. Editorial change  
6.4.1. Full 
Ophthalmic 
Examinations  
- Indirect 
ophthalmoscopy  Indirect ophthalmoscopy using in a standard way (i.e., 
usually using a head -mounted light source and a 20- 30 
dpt lens)will be performed only in the study eye 
(inclu ding evaluation of posterior segment 
abnormalities of the vitreous, optic nerve, peripheral retina and retinal vasculature, as well as retinal pigment epithelium detachment, ischemic events including cotton wool spots and microaneurysms) at Screening 
and p rior to ITV injection of IP and 0 -15 min after ITV 
injection of IP at each visit until Week 48.  Indirect ophthalmoscopy using in a standard way (i.e., 
usually using a head -mounted light source and a 20- 30 
dpt lens)will be performed only in  on the study eye  
(including evaluation of posterior segment 
abnormalities of the vitreous, optic nerve, peripheral retina and retinal vasculature, as well as retinal pigment epithelium detachment, ischemic events including cotton wool spots and microaneurysms) at Screening 
and prior to ITV injection of IP and 0- 15 min after ITV 
injection of IP at each visit until Week 48.  Editorial change  
6.4.2. Optical 
Coherence 
Tomography (OCT)  OCT will be performed only in the study eye at 
Screening and prior to ITV injection of IP at each study 
visit until Week 48. OCT will also be performed at any time during the visit at Week 52 (EOS visit) or ET 
visit.  OCT will be performed only in on the study eye at 
Screening and prior to ITV injection of IP at each study visit until Week 48. OCT will also be performed at any 
time during the visit at Week 52 (EOS visit) or ET 
visit.  Editorial change  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 130 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Only OCT devices registered and certified by central 
reading centre are allowed to be used in this study. If 
one or more OCT devices are registered and certified in an Investigational site, a subject should use the same 
OCT device consistently during the study period. If 
OCT devices registered and certified in an Investigational site are all from the same manufacturer and they use the same imaging syst em and the same 
version of software, the subject could use either of 
them during the study period.  Site staffs who will perform OCT scans in this study 
must be certified by the central reading centre 
before study starts. 
Only OCT devices registered and certified by 
central reading centre are allowed to be used in this 
study. If one or more OCT devices are registered 
and certified in an Investigational site, a subject 
should use the same OCT device consistently  OCT 
devices registered in an Investigational si te should 
be all from the same manufacture and meet the 
minimum software requirement. The subject should use the OCT devices registered by central reading 
centre during the study period. 
If OCT devices 
registered and certified in an Investigational site are 
all from the same manufacturer and they use the 
same imaging system and the same version of 
software, the subject could use either of them 
during the study period.  Editorial change  
6.4.3. Fundus 
Photography (FP) 
and Fluorescein Angiography (FA)
 FP/FA wi ll be performed only in the study eye at 
Screening and prior to ITV injection of IP at Week 24. FP/FA will also be performed at any time during the visit at Week 52 (EOS visit) or ET visit.  FP/FA will be performed only in on the study  both  
eyes at Screenin g and  those images taken from the 
both eyes will be sent to the central reading centre.  
FP/FA will also be performed on the study eye  prior 
to ITV injection of IP at Week 24 and. FP/FA will 
also be performed  at any time during the visit at Week 
52 (EOS vi sit) or ET visit. Those images taken from 
the study eye will be sent to the central reading centre. 
Site staffs who will perform FA/FP in this study must be certified by the central reading centre 
before study starts.  According to exclusion 
criteria #3, FP /FA 
images taken from the both eyes should be sent 
to the central reading 
centre at Screening. 
 Editorial change  
6.5. 
Pharmacokinetic Blood samples for PK will be collected in 
approximately 120 subjects (60 subjects per treatment Blood samples sampling  for PK will be collected in 
approximately 12040 subjects ( 6020 subjects per Number of subjects 
participating  in PK 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 131 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Assessment  group) partici pating in PK evaluation.  treatment group) participating in PK evaluation.  evaluation  is changed as 
per US FDA‚Äôs request.  
6.6. 
Immunogenicity 
Assessment  ‚Ä¶he or she could be asked to return for 
immunogenicity blood sampling after Week 52 (EOS visit) or ET visit until the antibody titres return to 
baseline or stabilize at a level acceptable to the 
Investigator and Sponsor.  ‚Ä¶he or she could be asked to return for 
immunogenicity blood sampling after Week 52 (EOS 
visit) or ET visit until the antibody titres return to 
baseline or stabilize  stabilise  at a level acceptable to 
the Investigator and Sponsor.  Editorial change  
6.7. NEI VFQ -25 Vision -related QOL will be assessed using NEI VFQ -
25. NEI VFQ- 25 should be performed at Week 0 (Day 
1) after randomisation, but prior to starting any other 
study procedures. Then, NEI VFQ -25 should be 
performed be fore starting any other study procedures at 
Week 12, Week 24, Week 36 and Week 52 (EOS visit) or ET visit. All questionnaires will be administered in the local language. A certified person will conduct a questionnaire survey with the subject in a quiet roo m. Vision -related QOL will be assessed using NEI VFQ -
25. NEI VFQ- 25 should be performed at Week 0 (Day 
1) after randomisation , but prior to starting any other 
study procedures . Then, NEI VFQ -25 should be 
performed before starting any other study 
procedures  dilation of pupil  at Week 0 (Day 
1), Week 12, Week 24 , Week 36  and Week 52 (EOS 
visit) or ET visit. All questionnaires will be administered in the local language. 
A certified person  
Investigator or delegated site staff  will conduct a 
questionnaire survey with the subject in a quiet room.  Frequency of NEI VFQ -
25 is changed as per US 
FDA‚Äôs request.  
 
 
   
Certification for the interviewer is not 
required for this study.  
7. Study 
Procedures -all 
page s ‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using ETDRS chart o r 2702 
Number chart (before dilation of the pupils and FP/FA and OCT assessment)  
 ‚Ä¢ IOP using Goldmann applanation tonometry only ‚Ä¢ Ocular assessments:  
‚Ä¢ BCVA examination using original series  ETDRS 
chart s or 2702 series  Number chart s (before dilation of 
the pupils and FP/FA and OCT assessment)  
 ‚Ä¢ IOP using Goldmann applanation tonometry
 only Clarification for charts 
used in this study 
   Editorial change  
7.1. Visit 1 
(Screening , D -21 
to D-1) If the subject is not randomized within 21 days after 
Screening , If the subject is not randomized  randomised  within 
21 days after Screening,  Editorial change  
‚Ä¢ Pregnancy test (serum, all female)  ‚Ä¢ Pregnancy test for women of childbearing potential  
(serum , all female ) Pregnancy test will be 
performed only for 
childbe aring potential 
female subjects.  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 132 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
If the subject is screen failed due to any reasons other 
than central review results, OCT and FP/FA images 
may not be transferred to central reading centre.  If the subject is screen failed due to any reasons  
before the I nvestigator send OCT and/or FP/FA 
images to central reading centre, the Investigator 
does not have to send the subject‚Äôs OCT and/or 
FP/FA images to central reading centre.  other than 
central review results, OCT and FP/FA images may 
not be transferred to ce ntral reading centre.  Editorial change  
NOTE  
A decrease in VA of > 15 letters (compared with the 
last assessment of VA) should be reported as 
AEs/SAEs as appropriate.  NOTE  
A decrease in VA of > ‚â•15 letters (compared with the 
last assessment of VA) should be reported as 
AEs/SAEs as appropriate.  Error correction  
7.2. Visit 2 (Week 
0/Day 1)  Before randomisation  
‚Ä¢ Investigator must confirm that the subject can read between 34 letters and 73 letters using ETDRS chart or 2702 Number chart (before dilation of the pupils and FP/FA or OCT assessment) prior to randomisation (Please see inclusion criteria #5).  Before randomisation  
‚Ä¢  Investigator must confirm that the subject can read 
between 34 letters and 73 letters using original series  
ETDRS chart s or 2702 series  Number chart s (before 
dilation of the pupils and FP/FA or OCT assessment) prior to randomisation (Please see inclusion criteria 
#5). Clarification for charts 
used in this study 
Randomisation  
‚Ä¢ After a subject‚Äôs eligibility is confirmed by the central reading centre and Investigator, subject should be 
randomized to either SB11 or Lucentis
¬Æ treatment 
group.  
‚Ä¢ IP injection and study procedures which should be 
performed before ITV injection of IP must be 
performed must be performed at the same day of randomi sation or the following day after randomisation 
at the latest with a proper reason.  Randomisation  
‚Ä¢ After a subject‚Äôs eligibility is confirmed by the central reading centre and Investigator, subject should be  
randomized  randomised to either SB11 or Lucenti s
¬Æ 
treatment group.  
‚Ä¢ The first ITV injection of  IP injection  and all other  
study procedures which should be performed before 
ITV injection of IP must be performed  must be 
performed at the same day of randomisation or the following day after randomisation at the latest with a 
proper reason.  Editorial change  
After randomisation  
Before ITV injection of IP  After randomisation  
Before ITV injection of IP  Requirement is changed . 
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 133 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
‚Ä¢ NEI VFQ -25 (prior to starting any other study 
procedures after randomisation)  ‚Ä¢ NEI VFQ -25 (prior to starting any other study 
procedures dilation of pupil  after randomisation)  
7.6. Visit 6 (Week 
12 ¬± 7 days)  
7.12. Visit 12 
(Week 36 ¬± 7 days)  Before ITV injection of IP  
‚Ä¢ NEI VFQ -25 (before starting any other study 
procedures)  Before IT V injection of IP  
‚Ä¢ NEI VFQ -25 (before starting any other study 
procedures)  Frequency of NEI VFQ -
25 is changed as per US 
FDA‚Äôs request.  
7.9. Visit 9 (Week 
24 ¬± 7 days)  
7.16. End of Study 
(Visit 16, Week 52 ¬± 7 days) or Early 
Termination Visit  Before ITV i njection of IP  
‚Ä¢ NEI VFQ -25 (before starting any other study 
procedures)  Before ITV injection of IP  
‚Ä¢ NEI VFQ -25 (before starting any other study 
procedures dilation of pupil ) Requirement is changed.  
8.1.1. Definition of 
Adverse Event  All AEs including oc ular AEs in the study eye and/or 
fellow eye as well as systemic AEs will be collected from the written informed consent is obtained from the subject until Week 52 (EOS visit) or ET visit.  All AEs including ocular AEs in the study eye and/or 
fellow eye as well as systemic AEs will be collected from the written informed consent is obtained from the subject until Week 52 (EOS visit) or ET visit. If the 
AMD is diagnosed in the fellow eye during the study 
period, the event should be also reported as AE.  To provi de guideline for 
AE reporting  for AMD in the fellow eye  
8.2.1. Definition of 
Serious Adverse Event  Not applicable  Life-threatening  
The term ‚Äúlife -threatening‚Äù in the definition of 
‚Äúserious‚Äù refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.  
Hospitalisation 
AEs reported from clinical studies associated with hospitalisation or prolongation of existing hospitalisation are con sidered serious.  
Any admission to a healthcare facility more than 24 hours meets these criteria. Admission also includes 
transfer within the hospital to an acute/intensive Clarification for ‚ÄúLife -
threatening‚Äù and ‚ÄúHospitalisation‚Äù  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 134 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
care unit (e.g., from the medical floor to a coronary 
care unit, neurological floor to a tuberculosis unit). 
Staying at the observation unit in the emergency 
room for more than 24 hours qualifies for 
hospitalisation.  
Any events leading to a subsequent emergency room 
visit or inpatient hospitalisation for less than 24 hours may be regarded  as medically important for 
its seriousness criteria, at the discretion of 
Investigator based on medical judgement.  
Hospitalisation or prolongation of existing 
hospitalisation in the absence of an AE is not in itself an SAE. Examples include:  
‚Ä¢ Admission for treatment of a pre- existing (prior to 
ICF signed) condition not associated with the 
development of a new AE or with a worsening of the 
pre-existing condition  
‚Ä¢ Diagnostic admission (e.g., for work -up of 
persistent pre- treatment laboratory abnormality)  
‚Ä¢ Social admission (e.g., study subject has no place to sleep)  
‚Ä¢ Administrative admission (e.g., for a regular check -up) 
‚Ä¢ Protocol -specified admission during a clinical 
study (e.g., for a procedure required by the study protocol)  
‚Ä¢ Elective admission not associated with an AE (e.g., 
for elective cosmetic surgery) ‚Ä¢ Pre -planned treatments or surgical procedures  
: Pre -planned treatments or surgical procedures 
should be noted in the relevant source document for 
the individual subject.   
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 135 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
‚Ä¢ A decrease in VA of > 30 letters (compared with the 
last assessment of VA) lasting > 1 hour (confirmed by 
re-assessment)  
‚Ä¢ A decrease in VA to the level of Light Perception or 
worse lasting > 1 hour (confirmed by re -assessment)  ‚Ä¢ A decrease in VA of > ‚â• 30 letters (compared with  
from  the last assessment of VA ) lasting > 1 hour 
(confirmed by re -assessment)  
‚Ä¢ A decrease in VA to the level of Light Perception or 
worse lasting > 1 hour (confirmed by re -assessment)  Error correction  
 SAE criteria are 
changed . 
8.2.2. Reporting 
Serious Adverse 
Events  In addition, an Investigator may be requested by 
Sponsor to obtain specific additional follow -up 
information in an expedited fashion.  In addition, an Investigator may be requested by 
Sponsor to obtain specific additional follow -up 
information in an expedited fashion.  Editorial change  
8.3. Adverse 
Events of Special Interest  ‚Ä¢ Any case of ocular infection such as endophthalmitis  ‚Ä¢ Any case of intra ocular infection such as 
endophthalmitis  Editorial change  
Not appli cable  ‚Ä¢ Iatrogenic traumatic cataract  
‚Ä¢ Arterial thromboembolic events defined as 
nonfatal st roke, nonfatal myocardial infarction, or 
vascular death (including deaths of unknowns 
cause)  Events are added as 
AESI as per EMA SmPC 
and FDA Prescribing 
Informati on. 
9.1. Analysis Sets  ‚Ä¢ Per -Protocol Set for CST (PPS -CST) consists of all 
FAS subjects who have the first IP injection at Week 0 (Day 1) and complete the procedures at Week 4 without any major protocol deviations that have impact 
on the CST assessment. This PPS -CST will be the 
primary analysis set for CST in addition to FAS. Major 
protocol deviations that will lead to exclusion from this set will be pre -defined prior to unmasking the treatment 
codes for analyses.  ‚Ä¢ Per -Protocol Set for CST (PPS -CST) cons ists of all 
FAS subjects who have the first IP injection at Week 0 (Day 1) and complete the procedures at Week 4 without any major protocol deviations that have impact 
on the CST assessment. This PPS -CST will be the 
primary analysis set for CST 
in addition to FAS . 
Major protocol deviations that will lead to exclusion 
from this set will be pre -defined prior to unmasking the 
treatment codes for analyses.  Clarification analysis set 
for CST  
9.2.4. 
Pharmacokinetics  Blood sampling for PK will be collected in 120  
subjects participating in PK evaluation (60 per 
treatment group).  Blood sampling for PK will be collected in  
approximately 12040 subjects participating in PK 
evaluation ( 6020 subjects per treatment group).  Number of subjects 
participating  in PK 
evaluation  is changed as 
per US FDA‚Äôs request.  
10.1. Data 
Confidentiality  A list linking the code and the subject‚Äôs name will be 
kept in the Investigational site files as required by 
International Conference on Harmonisation‚Äôs (ICH) A list linking the code and the subject‚Äôs name will be 
kept in the Investigational site files as required by 
International Conference on  Council for  Error correction  
SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 136 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
Guideline for Good Clinical Prac tice (GCP) to protect 
the subject‚Äôs confidentiality.  Harmonisation ‚Äôs (ICH) Guideline for Good Clinical 
Practice (GCP) to protect the subject‚Äôs confidentiality.  
LIST OF 
ABBREVIATION
S ICH: International Council on Harmonisation  ICH: International Council onfor Harmonisation  Error correction  
LOCF: Last Observation Carried Forward  LOCF: Last Obs ervation Carried Forward  
RPE: Retinal Pigment Epitheli al RPE: Retinal Pigment Epitheli al Epitheli um 
LIST OF STUDY 
STAFF  Clinical Project Manager  
 
 Clinical Project Manager  
 
 Responsible person is 
changed. 
Clinical Research Physician  
 
 Clinical Research Physician  
 Responsible person is 
changed. 
Statistician  
  Statistician  
 
 
 
 Responsible person is 
changed  
Project Safety Lead  
 Project Safety Lead  
 
 Responsible person is 
changed  
Appendix D: 
National Eye Institute 25 -Item 
Visual Function 
Questionnaire (NEI 
VFQ -25 Not applicable  National Eye Institute 25 -Item Visual Function 
Questionnaire is  added.  NEI VFQ -25 
questionnaire is added.  

SB11 (proposed ranibizu mab biosimilar)  
SB11 -G31-AMD  
Amendment 1, Sep 01, 2017  
 
Samsung Bioepis ‚Äì Confidential  
Page 137 of 137 Section Affected  Original Content  Amended/New Content  Rationale  
questionnaire)  
All pages  at Investigator‚Äôs discretion  at the Investigator‚Äôs discretion  Editorial change  
in the opinion of Investigator  in the opinion of the Investigator  Editorial change  
 